ezetimibe profile

Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	150311
CHEMBL ID	1138
CHEBI ID	49040
SCHEMBL ID	2871
MeSH ID	M0422151

Synonym
AC-1057
AKOS005572111
AB00639916-08
1-(4-fluorophenyl)-3(r)-[3-(4-fluorophenyl)-3(s)-hydroxypropyl]-4(s)-(4-hydroxyphenyl)-2-azetidinone
ezetimibe
mk-0653
ezetrol
(3r,4s)-1-(p-fluorophenyl)-3-((3s)-3-(p-fluorophenyl)-3-hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone
ezedoc
sch 58235
(-)-sch 58235
zetia
2-azetidinone, 1-(4-fluorophenyl)-3-((3s)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3r,4s)-
sch-58235
2-azetidinone, 1-(4-fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3r-(3alpha(s*),4beta))-
zient
sch58235
(1-(4-fluorophenyl)-(3r)-(3-(4-fluorophenyl)-(3s)-hydroxypropyl)-(4s)-(4-hydroxyphenyl)-2-azetidinone)
ezetimib
(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
ezetimiba
ezetimibum
MLS001424125
CHEBI:49040 ,
MLS000759443
smr000466334
DB00973
163222-33-1
D01966
zetia (tn)
ezetimibe (jan/usp/inn)
HMS2051K16
CHEMBL1138
mk0653
nsc-758923
ezetimibe [usan:inn:ban]
unii-eor26lqq24
eor26lqq24 ,
nsc 758923
hsdb 7737
dtxcid9024223
tox21_111443
dtxsid1044223 ,
cas-163222-33-1
HMS2236A04
c24h21f2no3
STK640490
CCG-100884
bdbm50371521
HY-17376
ezetimibe [mart.]
ezetimibe [mi]
ezetimibe [orange book]
nexlizet component ezetimibe
ezetimibe component of roszet
ezetimibe [inn]
ezetimibe [usan]
ezetimibe [who-dd]
ezetimibe [vandf]
ezetimibe [hsdb]
ezetimibe component of nexlizet
roszet component ezetimibe
ezetimibe [usp monograph]
2-azetidinone, 1-(4-fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)-, (3r-(3.alpha.(s*),4.beta.))-
ezetimibe [usp-rs]
ezetimibe component of vytorin
vytorin component ezetimibe
ezetimibe [jan]
AM84560
S1655
gtpl6816
AB00639916-06
NC00134
SCHEMBL2871
tox21_111443_1
NCGC00263575-01
KS-1170
(3r,4s)-1-(4-fluorophenyl)-3-[(s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-azetidin-2-one
OLNTVTPDXPETLC-XPWALMASSA-N
(3r,4s)-1-(4-fluorophenyl)-3-[(3 s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxy-propyl]-4-(4-hydroxyphenyl)azetidin-2-one
MLS006011921
ezetimibe, pharmaceutical secondary standard; certified reference material
(3r,4s)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one
AB00639916_09
EX-A795
ezetimibe, united states pharmacopeia (usp) reference standard
ezetimibe, >=98% (hplc)
HMS3715D06
NCGC00263575-07
Q417997
Z1541759501
ezetimibe (zetia) ,
(3r,4s)-1-(4-fluorophenyl)-3-((s)-3-(4-fluorophenyl)-
3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one
BRD-K42260897-001-09-2
EN300-122361
1-(4-fluorophenyl)-3-[3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-2-azetidinone
AR-270/43507897
2-azetidinone, 1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)-, (3r,4s)-
(3r,4s)-1-(4-fluorophenyl)-3-[(3s)-3-(4-fluorophenyl)- 3-hydroxypropyl]-4-(4-hydroxyphenyl)azetidin-2-one
ezetimibe anhydrate
(3~{r},4~{s})-1-(4-fluorophenyl)-3-[(3~{s})-3-(4-fluorophenyl)-3-oxidanyl-propyl]-4-(4-hydroxyphenyl)azetidin-2-one
h56 ,
BE164439
ezetimibe- bio-x
E1449
ezetimibe)
HY-17376R
CS-0694785
ezetimibe (standard)
ezetimibe (usp-rs)
ezetimibe (mart.)
(3r,4s)-1-(p-fluorophenyl)-3-((3s)-3-(p-fluorophenyl)-3- hydroxypropyl)-4-(p-hydroxyphenyl)-2-azetidinone
1-(4-fluorophenyl)-3(r)-(3-(4-fluorophenyl)-3(s)-hydroxypropyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
2-azetidinone, 1-(4-fluorophenyl)-3-(3-(4-fluorophenyl)-3- hydroxypropyl)-4-(4-hydroxyphenyl)-, (3r-(3alpha(s*),4beta))-
ezetimibe (usp monograph)
(3r,4s)-1-(4-fluorophenyl)-3-((3s)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one
c10ax09

Excerpt	Reference	Relevance
"Ezetimibe is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia, but its molecular target has been elusive. "	( The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Altmann, SW; Braun, MP; Bull, HG; Burnett, DA; Chapman, KT; Crona, JH; Davis, HR; Dean, DC; Detmers, PA; Garcia-Calvo, M; Graziano, MP; Hawes, BE; Hughes, M; Iyer, SP; Lisnock, J; Macintyre, DE; Makarewicz, AM; O'neill, KA; Ogawa, A; Shevell, DE; Smith, MM; Tang, YS; Thornberry, NA; Ujjainwalla, F, 2005)	2.13
"Ezetimibe acts as an antagonist of Niemann-Pick C1-Like 1 receptor required for HCV entry and theoretically can reduce HCV viremia."	( Association between ezetimibe usage and hepatitis C RNA levels in uninfected kidney transplant recipients who received hepatitis C infected kidneys. Azhar, A; Balaraman, V; Bhalla, A; Binari, LA; Concepcion, BP; Eason, JD; Forbes, RC; Hall, IE; Joglekar, K; Molnar, MZ; Rofaiel, G; Shaffer, D; Talwar, M; Tsujita, M, 2021)	1.67
"Ezetimibe is a widely used medication to reduce the plasma cholesterol level, particularly low-density lipoprotein level. "	( Impacts of ezetimibe on risks of various types of cancers: a meta-analysis and systematic review. Bai, H; Ge, J; He, J; Hu, J; Huang, J; Li, H; Liang, X; Sun, S; Wang, X; Zhao, T, 2023)	2.74
"Ezetimibe (ETZ) is a hypocholesterolemic agent with limited dissolution, poor water solubility, and subsequently demonstrates low oral bioavailability."	( Development of ezetimibe eutectic with improved biopharmaceutical and mechanical properties to design an optimized oral solid dosage formulation. Ghosh, A; Gour, A; Kumari, N; Nandi, U; Pandey, N; Raj, A; Roy, P; Srividya, B, 2022)	1.8
"Ezetimibe is a new class of antihyperlipidemic agent indicated for the prevention of atherosclerosis disease and for the treatment of hypercholesterolemia. "	( Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects. Cao, Y; Fu, Y; Gao, X; Jiang, X; Li, T; Li, X; Lin, P; Liu, Y; Ma, Y; Sun, F; Wang, C, 2023)	2.62
"Ezetimibe is a cholesterol-lowering drug having anti-inflammatory and pleiotropic properties."	( Ezetimibe alleviates acetic acid-induced ulcerative colitis in rats: targeting the Akt/NF-κB/STAT3/CXCL10 signaling axis. Abdel-Rahman, RF; Mostafa, RE, 2023)	3.07
"Ezetimibe is a lipid-lowering agent that selectively inhibits cholesterol absorption by binding to the Niemann-Pick C1-like 1 (NPC1L1) protein. "	( Ezetimibe Induces Vasodilation in Rat Mesenteric Resistance Arteries through Inhibition of Extracellular Ca Byeon, S; Choi, S; Choi, SK; Haam, CE; Lee, YH; Oh, EY, 2023)	3.8
"Ezetimibe (EZT) is a selective cholesterol absorption inhibitor with poor aqueous solubility (0.012mg/ml 23oC) and low oral bioavailability (about 35-65% for a once 10mg dose). "	( Dissolution rate enhancement of new co-crystals of ezetimibe with maleic acid and isonicotinamide. Kai, S; Li Na, D; Ling, F; Man, Z; Wen, L; Xiao-Hui, Z; Yan-Jie, H; Yu-Zhen, Y, 2019)	2.21
"Ezetimibe is a cholesterol-lowering drug that possesses the pharmacophore features to inhibit NTCP."	( The effect of twelve weeks of treatment with ezetimibe on HDV RNA level in patients with chronic hepatitis D. Abbas, M; Abbas, Z; Asim, M; Saad, M; Samejo, SA, 2020)	1.54
"Ezetimibe is a top-selling hypolipidemic drug for the treatment of cardiovascular diseases. "	( Efficient production of an ezetimibe intermediate using carbonyl reductase coupled with glucose dehydrogenase. Liu, ZQ; Tang, YQ; Wang, MY; Wu, D; Zhang, XJ; Zheng, YG; Zhou, R, 2021)	2.36
"Ezetimibe is a cholesterol-lowering agent with an oral bioavailability of 50% by virtue of its poor solubility and extensive hepatic and intestinal metabolism."	( Amorphous Solid Dispersion Based Oral Disintegrating Film of Ezetimibe: Development and Evaluation. Narayana, KA; Shrestha, S; Sudheer, P, 2021)	2.31
"Ezetimibe (EZM) is a selective inhibitor of the sterol transporter Niemann-Pick C1-Like 1 in the small intestine used as an adjunctive therapy to lower cholesterol levels in cases of hyperlipidemia. "	( Ezetimibe: A Review of Analytical Methods for the Drug Substance, Pharmaceutical Formulations and Biological Matrices. Cabral, LM; de Sousa, VP; Pinto, EC; Rocha, LP, 2022)	3.61
"Ezetimibe is a well-known drug that lowers blood cholesterol levels by reducing its absorption in the small intestine when joining to Niemann-Pick C1-like protein (NPC1L1). "	( Synthesis and Modeling of Ezetimibe Analogues. Díez, D; Garrido, NM; Manchado, A; Nieto, CT; Salgado, MM, 2021)	2.36
"Ezetimibe is an azetidine derivative which blocks Niemann Pick C1-Like 1 Protein; as its consequence, plasmatic concentration of low density lipoproteins and other apoB-containing lipoproteins, that are the substrate of lysosomal acid lipase, are decreased."	( Long term substrate reduction therapy with ezetimibe alone or associated with statins in three adult patients with lysosomal acid lipase deficiency. Bertamino, M; Bertolini, S; Di Rocco, M; Madeo, A; Pisciotta, L, 2018)	1.46
"Ezetimibe is a potent cholesterol absorption inhibitor, with an erratic pharmacokinetic (PK) profile, attributed to an extensive enterohepatic recirculation (EHC). "	( On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe. Karalis, V; Soulele, K, 2019)	2.18
"Ezetimibe is an FDA-approved drug that reduces cholesterol uptake by inhibiting the endocytosis through Niemman-Pick C1-Like 1 (NPC1L1) receptor, expressed on the membrane of enterocytes and hepatocytes."	( Ezetimibe inhibits dengue virus infection in Huh-7 cells by blocking the cholesterol transporter Niemann-Pick C1-like 1 receptor. Bautista-Carbajal, P; Cervantes-Salazar, M; De Jesús-González, LA; Del Ángel, RM; Farfan-Morales, CN; Hurtado-Monzón, AM; Osuna-Ramos, JF; Reyes-Ruiz, JM, 2018)	2.64
"Ezetimibe (EZE) is an extensively used antihyperlipidemic drug with an important cholesterol lowering activity. "	( Development of a joint population pharmacokinetic model of ezetimibe and its conjugated metabolite. Karalis, V; Soulele, K, 2019)	2.2
"Ezetimibe is a selective cholesterol absorption inhibitor, whether it has a positive effect on CVD events remains uncertain."	( Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Liu, F; Shu, M; Tang, M; Wu, X; Xia, P; Zhan, S, 2018)	2.64
"Ezetimibe is an effective lipid-lowering drug, an inhibitor of intestinal absorption of cholesterol, which was investigated in many international and Russian studies, the results of which have demonstrated good tolerability, safety and efficacy (reduction of LDL-C levels by 18% in monotherapy)."	( [Possibilities of clinical use of ezetimibe Otrio (JSC "AKRIKHIN", Russia) in patients with high and very high cardiovascular risk who have not reached the target values of lipid metabolism. Conclusion of the Board of experts]. Galyavich, AM; Gurevich, VS; Kaminnyi, AI; Kashtalap, VV; Kobalava, JD; Mareev, VY; Shaposhnik, II; Susekov, AV, 2019)	1.51
"Ezetimibe is a unique inhibitor of intestinal cholesterol absorption. "	( [An inhibitor of intestinal cholesterol transporter]. Sano, M, 2013)	1.83
"Ezetimibe is a newer lipid-lowering agent, with fewer side effects."	( Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: the SAFE-ES study. Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Grosdidier, C; Morange, P; Pankert, M; Quilici, J; Verdier, V, 2014)	1.38
"Ezetimibe is a new lipid lowering agent that inhibits cholesterol absorption."	( Inhibition of smooth muscle cell proliferation by ezetimibe via the cyclin D1-MAPK pathway. Gong, YZ; Li, GY; Li, XL; Liao, DF; Luo, HD; Qin, L; Xie, XJ; Yang, YB; Yang, YX; Zheng, XL, 2014)	1.38
"Ezetimibe is a potent inhibitor of Niemann-Pick type C1-Like 1 and has been approved for the treatment of hypercholesterolemia. "	( Ezetimibe-mediated protection of vascular smooth muscle cells from cholesterol accumulation through the regulation of lipid metabolism-related gene expression. Gong, YZ; Liao, DF; Sun, SW; Tan, X; Tuo, QH; Xie, XJ; Xiong, Y; Yang, XF; Yuan, HY; Zheng, XL, 2014)	3.29
"Ezetimibe is a novel lipid-lowering agent that inhibits intestinal absorption of dietary and biliary cholesterol. "	( Development and validation of a novel stability-indicating HPLC method for the quantitative determination of eleven related substances in ezetimibe drug substance and drug product. Deng, Z; Hou, C; Liu, Y; Luo, Z; Tang, M; Wang, G; Yang, R; Yang, W; Zhou, H, 2015)	2.06
"Ezetimibe is a selective inhibitor of Niemann-Pick C1-like 1 (NPC1L1) protein that regulates the cholesterol uptake from the small intestine into the enterocytes."	( [Ezetimibe in clinical practice: from laboratory investigations to the IMPROVE-IT trial results]. Borghi, C; Filardi, PP, )	1.76
"Ezetimibe is a non-statin agent that inhibits intestinal cholesterol absorption, leading to reductions in low-density lipoprotein cholesterol (LDL-C)."	( The Role of Ezetimibe in the Treatment of Cardiovascular Disease. Agarwala, A; Kajani, Z; Miedema, MD; Virani, SS, 2016)	1.53
"Ezetimibe is a selective cholesterol absorption inhibitor that blocks Niemann Pick C1-like 1 protein, but may exert its effect through suppression of CD36."	( The Glucotoxicity Protecting Effect of Ezetimibe in Pancreatic Beta Cells via Inhibition of CD36. Kim, YW; Lee, HW; Moon, JS; Won, KC; Yoon, JS, 2016)	1.42
"Ezetimibe, which is a currently marketed drug, could hold promise as an adjunctive, host-directed therapy for TB."	( Potential effect of ezetimibe against Mycobacterium tuberculosis infection in type II diabetes. Chien, MN; Ho, HT; Kuo, CP; Lin, AB; Lu, YT; Tsai, IF; Wei, TY; Wu, CL, 2017)	2.22
"Ezetimibe is a selective cholesterol absorption inhibitor, which potently inhibits the uptake and absorption of biliary and dietary cholesterol from the small intestine without affecting the absorption of fat-soluble vitamins, triglycerides or bile acids. "	( Cholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 [NPC1L1). Altmann, SW; Basso, F; Davis, HR; Hoos, LM; Lally, SM; Tetzloff, G, 2008)	1.79
"Ezetimibe (EZET) is a cholesterol-lowering agent that specifically inhibits intestinal cholesterol absorption."	( Ezetimibe prevents cholesterol gallstone formation in mice. Amigo, L; Arrese, M; Azocar, L; Jarufe, N; Lammert, F; Miquel, JF; Molina, H; Nervi, F; Pimentel, F; Zúñiga, S, 2008)	2.51
"Ezetimibe is a new lipid-lowering agent that inhibits intestinal absorption of dietary cholesterol. "	( Impact of ezetimibe on atherosclerosis: is the jury still out? Al Badarin, FJ; Kopecky, SL; Kullo, IJ; Thomas, RJ, 2009)	2.2
"Ezetimibe is a selective acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor used in hypercholesterolemia. "	( Burkholderia cenocepacia: a new biocatalyst for efficient bioreduction of ezetimibe intermediate. Banerjee, UC; Basit, A; Singh, A, 2009)	2.03
"Ezetimibe (Zetia) is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia. "	( Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Aoyama, N; Hatakeyama, Y; Izumi, T; Kosugi, R; Machida, Y; Masuda, T; Tojo, T; Yamaoka-Tojo, M; Yoshida, Y, 2009)	2.19
"Ezetimibe is a novel cholesterol absorption inhibitor that reduces the level of low-density lipoprotein (LDL)-cholesterol (C). "	( Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. Michishita, I; Mizuguchi, I; Nozue, T, 2010)	2.19
"Ezetimibe is a drug that inhibits the absorption of both dietary and biliary cholesterol in the small intestine."	( Ezetimbe as potential treatment for cholesterol gallstones: the need for clinical trials. Ahmed, MH, 2010)	1.08
"Ezetimibe is a lipid lowering medication that is able to inhibit dietary cholesterol. "	( Ezetimibe and recent clinical trials: a look on the bright side. Ahmed, MH, 2010)	3.25
"Ezetimibe (EZ) is a novel pharmaceutical compound that reduces intestinal cholesterol absorption."	( Model of intestinal chylomicron over-production and ezetimibe treatment: impact on the retention of cholesterol in arterial vessels. Mangat, R; Proctor, SD; Russell, JC; Uwiera, R; Vine, DF; Wang, Y; Warnakula, S, 2010)	1.33
"Ezetimibe is a potent inhibitor of cholesterol absorption by enterocytes. "	( Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal. Howles, PN; Hui, DY; Ji, Y; Kohan, AB; Lai, J; Li, X; Tso, P; Wang, DQ; Yang, L, 2010)	2.21
"Ezetimibe is a well-tolerated and effective (in terms of achieving LDL-C targets) option inpatients with hyperlipidemia with or without diabetes."	( Ezetimibe in diabetes: more than cholesterol lowering? Katsiki, N; Mikhailidis, DP; Sarigianni, M, 2010)	2.52
"Ezetimibe is a relatively new drug that inhibits the absorption of dietary cholesterol in the small intestine. "	( Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events. Ahmed, MH; Byrne, CD, 2010)	2.09
"Ezetimibe is a novel cholesterol absorption inhibitor used in combination with statins."	( A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms. Choke, E; Cockerill, GW; Dawson, JA; Loftus, IM; Thompson, MM, 2011)	1.09
"Ezetimibe is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia. "	( Ezetimibe and reactive oxygen species. Izumi, T; Masuda, T; Takahira, N; Tojo, T; Yamaoka-Tojo, M, 2011)	3.25
"Ezetimibe is a new lipid-lowering agent that blocks the intestinal absorption of dietary and biliary cholesterol and reduces LDL-C levels, especially when combined with statins."	( Ezetimibe and vascular endothelial function. Ikeda, S; Maemura, K, 2011)	2.53
"Ezetimibe is a lipid-lowering agent that inhibits intestinal absorption of dietary cholesterol. "	( Role of ezetimibe in the prevention of cardiovascular disease: absence of evidence. Goldstein, MR; Mascitelli, L; Pezzetta, F, 2010)	2.24
"Ezetimibe is a lipid-lowering compound that selectively inhibits the absorption of cholesterol and related phytosterols from the intestine. "	( Design and characterization of nanocrystal formulations containing ezetimibe. Gulsun, T; Gursoy, RN; Oner, L, 2011)	2.05
"Ezetimibe is a hypolipidemic agent acting via inhibition of cholesterol absorption from the small intestine. "	( Ezetimibe is effective in the treatment of persistent hyperlipidemia of renal allograft recipients. Benou, A; Fourtounas, C; Goumenos, D; Kalliakmani, P; Koukoulaki, M; Papachristou, E; Roumeliotou, M; Savvidaki, E; Vlachojannis, JG, 2011)	3.25
"Ezetimibe is a cholesterol-lowering agent targeting Niemann-Pick C1-like 1, an intestinal cholesterol transporter. "	( Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes. Choi, JM; Kim, BJ; Kim, L; Kim, SW; Kim, WJ; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ; Sohn, JH; Yang, SJ, 2011)	2.11
"Ezetimibe glucuronide is a substrate of human MRP2. "	( Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Auge, D; Fahrmayr, C; Fromm, MF; König, J; Mieth, M, 2012)	1.82
"Ezetimibe/simvastatin is an effective and generally well tolerated adjunct to dietary therapy for markedly reducing low-density lipoprotein cholesterol (LDL-C) levels and improving other lipid parameters across diverse patient populations."	( Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia. Lyseng-Williamson, KA, 2012)	2.54
"Ezetimibe is a cholesterol uptake inhibitor that targets the Niemann-Pick C1-like 1 cholesterol transporter. "	( Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. Adeli, K; Baker, C; Hussain, MM; Iqbal, J; Lino, M; Naples, M, 2012)	3.26
"Ezetimibe is an inhibitor of cholesterol absorption in the intestine. "	( Ezetimibe improves endothelial function and inhibits Rho-kinase activity associated with inhibition of cholesterol absorption in humans. Fukumoto, Y; Miura, M; Nochioka, K; Shiba, N; Shimokawa, H; Tanaka, S; Zhulanqiqige, do E, 2012)	3.26
"Ezetimibe is an effective LDL-C lowering agent and is safe and well tolerated."	( Ezetimibe therapy: mechanism of action and clinical update. Dayspring, TD; Phan, BA; Toth, PP, 2012)	2.54
"Ezetimibe is a lipid-lowering drug that inhibits the intestinal absorption of dietary and biliary cholesterol by blocking passage across the intestinal wall. "	( Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Bays, HE; Cho, M; Gagné, C; Gumbiner, B; Mata, P; Melino, M; Musliner, TA; Quinto, K; Weiss, SR, 2002)	2.07
"Ezetimibe is a cholesterol absorption inhibitor that significantly lowers low- density lipoprotein cholesterol (LDL-C), and favourably affects triglyceride and high-density lipoprotein cholesterol blood levels in monotherapy and in combination with statins. "	( Ezetimibe. Bays, H, 2002)	3.2
"Ezetimibe is a selective cholesterol absorption inhibitor, with a site of action at the intestinal epithelium."	( The future direction of cholesterol-lowering therapy. Evans, M; Rees, A; Roberts, A, 2002)	1.04
"Ezetimibe is a novel cholesterol absorption inhibitor that blocks intestinal absorption of dietary and biliary cholesterol. "	( Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Dujovne, CA; Knopp, RH; Le Beaut, A; Lipka, LJ; Suresh, R; Veltri, EP, 2003)	2.01
"Ezetimibe is a new cholesterol absorption inhibitor that is safe and effective in total cholesterol and LDL-C reduction."	( Clinical use of ezetimibe. Cheng, AY; Leiter, LA, 2003)	1.39
"Ezetimibe (Zetia) is a novel, selective cholesterol absorption inhibitor. "	( Ezetimibe for hypercholesterolemia. Morris, S; Tiller, R, 2003)	3.2
"Ezetimibe is an option for monotherapy in patients with mild hypercholesterolemia or in those requiring adjunctive drug therapy for reduction of LDL-C levels. "	( Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Cheng, JW; Jeu, L, 2003)	2.04
"Ezetimibe is an effective treatment option that may enable more patients with hypercholesterolemia to achieve optimal cholesterol levels and reduce their risk for coronary heart disease."	( Role of selective cholesterol absorption inhibition in the management of dyslipidemia. Ballantyne, CM, 2004)	1.04
"Ezetimibe is a prototype of a new class of agents that specifically block the absorption of cholesterol from the gastrointestinal tract."	( Hypolipidemic therapy and cholesterol absorption. Farmer, JA; Manhas, A, 2004)	1.04
"Ezetimibe is a cholesterol absorption inhibitor which decreases low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia. "	( Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Cutler, DL; Kosoglou, T; Maxwell, SE; Meyer, I; Musiol, B; Statkevich, P; Veltri, EP; Yang, B; Zhu, Y, 2004)	2.16
"Ezetimibe is a lipid-lowering drug indicated for the treatment of hypercholesterolemia as co-administration with HMG-CoA reductase inhibitors (statins) or as monotherapy. "	( Pharmacodynamic interaction between ezetimibe and rosuvastatin. Boutros, T; Cutler, DL; Kosoglou, T; Maxwell, SE; Statkevich, P; Suresh, R; Tiessen, R; Yang, B; Zhu, Y, 2004)	2.04
"Ezetimibe (Zetia) is a novel inhibitor of intestinal absorption of cholesterol that is approved for the treatment of primary hypercholesterolemia. "	( Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Boutros, T; Kosoglou, T; Reyderman, L; Seiberling, M; Statkevich, P, 2004)	2.04
"Ezetimibe is a US Food and Drug Administration-approved novel drug that targets the absorption of cholesterol in the intestine. "	( Ezetimibe: a novel cholesterol-lowering agent that highlights novel physiologic pathways. Patel, SB, 2004)	3.21
"Ezetimibe is a novel lipid-lowering drug that prevents intestinal absorption of dietary and biliary cholesterol leading to significant reduction in total-C, LDL-C, Apo B, and TG and increases in HDL-C in patients with hypercholesterolemia. "	( Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Affrime, M; Batra, V; Boutros, T; Kosoglou, T; Maxwell, SE; Pember, L; Reyderman, L; Statkevich, P, 2004)	2.01
"Ezetimibe is a specific inhibitor of intestinal cholesterol absorption recently introduced into medical practice; its mechanism of action, however, is still unknown."	( Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane. Corsiero, D; Frick, W; Girbig, F; Hochleitner, EO; Jähne, G; Kramer, W; Lottspeich, F; Orsó, E; Pfenninger, A; Rhein, M; Schmitz, G; Wendler, W, 2005)	1.27
"Ezetimibe is a new cholesterol absorption inhibitor that selectively inhibits dietary and biliary cholesterol absorption from the intestine. "	( [Ezetimibe (Ezetrol): the statins' partner]. Ducobu, J; Sternon, J, 2004)	2.68
"Ezetimibe is a newly approved drug that is a potent and highly specific inhibitor of an intestinal sterol permease; in daily doses as low as 10 mg, it suppresses intestinal absorption of cholesterol and decreases serum LDL cholesterol by approximately 18%."	( An ezetimibe-policosanol combination has the potential to be an OTC agent that could dramatically lower LDL cholesterol without side effects. McCarty, MF, 2005)	1.67
"Ezetimibe is a useful addition to statins in patients with familial hyperlipidaemias but shows a highly variable response profile."	( Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. Chik, G; Crook, MA; Doherty, E; Lumb, PJ; Wierzbicki, AS, 2005)	2.15
"Ezetimibe (EZE) is a cholesterol-lowering drug that inhibits absorption of dietary and biliary cholesterol across the intestinal wall without affecting absorption of bile acids, fatty acids, fat-soluble vitamins, or triglycerides. "	( Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Cho, M; Gagné, C; Gumbiner, B; Johnson-Levonas, AO; Masana, L; Mata, P; Meehan, A; Sirah, W; Troxell, JK, 2005)	2
"Ezetimibe is a recently developed compound, which inhibits intestinal cholesterol absorption. "	( [Optimization of cholesterol reduction principles and clinical results of dual inhibition]. von Hodenberg, E, 2005)	1.77
"Ezetimibe is an effective LDL cholesterol-lowering agent in the kidney transplant population. "	( Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population. Keough-Ryan, T; Kiberd, BA; Kiberd, M; Lawen, J; Puthenparumpil, JJ, 2005)	2.04
"Ezetimibe/simvastatin is a highly efficacious, well-tolerated treatment option for hypercholesterolemic patients."	( Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Abate, N; Ballantyne, CM; King, TR; Palmisano, J; Yuan, Z, 2005)	1.31
"Ezetimibe is a novel lipid-lowering agent that inhibits intestinal absorption of dietary and biliary cholesterol. "	( Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver. Matsui, T; Nakamura, K; Sato, T; Takeuchi, M; Yamagishi, S, 2006)	2.03
"Ezetimibe is a new intestinal cholesterol uptake inhibitor, which reduces LDL cholesterol in monotherapy or in combination with statins."	( [New results in the management of hypercholesterolemia]. Sármán, B, 2005)	1.05
"Ezetimibe (Ezetrol) is a novel cholesterol lowering drug which disposition is not fully understood in man. "	( A LC-MS/MS method to quantify the novel cholesterol lowering drug ezetimibe in human serum, urine and feces in healthy subjects genotyped for SLCO1B1. Cascorbi, I; Oswald, S; Scheuch, E; Siegmund, W, 2006)	2.01
"Ezetimibe is an inhibitor of cholesterol absorption that is liver glucuronized after its rapid absorption, and is mobilized to the enterocytes, where together with its metabolites it exerts hypolipidemic effects, avoiding the absorption of cholesterol, through the reduction of specific cholesterol-transporter enzymes in the gut. "	( [Ezetimibe--pharmacokinetics and therapeutics]. Araújo, RG; Casella Filho, A; Chagas, AC, 2005)	2.68
"Ezetimibe seems to be an effective therapy for uncontrolled hypercholesterolemia in renal transplant patients when combined with high-dose statin therapy."	( Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation. Heemann, U; Kohnle, M; Kribben, A; Philipp, T; Pietruck, F; Witzke, O, 2006)	2.5
"Ezetimibe is a novel cholesterol absorption inhibitor that blocks the translocation of dietary and biliary cholesterol from the gastrointestinal lumen into the intracellular space of jejunal enterocytes."	( Cholesterol absorption blockade with ezetimibe. Davidson, MH; Toth, PP, 2005)	1.32
"Ezetimibe is an inhibitor of the cholesterol uptake transporter Niemann-Pick C1-like protein (NPC1L1). "	( Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in Adam, U; Cascorbi, I; Dazert, E; Fricke, C; Giessmann, T; Haenisch, S; Jedlitschky, G; Kroemer, HK; Oswald, S; Remmler, C; Siegmund, W; Sudhop, T; von Bergmann, K; Wacke, W; Warzok, R; Weitschies, W, 2006)	1.96
"Ezetimibe is a highly-selective inhibitor of cholesterol absorption and simvastatin is an evidence-based inhibitor of cholesterol synthesis."	( Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Daskalopoulou, SS; Mikhailidis, DP, 2006)	1.26
"Ezetimibe (E) is a new cholesterol adsorption inhibitor which prevents the adsorption of dietary and biliary cholesterol by binding to a recently described cholesterol transporter. "	( Safety and effects on the lipid and C-reactive protein plasma concentration of the association of ezetimibe plus atorvastatin in renal transplant patients treated by cyclosporine-A: a pilot study. Barsotti, G; Carpi, A; Consani, C; Manca-Rizza, G; Mantuano, E; Marchetti, V; Panichi, V; Paoletti, S; Sbragia, G; Taccola, D, 2006)	1.99
"Ezetimibe is a selective inhibitor of intestinal cholesterol absorption that results in an additional 15% to 25% reduction of LDL-C."	( Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Genest, J, 2006)	1.36
"Ezetimibe (EZ) is a selective cholesterol absorption inhibitor approved for use in Canada. "	( The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. Francis, GA; Gilchrist, DM; Gyenes, GT; Opgenorth, A; Pearson, GJ; Romney, JS, 2006)	2.04
"Ezetimibe is a novel CAI that inhibits the absorption of dietary and biliary cholesterol without affecting the absorption of triglycerides or fat-soluble vitamins."	( Safety considerations with gastrointestinally active lipid-lowering drugs. Armani, A; Guyton, JR; Jacobson, TA; McKenney, JM, 2007)	1.06
"Ezetimibe is a lipid-lowering agent that inhibits the intestinal absorption of cholesterol and other related phytosterols. "	( Ezetimibe-induced acute pancreatitis. Ahmad, I; Hotiana, M; Hussain, M; Rahman, F; Ruby, E; Usman, H, 2007)	3.23
"Ezetimibe is a novel cholesterol-lowering drug that acts at the brush border of the small intestine."	( Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Johnson, RR; Sweeney, ME, 2007)	2.5
"Ezetimibe is a FDA-approved, intestinal cholesterol absorption inhibitor that lowers plasma LDL cholesterol in humans and animals and inhibits aortic root atherosclerosis in apoE KO mice, but has not been proven to reduce CHD."	( Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Acton, S; Braun, A; Broschat, KO; Krieger, M; Krul, ES; Napawan, N; Stagliano, N; Yesilaltay, A, 2008)	1.32
"Ezetimibe is a drug that impairs intestinal cholesterol absorption and decreases blood cholesterol levels. "	( Ezetimibe plus simvastatin cardiovascular outcomes study program. Padial, LR, 2008)	3.23
"Ezetimibe is a relatively new lipid lowering agent, which is indicated for the treatment of primary hypercholesterolaemia, either as monotherapy or in combination with other hypolipidaemic drugs. "	( Ezetimibe-associated adverse effects: what the clinician needs to know. Elisaf, MS; Florentin, M; Liberopoulos, EN, 2008)	3.23
"Ezetimibe is a safe alternative option for hyperlipidaemic patients intolerant to other lipid lowering drugs as well as a beneficial supplementary agent for patients who do not reach the recommended serum cholesterol level with their current hypolipidaemic treatment. "	( Ezetimibe-associated adverse effects: what the clinician needs to know. Elisaf, MS; Florentin, M; Liberopoulos, EN, 2008)	3.23
"Ezetimibe is a novel cholesterol and plant sterol absorption inhibitor that reduces plasma low-density lipoprotein-cholesterol by selectively binding to the intestinal cholesterol transporter, Niemann-Pick C1-Like 1. "	( Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice. Cook, J; Davis, H; Hoos, L; Hwa, JJ; Tetzloff, G; van Heek, M; Zheng, S, 2008)	3.23
"Ezetimibe is a cholesterol absorption inhibitor that blocks the intestinal absorption of both biliary and dietary cholesterol. "	( Ezetimibe: cholesterol lowering and beyond. Bays, HE; Neff, D; Tershakovec, AM; Tomassini, JE, 2008)	3.23
"Ezetimibe is a novel approach to reduce biliary cholesterol content and a promising strategy for preventing or treating cholesterol gallstones by inhibiting intestinal cholesterol absorption."	( Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Mendez-Sanchez, N; Portincasa, P; Uribe, M; Wang, DQ; Wang, HH, 2008)	2.19
"Ezetimibe is a cholesterol-lowering agent that modulates intestinal absorption of sterols. "	( Severe jaundice following treatment with ezetimibe. Black, PN; Orr, DW; Ritchie, SR, 2008)	2.05
"Ezetimibe is a novel selective inhibitor of intestinal cholesterol absorption, which has been shown to significantly decrease low-density lipoprotein cholesterol (LDL-C). "	( The plasma concentration and LDL-C relationship in patients receiving ezetimibe. Batra, V; Ezzet, F; Kosoglou, T; Lipka, L; Mellars, L; Patrick, J; Statkevich, P; Veltri, E; Wexler, D, 2001)	1.99
"Ezetimibe (SCH 58235) is a novel cholesterol absorption inhibitor that selectively and potently blocks intestinal absorption of dietary and biliary cholesterol."	( Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Bays, HE; Cuffie-Jackson, C; Drehobl, MA; Dujovne, CA; Knopp, RH; Lebeaut, AP; Lipka, LJ; Mellars, LE; Moore, PB; Rosenblatt, S; Toth, PD; Veltri, EP; Yang, B, 2001)	2.03
"4. Ezetimibe is a potent inhibitor of intestinal free cholesterol absorption that does not require exocrine pancreatic function for activity."	( Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Compton, DS; Davis, HR; Farley, C; Hoos, L; van Heek, M, 2001)	2.27
"Ezetimibe (Sch-58235) is a cholesterol absorption inhibitor being developed by Schering-Plough for the potential treatment of atherosclerosis and hypercholesterolemia. "	( Ezetimibe (Schering-Plough). Meng, CQ, 2001)	3.2
"Ezetimibe (SCH58235) is a potent, selective, cholesterol absorption inhibitor. "	( Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Compton, DS; Davis, HR; Hoos, L; Tetzloff, G, 2001)	3.2
"Ezetimibe (Sch-58235) is a cholesterol absorption inhibitor under development by Schering-Plough (SP), in collaboration with Merck, for the potential treatment of hypercholesterolemia. "	( Ezetimibe. Schering-Plough. Meng, CQ, 2002)	3.2

Excerpt	Reference	Relevance
"Ezetimibe has an atheroprotective activity through inhibition of the expression of vascular adhesion molecule-I and vascular CD14, a marker of the infiltration of mononuclear leukocytes."	( Effects of Ezetimibe, Simvastatin, and their Combination on Inflammatory Parameters in a Rat Model of Adjuvant-Induced Arthritis. Ames, FQ; Barbosa, CP; Bersani-Amado, CA; Bracht, L; de Souza Silva-Comar, FM; Tronco, RP, 2017)	1.57
"Ezetimibe has a lipid lowering-independent vascular protective effect in patients with hypercholesterolemia through decreasing oxidative stress."	( Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. Aihara, K; Akaike, M; Fujimoto, E; Higashida, M; Hirata, Y; Kanbara, T; Kinoshita, H; Kitagawa, T; Kitaichi, T; Kurobe, A; Kurobe, H; Matsumoto, T; Matsuoka, Y; Nakayama, T; Nishiya, M; Sata, M; Sugano, M; Sugasawa, N, 2011)	3.25
"Ezetimibe also has an adverse-event profile that is similar to placebo when used as monotherapy or in combination with statins and fenofibrate."	( Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors. Gupta, EK; Ito, MK, )	2.3
"Ezetimibe has a relatively flat dose-response curve and titration is not required."	( Hypolipidemic therapy and cholesterol absorption. Farmer, JA; Manhas, A, 2004)	1.04
"Ezetimibe has a favorable pharmacokinetic profile, which allows it to be administered once daily and to be given in conjunction with statins."	( Ezetimibe: a novel option for lowering cholesterol. Davidson, MH, 2003)	2.48
"Ezetimibe has an antioxidative effect when given as monotherapy or as an add-on to the statin, simvastatin. "	( Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Hussein, O; Itzkovich, Y; Minasian, L; Shestatski, K; Solomon, L; Zidan, J, 2008)	3.23
"Ezetimibe (EZE) has been reported to have anti-inflammatory and antioxidative properties in hepatology-related diseases, but its potential role in SCI remains unclear."	( Ezetimibe attenuates functional impairment via inhibition of oxidative stress and inflammation in traumatic spinal cord injury. Deng, J; Li, H; Rong, W; Xiao, S; Yang, H; Yuan, B; Zhang, C; Zhu, J, 2023)	3.07
"Ezetimibe has unique lipid lowering profile increasing HDL-C concomitant with decreasing LDL-C and TG."	( [An inhibitor of intestinal cholesterol transporter]. Sano, M, 2013)	1.11
"Ezetimibe use has decreased in the US post-ENHANCE, whereas use has gradually but steadily increased in Canada."	( Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada. Jackevicius, CA; Ko, DT; Krumholz, HM; Lu, L; Ross, JS; Tu, JV, 2014)	1.39
"Ezetimibe use has steadily increased in Canada during the past decade even in the absence of evidence demonstrating a beneficial effect on clinical outcomes. "	( Impact of drug policy on regional trends in ezetimibe use. Jackevicius, CA; Ko, DT; Krumholz, HM; Lu, L; Ross, JS; Tu, JV, 2014)	2.11
"Ezetimibe has been reported to provide significant incremental reduction in low-density-lipoprotein cholesterol (LDL-C) when added to a statin; however, its effect on coronary atherosclerosis has not yet been evaluated in detail. "	( Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Dohi, K; Fujimoto, N; Ito, M; Masuda, J; Miyahara, M; Nakamura, M; Nakata, T; Nishikawa, M; Nishimura, Y; Sasou, T; Sawai, T; Tanigawa, T; Yamada, T, 2015)	2.14
"Ezetimibe has been demonstrated to significantly reduce LDL cholesterol levels in combination with statins and recent trials support its role in reducing the risk of cardiovascular events."	( [Ezetimibe in clinical practice: from laboratory investigations to the IMPROVE-IT trial results]. Borghi, C; Filardi, PP, )	1.76
"Ezetimibe has been reported to inhibit viral entry and to reduce BMI and has been proposed as a novel therapeutic agent for chronic hepatitis C (CHC), potentiating the effects of pegylated interferon and ribavirin (peg-IFN/RBV)."	( Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients. Abd-Ellah, MF; Gad, MA; Helal, GK; Mahgoup, EM, 2016)	2.2
"Ezetimibe use has increased rapidly in Australia since receiving public subsidy. "	( Ezetimibe: Use, costs, and adverse events in Australia. David, MC; Hollingworth, SA; Martin, JH; Ostino, R; Tett, SE, 2017)	3.34
"Ezetimibe has an atheroprotective activity through inhibition of the expression of vascular adhesion molecule-I and vascular CD14, a marker of the infiltration of mononuclear leukocytes."	( Effects of Ezetimibe, Simvastatin, and their Combination on Inflammatory Parameters in a Rat Model of Adjuvant-Induced Arthritis. Ames, FQ; Barbosa, CP; Bersani-Amado, CA; Bracht, L; de Souza Silva-Comar, FM; Tronco, RP, 2017)	1.57
"Ezetimibe has been shown to be a selective inhibitor of the Niemann-Pick C1-like 1 (NPC1L1) transporter of cholesterol across the intestinal wall."	( Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia. Miura, S; Saku, K, 2008)	1.38
"Ezetimibe has been reported to improve lipid control in patients with established cardiovascular disease (CVD)."	( Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data regis Ara, R; Chilcott, J; Duenas, A; Durrington, P; Paisley, S; Pandor, A; Tumur, I; Wilkinson, A; Williams, R, 2008)	2.03
"Ezetimibe has proved effective for the treatment of dyslipidemia in these patients."	( Treatment with ezetimibe in kidney transplant recipients with uncontrolled dyslipidemia. Burgos, D; Cabello, M; González Molina, M; Gutiérrez, C; Gutiérrez, E; López, V; Sola, E, 2008)	1.42
"Ezetimibe has not been associated with serious adverse effects."	( Lipid-lowering drugs acting at the level of the gastrointestinal tract. Filippatos, TD; Mikhailidis, DP, 2009)	1.07
"Ezetimibe has been reported to reduce LDL-C safely with both monotherapy and combination therapy with statins."	( Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Aoyama, N; Hatakeyama, Y; Izumi, T; Kosugi, R; Machida, Y; Masuda, T; Tojo, T; Yamaoka-Tojo, M; Yoshida, Y, 2009)	1.46
"Ezetimibe has been more particularly studied in patients with type 2 diabetes whose high cardiovascular risk is well known."	( [Ezetimibe (Ezetrol) in patients with diabetes]. Radermecker, RP; Scheen, AJ, 2009)	1.98
"Ezetimibe therapy has beneficial effects on fibrinolytic activity and homeostasis between oxidant and antioxidant activity in hyperlipidemic patients This may be through lowering lipid levels or other mechanisms such as decreasing insulin resistance and the pleiotropic effects of the drug."	( Ezetimibe therapy and its influence on oxidative stress and fibrinolytic activity. Balci, H; Caner, M; Ercan, MA; Genc, H; Karter, YH; Sipahioglu, F; Turfaner, N; Uzun, H, 2010)	3.25
"Ezetimibe has been reported to reduce LDL-cholesterol safely with both monotherapy and combination therapy with statins."	( Ezetimibe and reactive oxygen species. Izumi, T; Masuda, T; Takahira, N; Tojo, T; Yamaoka-Tojo, M, 2011)	2.53
"Ezetimibe has a lipid lowering-independent vascular protective effect in patients with hypercholesterolemia through decreasing oxidative stress."	( Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. Aihara, K; Akaike, M; Fujimoto, E; Higashida, M; Hirata, Y; Kanbara, T; Kinoshita, H; Kitagawa, T; Kitaichi, T; Kurobe, A; Kurobe, H; Matsumoto, T; Matsuoka, Y; Nakayama, T; Nishiya, M; Sata, M; Sugano, M; Sugasawa, N, 2011)	3.25
"Ezetimibe treatment has been shown to cause significant decreases in plasma cholesterol levels in patients with hypercholesterolemia and familial hypercholesterolemia."	( Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. Adeli, K; Baker, C; Hussain, MM; Iqbal, J; Lino, M; Naples, M, 2012)	2.54
"Ezetimibe has been shown to inhibit dietary cholesterol absorption in animal models and humans, but studies on lymphatic lipid transport have not yet been performed. "	( Ezetimibe inhibits lymphatic transport of esterified cholesterol but not free cholesterol in thoracic lymph duct-cannulated rats. Furukawa, Y; Imaizumi, K; Nakamura, Y; Sato, M; Shiraishi, A; Shirouchi, B; Tomoyori, H, 2012)	3.26
"Ezetimibe has been shown to inhibit cholesterol absorption in animal models, but studies on cholesterol absorption in humans have not been performed thus far."	( Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Igel, M; Kodal, A; Lütjohann, D; Perevozskaya, I; Shah, S; Sudhop, T; Tribble, DL; von Bergmann, K, 2002)	2.01
"Ezetimibe also has an adverse-event profile that is similar to placebo when used as monotherapy or in combination with statins and fenofibrate."	( Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors. Gupta, EK; Ito, MK, )	2.3
"Ezetimibe has minimal systemic absorption and a metabolic pathway involving enterohepatic circulation that allows for once a day administration due to a prolonged half-life."	( Hypolipidemic therapy and cholesterol absorption. Farmer, JA; Manhas, A, 2004)	1.04
"Ezetimibe has a favorable pharmacokinetic profile, which allows it to be administered once daily and to be given in conjunction with statins."	( Ezetimibe: a novel option for lowering cholesterol. Davidson, MH, 2003)	2.48
"Ezetimibe/simvastatin has also been associated with other beneficial effects on lipids, and it achieves greater efficacy than monotherapy with the use of lower, safer doses of the statin."	( Enhanced hypercholesterolemia therapy: the ezetimibe/simvastatin tablet. Cole, P; Rabasseda, X, 2005)	1.31
"Ezetimibe has no effect on the activity of major drug metabolizing enzymes (CYP450), which reduces any potential drug-drug interactions with other medications."	( Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. Davis, HR; Veltri, EP, 2007)	1.06
"Ezetimibe has shown efficacy in the therapy of hypercholesterolemia in renal transplant patients. "	( Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Heemann, U; Kohnle, M; Kribben, A; Nürnberger, J; Philipp, T; Türk, TR; Voropaeva, E; Witzke, O, 2008)	3.23
"Ezetimibe has an antioxidative effect when given as monotherapy or as an add-on to the statin, simvastatin. "	( Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Hussein, O; Itzkovich, Y; Minasian, L; Shestatski, K; Solomon, L; Zidan, J, 2008)	3.23

Excerpt	Reference	Relevance
"Ezetimibe may increase the risk of intestine cancer and has a trend of increasing the risk of breast cancer. "	( Impacts of ezetimibe on risks of various types of cancers: a meta-analysis and systematic review. Bai, H; Ge, J; He, J; Hu, J; Huang, J; Li, H; Liang, X; Sun, S; Wang, X; Zhao, T, 2023)	2.74
"Ezetimibe (EZE) can inhibit both hepatic and intestinal NPC1L1."	( FGF15 promotes hepatic NPC1L1 degradation in lithogenic diet-fed mice. Chen, H; Chen, W; Hu, F; Jiang, X; Li, S; Li, Y; Mo, P; Shan, G; Xu, G; Zhang, F, 2022)	1.44
"Ezetimibe is known to inhibit cholesterol absorption by blocking the activity of Niemann-Pick C1 like 1 (NPC1L1) protein, and simvastatin is known to enhance NPC1L1 expression in the human body's small intestine."	( A prospective mechanism and source of cholesterol uptake by Plasmodium falciparum-infected erythrocytes co-cultured with HepG2 cells. Hayakawa, EH; Kato, H; Nardone, GA; Usukura, J, 2021)	1.34
"Ezetimibe did not cause side effects on FBG (WMD -0.62, 95% CI: -3.13 to 1.90) and HbA1c (WMD 0.07, 95% CI: -0.07 to 0.20%)."	( Effect of ezetimibe on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Shang, H; Wu, H; Wu, J, 2018)	1.6
"Ezetimibe does not increase circulating PCSK9 concentrations while simvastatin does. "	( Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. Benjannet, S; Berthold, HK; Gouni-Berthold, I; Seidah, NG, 2013)	2.08
"Ezetimibe-induced increase in cholesterol efflux was approximately 2.5-fold greater in mice having endogenous ATP-binding cassette G5/G8 heterodimer, the major sterol efflux transporter of enterocytes, than the knockout counterparts, suggesting that the heterodimer confers additional rapid BBM-to-lumen cholesterol efflux in response to NPC1L1 inhibition."	( Ezetimibe Promotes Brush Border Membrane-to-Lumen Cholesterol Efflux in the Small Intestine. Awata, T; Inoue, I; Katayama, S; Murakoshi, T; Nakano, T; Ono, H; Takenaka, Y, 2016)	2.6
"Ezetimibe may increase and stabilize the anticoagulant effect of warfarin, especially in patients taking statins."	( Ezetimibe enhances and stabilizes anticoagulant effect of warfarin. Ako, J; Fujiyoshi, K; Hashikata, T; Hashimoto, T; Ishii, S; Kakizaki, R; Kameda, R; Kitasato, L; Namba, S; Nemoto, T; Shimohama, T; Tojo, T; Yamaoka-Tojo, M, 2017)	2.62
"Ezetimibe may produce serious toxic hepatitis and prompt withdrawal is mandatory in case of a significant abnormality in liver testing after beginning or during treatment with ezetimibe."	( Serious drug-induced liver disease secondary to ezetimibe. Ariza, J; Castellote, J; Girbau, A; Rota, R; Xiol, X, 2008)	1.32
"Ezetimibe increase high density lipoprotein (HDL)-cholesterol only in patients with baseline HDL-cholesterol above 1.3 mM/L (p < 0.05)."	( Impact of ezetimibe on cholesterol subfractions in dyslipidemic cardiac transplant recipients receiving statin therapy. Carrier, M; Cossette, M; Le, VV; Pelletier, GB; Racine, N; White, M, )	1.26
"ezetimibe) plays a pivotal role and is often initiated or modified in rehabilitation centres."	( Drug utilization of ezetimibe in rehabilitation centres: registry analysis of factors influencing prescription and effectiveness of treatment. Benecke, H; Bestehorn, K; Karmann, B; Renner, H; Völler, H; Wegscheider, K, 2006)	1.38
"Ezetimibe may rarely cause hepatotoxicity, severe cholestatic hepatitis, or acute autoimmune hepatitis."	( Severe hepatic side effects of ezetimibe. Becx, MC; Kuypers, KC; Seldenrijk, CA; Stolk, MF, 2006)	2.06

Excerpt	Reference	Relevance
"Ezetimibe treatment significantly ameliorated all the aforementioned parameters."	( Ezetimibe alleviates acetic acid-induced ulcerative colitis in rats: targeting the Akt/NF-κB/STAT3/CXCL10 signaling axis. Abdel-Rahman, RF; Mostafa, RE, 2023)	3.07
"Ezetimibe treatment mitigates UC via downregulation of the Akt/NF-κB/STAT3/CXCL10 signaling axis."	( Ezetimibe alleviates acetic acid-induced ulcerative colitis in rats: targeting the Akt/NF-κB/STAT3/CXCL10 signaling axis. Abdel-Rahman, RF; Mostafa, RE, 2023)	3.07
"Ezetimibe treatment significantly reduced the apparent absorption of 5β,6β-epoxycholesterol (5,6β-epoxy) and its levels in the proximal intestinal mucosa in OC-fed rats. "	( Inhibition of Niemann-Pick C1-Like 1 by Ezetimibe Reduces Dietary 5β,6β-Epoxycholesterol Absorption in Rats. Furukawa, Y; Imaizumi, K; Kawauchi, A; Nakamura, Y; Oku, H; Sato, M; Shirouchi, B, 2019)	2.22
"Ezetimibe treatment for 2 weeks completely restored both biliary and fecal excretion of [(3)H]-tracer in the neutral sterol fraction in L1(LivOnly) mice."	( Ezetimibe inhibits hepatic Niemann-Pick C1-Like 1 to facilitate macrophage reverse cholesterol transport in mice. Guo, F; Jia, L; Jiang, XC; Ma, Y; Miao, H; Ou, J; Wang, N; Xie, P; Yazdanyar, A; Yu, L, 2013)	2.55
"Ezetimibe treatment inhibited intestinal cholesterol absorption by 74% (p < 0.01), but also the bile acid sequestrant cholestyramine decreased cholesterol absorption significantly (24%, p < 0.01)."	( rHDL administration increases reverse cholesterol transport in mice, but is not additive on top of ezetimibe or cholestyramine treatment. Annema, W; Blum, D; Mary, JL; Maugeais, C; Tietge, UJ, 2013)	1.33
"Ezetimibe/simvastatin treatment (versus atorvastatin) was a significant predictor for change in most efficacy variables."	( Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patient Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Robinson, JG; Rosen, JB; Shah, AK; Tershakovec, AM; Tomassini, JE, )	1.04
"Ezetimibe/simvastatin treatment was found to be consistently more effective than atorvastatin at the specified dose comparisons across these subgroups."	( Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patient Ballantyne, CM; Hsueh, WA; Lin, J; Lowe, RS; Robinson, JG; Rosen, JB; Shah, AK; Tershakovec, AM; Tomassini, JE, )	1.04
"Ezetimibe treatment approximately doubled the flux of plasma-derived cholesterol into fecal neutral sterols, in association with increases in total fecal neutral sterol excretion, FCR of plasma cholesterol ester, and plasma de novo cholesterol synthesis. "	( Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans. Boban, D; Davidson, MH; Decaris, J; Glass, A; Hellerstein, M; Killion, S; Lu, Y; Luchoomun, J; Mohammad, H; Musliner, T; Neese, R; Neff, D; Tomassini, JE; Turner, S; Villegas, D; Voogt, J, 2013)	2.08
"Ezetimibe treatment was well tolerated in all patients and resulted in significant reductions in total cholesterol (-11.4%, p = .002), LDL-cholesterol (-20.4%, p = .003), non-HDL-cholesterol (-13.4%, p = .002) and apolipoprotein B (-9.1%, p = .021). "	( Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial. Cofán, M; Forga, MT; Larrousse, M; Leyes, P; Martínez, E; Pérez-Heras, AM; Ros, E; Trabal, J, 2014)	2.23
"Ezetimibe treatment virtually reversed all of the transgene-related phenotypes in DKO/L1(IntOnly) mice."	( Genetic demonstration of intestinal NPC1L1 as a major determinant of hepatic cholesterol and blood atherogenic lipoprotein levels. Jia, L; Ma, Y; Shi, H; Tang, W; Wang, Y; Xie, P; Xue, B; Yu, L; Zhu, H, 2014)	1.12
"Ezetimibe treatment was given to ten patients with diabetes without statin therapy and ten patients with statin therapy. "	( Impact of Ezetimibe Alone or in Addition to a Statin on Plasma PCSK9 Concentrations in Patients with Type 2 Diabetes and Hypercholesterolemia: A Pilot Study. Doi, M; Ito, H; Miyoshi, T; Nakamura, K, 2015)	2.26
"Ezetimibe treatment for 8weeks attenuated increases in oxycholesterols in the HCD group almost completely in liver, but reduced only levels of 4β-hydroxycholesterol in left ventricular (LV) myocardium."	( The pathophysiological role of oxidized cholesterols in epicardial fat accumulation and cardiac dysfunction: a study in swine fed a high caloric diet with an inhibitor of intestinal cholesterol absorption, ezetimibe. Fukuda, D; Hirata, Y; Kim-Kaneyama, JR; Kitagawa, T; Kurobe, H; Lei, XF; Masuzaki, H; Okawa, C; Sata, M; Sato, M; Shimabukuro, M; Soeki, T; Sugasawa, N; Takao, S; Tanaka, Y; Uematsu, E; Yagi, S; Yamada, H; Yanagi, S, 2016)	1.34
"Ezetimibe treatment may be a beneficial and effective strategy for preventing progressing stroke."	( Effects of ezetimibe and anticoagulant combined therapy on progressing stroke: a randomized, placebo-controlled study. Shi, L; Wang, J; Wang, X; Yang, L; Zhao, J; Zhao, P, 2016)	1.55
"Ezetimibe treatment resulted in higher tumor cholesterol."	( Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. Alfaqih, MA; Barry, WT; Dambal, SK; Dewhirst, MW; Freedland, AR; Freedland, SJ; Freeman, MR; Macias, E; Masko, EM; Muehlbauer, MJ; Newgard, CB; Phillips, TE; Pizzo, SV; Poulton, SH; Sanders, SE; Solomon, KR; Sun, S; Valilis, NA, 2017)	1.18
"Ezetimibe treatment (10mg/day) for 6 months significantly decreased circulating levels of LDL-cholesterol, triglycerides and ADMA, while it increased HDL-cholesterol levels."	( Ezetimibe decreases serum levels of asymmetric dimethylarginine (ADMA) and ameliorates renal injury in non-diabetic chronic kidney disease patients in a cholesterol-independent manner. Adachi, H; Fujiwara, N; Kawagoe, Y; Nakamura, T; Okuda, S; Sato, E; Suzuki, T; Ueda, S; Ueda, Y; Yamagishi, S, 2009)	2.52
"Ezetimibe/simvastatin treatment reduced campesterol levels by 68% and sitosterol levels by 62%; reductions were most pronounced in subjects with the highest cholesterol absorption markers at baseline, the so-called high absorbers (P < 0.001)."	( Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. Groen, AK; Hutten, BA; Jakulj, L; Kastelein, JJ; Lutjohann, D; Veltri, EP; Vissers, MN, 2010)	1.33
"Ezetimibe/simvastatin treatment resulted in a significant decrease in ALT (63.78+/-5.12 vs 32.57+/-3.92 U/L; p<0.0001) and AST (50.79+/-3.66 vs 23.68+/-3.42 U/L; p<0.0001). "	( Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Abel, T; Dinya, E; Eldin, MG; Fehér, J; Kovács, A, 2009)	2.08
"Ezetimibe treatment of db/db mice significantly improved vascular endothelial function, which was associated with the restoration of the decreased phospho-Akt and phospho-endothelial nitric-oxide synthase (eNOS)."	( Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice. Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yasuda, O, 2010)	2.52
"Ezetimibe treatment decreased "inflammatory" (SAA-containing) HDL3, and may thus have restored the anti-atherogenic function of HDL particles in ESRD patients."	( Ezetimibe decreases serum amyloid A levels in HDL3 in hemodialysis patients. Hirano, T; Hyodo, T; Nakanishi, N; Nohtomi, K; Taira, T; Watanabe, T, 2010)	3.25
"Ezetimibe treatment also had no impact on NBD-cholesterol absorption by Npc1l1(+/+) mice."	( Use of NBD-cholesterol to identify a minor but NPC1L1-independent cholesterol absorption pathway in mouse intestine. Adams, MR; Cash, JG; Hui, DY; Konaniah, E, 2011)	1.09
"Ezetimibe treatment for 4 weeks significantly suppressed postprandial elevation in TG (area under the incremental curve, from 1419±594 to 968±32 1 mg h/dl, P<0.05), remnant lipoprotein cholesterol (from 66.9±27.6 to 38.9±15.4 mg h/dl, P<0.01) and apoB-48 (from 58.8±27.5 to 36.2±17.0 μg h/ml, P<0.05) concentrations, and postprandial endothelial dysfunction assessed by %FMD (maximum reduction in %FMD, from -2.6±1.1% to -1.2±0.8%, P<0.05), whereas no significant changes were observed in the control group."	( Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Enko, K; Ito, H; Kohno, K; Kusano, KF; Miyoshi, T; Morita, H; Nakamura, K; Yunoki, K, 2011)	2.53
"Ezetimibe treatment significantly reduced serum levels of low-density lipoprotein cholesterol (LDL-C) and malondialdehyde-modified low-density lipoprotein (MDA-LDL). "	( Ezetimibe monotherapy ameliorates vascular function in patients with hypercholesterolemia through decreasing oxidative stress. Aihara, K; Akaike, M; Fujimoto, E; Higashida, M; Hirata, Y; Kanbara, T; Kinoshita, H; Kitagawa, T; Kitaichi, T; Kurobe, A; Kurobe, H; Matsumoto, T; Matsuoka, Y; Nakayama, T; Nishiya, M; Sata, M; Sugano, M; Sugasawa, N, 2011)	3.25
"Ezetimibe treatment has been shown to cause significant decreases in plasma cholesterol levels in patients with hypercholesterolemia and familial hypercholesterolemia."	( Ezetimibe ameliorates intestinal chylomicron overproduction and improves glucose tolerance in a diet-induced hamster model of insulin resistance. Adeli, K; Baker, C; Hussain, MM; Iqbal, J; Lino, M; Naples, M, 2012)	2.54
"Ezetimibe treatment significantly decreased glycated haemoglobin (HbA(1c)), low-density lipoprotein-cholesterol (LDL-C), triglycerides and UAE, and significantly increased high-density lipoprotein-cholesterol and albumin. "	( Ezetimibe reduces urinary albumin excretion in hypercholesterolaemic type 2 diabetes patients with microalbuminuria. Amaha, M; Inoue, H; Kawagoe, Y; Maeda, S; Nakamura, T; Sato, E; Yamagishi, SI, 2012)	3.26
"Ezetimibe treatment in the high-potency group produced significantly greater reductions from baseline in LDL-C than medium-/low-potency groups (-29.1% vs."	( Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients. Lin, J; Lowe, RS; Schaefer, EJ; Shah, AK; Tershakovec, AM; Thongtang, N; Tomassini, JE, 2012)	1.49
"Ezetimibe treatment improved other lipid parameters across groups, including triglyceride, high-density lipoprotein cholesterol, non-high-density ilpoprotein cholesterol, and total cholesterol levels."	( Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness t Battisti, WP; Brady, WE; Denke, MA; Gazzara, RA; McBride, PE; Palmisano, J; Pearson, TA, 2006)	1.39
"Ezetimibe treatment significantly reduced aortic root (57%) and coronary arterial (68%) atherosclerosis, cardiomegaly (24%) and cardiac fibrosis (57%), and prolonged the lives of the mice (27%)."	( Inhibition of intestinal absorption of cholesterol by ezetimibe or bile acids by SC-435 alters lipoprotein metabolism and extends the lifespan of SR-BI/apoE double knockout mice. Acton, S; Braun, A; Broschat, KO; Krieger, M; Krul, ES; Napawan, N; Stagliano, N; Yesilaltay, A, 2008)	1.32
"Treatment with ezetimibe attenuated the IL-1β-induced degradation of the extracellular matrix, including aggrecan and collagen II. "	( Ezetimibe Prevents IL-1β-induced Inflammatory Reaction in Mouse Chondrocytes Han, J; Hu, T; Luo, J; Shen, X; Weng, Q; Zhang, Y, 2022)	2.52
"Treatment with ezetimibe (2.4%) or PCSK9 inhibitors (0.24%) was rare and 62.6% of the overall cohort had an LDL-C above target at ≥70 mg/dl."	( Lipid-lowering treatment among older patients with atherosclerotic cardiovascular disease. Calvert, SB; Cziraky, MJ; Eapen, Z; Granger, CB; Haynes, K; Nanna, MG; Nelson, AJ; Pagidipati, NJ; Shambhu, S, 2023)	1.25
"Treatment with ezetimibe, an FDA-approved drug, resulted in decreased levels of free cholesterol and neutral lipids, and a reduction of bacterial growth in vivo."	( Early cell-autonomous accumulation of neutral lipids during infection promotes mycobacterial growth. McClean, CM; Tobin, DM, 2020)	0.9
"Treatment with ezetimibe resulted in significant FMD changes in MetS patients (from 3.4 to 4.9%, P = 0.002), but not in control patients (from 5.1 to 5.4%, P = 0.216)."	( Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease. Endo, H; Kanazawa, M; Kondo, M; Nakamura, A; Nozaki, E; Sato, K; Takahashi, T, 2019)	1.12
"Treatment with ezetimibe reduced hepatic steatosis, insulin levels, and glucose production from pyruvate in mice fed the high-fat diet, suggesting a reduction of insulin resistance in the liver."	( Ezetimibe prevents hepatic steatosis induced by a high-fat but not a high-fructose diet. Kashiwagi, A; Kume, S; Maegawa, H; Maeno, Y; Morino, K; Nagai, Y; Nishio, Y; Sekine, O; Ugi, S; Ushio, M; Yoshizaki, T, 2013)	2.17
"The treatment of ezetimibe or atorvastatin alone decreased effectively the deposition of lipids in the vascular wall, and a combined dose showed a synergistic effect."	( Characterization of the pharmaceutical effect of drugs on atherosclerotic lesions in vivo using integrated fluorescence imaging and Raman spectral measurements. Chang, WT; Huang, SK; Liau, I; Yang, YC, 2014)	0.73
"Co-treatment with ezetimibe (3 μmol/L) significantly decreased the cellular levels of TC, CE and FC, which was accompanied by elevation of caveolin-1 expression, and by a reduction of SREBP-1 expression and nuclear translocation."	( Ezetimibe suppresses cholesterol accumulation in lipid-loaded vascular smooth muscle cells in vitro via MAPK signaling. Gong, YZ; Li, SX; Liao, DF; Qin, L; Yang, YB; Yang, YX; Zhang, CP; Zhu, N, 2014)	2.17
"Treatment with ezetimibe was associated with decreased cholesterol absorption markers (campesterol-to-cholesterol ratio -43.0%, p = .001; sitosterol-to-cholesterol ratio -41.9%, p = .001) and increased synthesis markers (lathosterol-to-cholesterol ratio 53.2%, p = .005)."	( Effects of ezetimibe on cholesterol metabolism in HIV-infected patients with protease inhibitor-associated dyslipidemia: a single-arm intervention trial. Cofán, M; Forga, MT; Larrousse, M; Leyes, P; Martínez, E; Pérez-Heras, AM; Ros, E; Trabal, J, 2014)	1.13
"Treatment with ezetimibe significantly increased intestinal LDLR (+16.2%; P = .01), 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoAR; +14.0%; P = .04) and acetyl-Coenzyme A acetyltransferase 2 (ACAT-2) mRNA expression (+12.5%; P = .03)."	( Ezetimibe increases intestinal expression of the LDL receptor gene in dyslipidaemic men with insulin resistance. Couture, P; Drouin-Chartier, JP; Lamarche, B; Lemelin, V; Lépine, MC; Tremblay, AJ, 2016)	2.22
"Co-treatment with ezetimibe significantly reduced plasma cholesterol (by 76%; from 1592 to 381mg/dL) and LDL cholesterol (by 78%; from 1515 to 319mg/dL), and increased HDL cholesterol (by 187%; from 16 to 46mg/dL) in high-fat diet mice."	( Vascular protective effects of ezetimibe in ApoE-deficient mice. Hanayama, R; Hayashi, H; Koriyama, H; Mori, M; Morishita, R; Nakagami, H; Osako, MK; Shimizu, H; Takami, Y, 2009)	0.96
"Treatment with ezetimibe 10 mg/day led to significant mean percentage reductions from baseline in plasma concentrations of sitosterol (-43.9%; p < 0.001), campesterol (-50.8%; p < 0.001), low-density lipoprotein (LDL) sterols (-13.1%; p < 0.050), total sterols (-10.3%; p < 0.050) and apolipoprotein (apo) B (-10.1%; p < 0.050). "	( Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study. Johnson-Levonas, AO; Lin, J; Lütjohann, D; Macdonell, G; Musliner, T; Sapre, A; Shah, A; Sirah, W; von Bergmann, K, 2008)	0.98
"Treatment with ezetimibe reduced the fasting serum insulin level (p<0.05) and HbA1c (p<0.05), increased serum adiponectin (p<0.01), and showed a significant decrease of high-sensitive C-reactive protein (hsCRP, p<0.01)."	( The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia. Hasegawa, K; Hiramitsu, S; Hishida, H; Ishiguro, Y; Kani, A; Kato, K; Matsubara, Y; Matsuyama, H; Noba, M; Ozaki, Y; Uemura, A; Yamada, K; Yoshida, S, 2010)	1.05
"Treatment with ezetimibe/simvastatine was effective improving the lipid profile as well as the endothelial function of these patients."	( Effect of ezetimibe-simvastatine over endothelial dysfunction in dyslipidemic patients: assessment by 13N-ammonia positron emission tomography. Alexanderson, E; Alexanderson, G; Calleja, R; García-Rojas, L; Jácome, R; Jiménez, M; Martínez, A; Meave, A; Ochoa, JM, 2010)	1.1
"Treatment with ezetimibe did not change HDL-cholesterol, triglyceride and HbA1c values but caused a significant reduction in remnant like particles-cholesterol (RLP-C, p<0.05) and high-sensitive C-reactive protein (hsCRP, p<0.05)."	( Efficacy and safety of ezetimibe in patients undergoing hemodialysis. Hattori, S; Hattori, Y, 2010)	1.01
"Treatment with ezetimibe/simvastatin resulted in significantly greater reductions in LDL compared with rosuvastatin or atorvastatin (37 vs 25 and 26 mg/dL, respectively; P <0.05). "	( Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients. Furman, A; Lopez, JR; Malmstrom, RA; Meier, JL; Schaefer, S, 2011)	1.03
"Men treated with ezetimibe+statin experienced significantly greater changes in LDL-C (p = 0.0066), non-HDL-C, total cholesterol, triglycerides, HDL-C, apolipoprotein A-I (all p < 0.0001) and apolipoprotein B (p = 0.0055) compared with women treated with ezetimibe+statin."	( Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients. Abramson, BL; Benlian, P; Hanson, ME; Lin, J; Shah, A; Tershakovec, AM, 2011)	0.98
"Dual treatment with ezetimibe/simvastatin is more effective than monotherapy with an HMG-CoA reductase inhibitor (statin), and the addition of ezetimibe to current statin therapy is more effective than doubling the statin dose."	( Ezetimibe/simvastatin: a guide to its clinical use in hypercholesterolemia. Lyseng-Williamson, KA, 2012)	2.14
"Treatment with ezetimibe in an amount sufficient to block intestinal cholesterol absorption caused small intestinal transit time to return to normal."	( Augmented cholesterol absorption and sarcolemmal sterol enrichment slow small intestinal transit in mice, contributing to cholesterol cholelithogenesis. Andrade, JD; Carey, MC; Fox, JG; Kotecha, VR; Xie, M, 2012)	0.72
"Treatment with ezetimibe did not affect food intake, body weight gain, adiposity, or blood pressure in db/db mice. "	( Ezetimibe ameliorates early diabetic nephropathy in db/db mice. Arai, H; Matsubara, T; Minami, M; Murayama, T; Tamura, Y; Yokode, M, 2012)	2.17
"Oral treatment with ezetimibe, significantly decreased plasma lipid levels and prevented the acceleration of plaque destabilization and rupture induced by dietary oxysterol."	( Dietary cholesterol oxidation products accelerate plaque destabilization and rupture associated with monocyte infiltration/activation via the MCP-1-CCR2 pathway in mouse brachiocephalic arteries: therapeutic effects of ezetimibe. Egashira, K; Katsuki, S; Matoba, T; Nakano, K; Osada, K; Sato, K; Sawamura, T; Sunagawa, K, 2012)	0.88
"Treatment with ezetimibe significantly improved lipid profiles. "	( Effects of ezetimibe on visceral fat in the metabolic syndrome: a randomised controlled study. Dohi, Y; Goto, Y; Hashimoto, T; Kimura, G; Okado, T; Takase, H, 2012)	1.12
"Treatment with ezetimibe inhibited establishment of intrahepatic cccDNA and expression of viral replication markers when cells were infected with HBV virions, while we observed no effect when the HBV viral genome was transduced via an adenoviral vector."	( Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Esser, K; Lucifora, J; Protzer, U, 2013)	2.17
"Treatment with ezetimibe/simvastatin also led to greater reductions in total cholesterol, triglyceride, non-high-density lipoprotein cholesterol, and apolipoprotein B levels compared with simvastatin alone; both treatments increased high-density lipoprotein cholesterol levels similarly."	( Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Capece, R; Goldberg, AC; Liu, J; Mitchel, YB; Sapre, A, 2004)	0.97
"Treatment with ezetimibe + statin led to significantly greater reductions in low-density lipoprotein cholesterol (LDL-C), total cholesterol, triglycerides, non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B and increases in HDL-C, compared to statin alone."	( Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Ballantyne, CM; Davidson, MH; Kerzner, B; Lipka, L; Melani, L; Sager, PT; Strony, J; Suresh, R; Veltri, E, 2004)	0.97
"Treatment with ezetimibe reduced TC, LDL-, and triglycerides, and increased high-density lipoprotein cholesterol (HDL-) significantly from baseline, and to similar extents, in both groups, lowering TC from baseline by 13.7% in APOE3/APOE3 homozygotes compared with 12.1% in epsilon4 allele carriers (p = 0.139); LDL-C by 22.8% (vs. "	( Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes. Dani, G; Fazekas, O; Katona, A; Kovacs, H; Mark, L; Szüle, O, 2007)	1.08
"Treatment with ezetimibe, simvastatin or their combination does not alter circulating levels of adiponectin, leptin or resistin in adult healthy men."	( Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Berthold, HK; Chamberland, JP; Gouni-Berthold, I; Krone, W; Mantzoros, CS, 2008)	1
"Treatment with ezetimibe in addition to simvastatin has an additive antioxidative effect on LDL."	( Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. Hussein, O; Itzkovich, Y; Minasian, L; Shestatski, K; Solomon, L; Zidan, J, 2008)	2.13
"(2) Treatment with ezetimibe abolishes the increases in serum and liver cholesterol."	( Dramatically increased intestinal absorption of cholesterol following hypophysectomy is normalized by thyroid hormone. Angelin, B; Bonde, Y; Gälman, C; Matasconi, M; Rudling, M, 2008)	0.66
"Treatment with ezetimibe promoted the dissolution of gallstones by forming an abundance of unsaturated micelles."	( Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones. Mendez-Sanchez, N; Portincasa, P; Uribe, M; Wang, DQ; Wang, HH, 2008)	1.09

Excerpt	Reference	Relevance
" Ezetimibe was safe and well tolerated."	( Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Bruckert, E; Gagné, C; Gaudet, D, 2002)	1.54
" Safety evaluations included adverse event (AE) reports and laboratory test results."	( Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Alizadeh, J; Ballantyne, CM; Lipka, LJ; Sager, PT; Strony, J; Suresh, R; Veltri, EP, 2004)	0.58
" Ezetimibe plus statin therapy was generally well tolerated, with similar incidence of adverse events, serious adverse events and changes in liver function and muscle enzymes in the given age groups compared with statin therapy alone."	( Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Lipka, L; Sager, P; Strony, J; Suresh, R; Veltri, E; Yang, B, 2004)	1.5
" There were no clinically meaningful differences between the EZE and PBO groups with regard to the incidence of treatment-related adverse events (AEs) (19% vs 17%, respectively), discontinuations due to AEs (7% vs 10%), serious AEs (12% vs 17%), consecutive elevations in liver function tests > or =3 times the upper limit of normal (ULN) (0."	( Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Cho, M; Gagné, C; Gumbiner, B; Johnson-Levonas, AO; Masana, L; Mata, P; Meehan, A; Sirah, W; Troxell, JK, 2005)	0.56
" There were no serious adverse events caused by study treatment."	( The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Adu, D; Altmann, P; Armitage, J; Baigent, C; Ball, S; Baxter, A; Blackwell, L; Cairns, HS; Carr, S; Collins, R; Kourellias, K; Landray, M; Leaper, C; Rogerson, M; Scoble, JE; Tomson, CR; Warwick, G; Wheeler, DC, 2006)	0.53
" Tolerability was assessed by adverse event reports and laboratory and vital signs assessments throughout the study."	( Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials. Davidson, M; Feldman, T; Maccubbin, D; Meehan, A; Mitchel, Y; Shah, A; Tribble, D; Veltri, E; Zakson, M, 2006)	0.57
" Clinical chemistry profiles and proportions of adverse events were similar in both groups at baseline and follow-up."	( Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Hughes, EA; Patel, JV, 2006)	0.59
" However, case reports and pharmacokinetic data disclose 3 kinds of adverse effects: (1) the decreased absorption of concomitant medications and sometimes of certain vitamins; (2) the physicochemical alteration of intestinal contents leading to constipation and, very rarely, intestinal obstruction; and (3) modest increases in plasma triglyceride levels due to the alteration of hepatic lipid metabolism."	( Safety considerations with gastrointestinally active lipid-lowering drugs. Armani, A; Guyton, JR; Jacobson, TA; McKenney, JM, 2007)	0.34
" Clinical chemistry profiles and the incidence of adverse events were similar in both groups."	( Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Blagden, MD; Chipperfield, R, 2007)	0.65
" Ezetimibe was well tolerated; no hepatic or muscle-related adverse events were observed."	( Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy. Carranza, J; Cervantes, JL; Fernández, P; González, CA; Leyva, JL; Morales, E; Pavía, A; Redding, FJ; Robles, FJ; Rodríguez, L; Rubio-Guerra, AF; Yza, R; Zacarías, JL, 2007)	1.54
"Addition of ezetimibe to statin treatment was both efficacious and safe when used for further reduction of serum LDL-C in dyslipidaemic patients who had not reached their LDL-C treatment goal while taking statin monotherapy."	( Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy. Carranza, J; Cervantes, JL; Fernández, P; González, CA; Leyva, JL; Morales, E; Pavía, A; Redding, FJ; Robles, FJ; Rodríguez, L; Rubio-Guerra, AF; Yza, R; Zacarías, JL, 2007)	1.01
" Moreover, we aimed to comment on the possible drug interactions of ezetimibe and present current guidelines regarding its safe use."	( Ezetimibe-associated adverse effects: what the clinician needs to know. Elisaf, MS; Florentin, M; Liberopoulos, EN, 2008)	2.02
"Compelling evidence from the majority of the data reviewed here showed that adverse effects associated with ezetimibe use are few and mild without having been associated with serious clinical outcomes."	( Ezetimibe-associated adverse effects: what the clinician needs to know. Elisaf, MS; Florentin, M; Liberopoulos, EN, 2008)	2
"Ezetimibe is a safe alternative option for hyperlipidaemic patients intolerant to other lipid lowering drugs as well as a beneficial supplementary agent for patients who do not reach the recommended serum cholesterol level with their current hypolipidaemic treatment."	( Ezetimibe-associated adverse effects: what the clinician needs to know. Elisaf, MS; Florentin, M; Liberopoulos, EN, 2008)	3.23
"001) because of clinical adverse experiences (primarily flushing)."	( Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. Brown, BG; Fazio, S; Guyton, JR; Polis, A; Tershakovec, AM; Tomassini, JE, 2008)	0.62
" Adverse event (AE) reports for EZE monotherapy-treated patients were summarised for 3-month intervals to allow for comparison with the placebo group of the 3-month base studies."	( Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years. Dujovne, CA; Maccubbin, D; McCrary Sisk, C; Strony, J; Suresh, R; Veltri, E, 2008)	0.66
" During the extension study, investigators assessed adverse events (AEs)."	( Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Bays, H; Capece, R; Liu, J; Sapre, A; Taggart, W; Tershakovec, A, 2008)	0.63
" Safety and tolerability were assessed through clinical and laboratory adverse experiences (AEs)."	( Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study. Hanson, ME; Strony, J; Veltri, EP; Yang, B, 2008)	0.62
" CPK surveillance is recommended because of a slight continued risk of adverse effects."	( The efficacy and safety of ezetimibe for treatment of dyslipidemia after heart transplantation. Castro-Beiras, A; Crespo-Leiro, MG; Flores, X; Franco, R; Grille, Z; Marzoa, R; Mosquera, V; Naya, C; Paniagua, MJ; Rodriguez, JA, 2008)	0.64
" The incidences of clinical and laboratory adverse experiences were generally similar between groups."	( Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Bays, HE; Bird, SR; Conard, SE; Leiter, LA; Lowe, RS; Rubino, J; Tershakovec, AM; Tomassini, JE, 2008)	0.66
" Safety and tolerability profiles and incidence of liver and muscle adverse experiences were generally similar between groups."	( Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Bays, H; Bird, S; Conard, S; Hanson, ME; Leiter, LA; Rubino, J; Tershakovec, AM; Tomassini, JE, 2008)	0.66
"These findings indicate that ezetimibe/simvastatin combination therapy is safe and effective in patients with type 2 diabetes and nonalcoholic fatty liver disease."	( [Efficacy and safety of ezetimibe/simvastatin combination therapy in patients with type 2 diabetes and nonalcoholic fatty liver disease]. Abel, T; Dinya, E; Fehér, J; Gamal Eldin, M; Kovács, A, 2009)	0.95
" The incidence of liver, muscle, and gastrointestinal-, hepatitis- and allergic reaction/rash-related adverse events were low and generally similar to those in previous studies of ezetimibe/simvastatin and/or atorvastatin."	( Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). Adewale, AJ; Ballantyne, CM; Grundy, SM; Hsueh, WA; Parving, HH; Polis, AB; Robinson, JG; Rosen, JB; Tershakovec, AM; Tomassini, JE, 2009)	0.82
" Efficacy and safety were evaluated using lipid profiles, trough calcineurin inhibitor levels, allograft function, and adverse effects."	( The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Choi, BS; Hwang, HS; Hyoung, BJ; Jeon, YJ; Kim, YS; Lee, SY; Song, JC; Yang, CW; Yoon, HE, 2009)	0.65
" No significant change in the trough calcineurin inhibitor levels or allograft function occurred, and no serious adverse effects were observed."	( The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Choi, BS; Hwang, HS; Hyoung, BJ; Jeon, YJ; Kim, YS; Lee, SY; Song, JC; Yang, CW; Yoon, HE, 2009)	0.65
"Ezetimibe and low-dose statin treatment is safe and effective as a primary treatment for dyslipidemia in renal transplant patients."	( The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients. Choi, BS; Hwang, HS; Hyoung, BJ; Jeon, YJ; Kim, YS; Lee, SY; Song, JC; Yang, CW; Yoon, HE, 2009)	2.09
"Statins are safe in PBC patients who might benefit from their use."	( Statins in primary biliary cirrhosis: are they safe? Abu Rajab, M; Kaplan, MM, 2010)	0.36
"These results showed that both the combined ezetimibe/simvastatin treatment and the simvastatin monotherapy proved to be effective and safe in patients with NAFLD and in cases of high cardiovascular risk."	( Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Abel, T; Dinya, E; Eldin, MG; Fehér, J; Kovács, A, 2009)	0.9
" The primary end point, the safety of E/S plus niacin, included prespecified adverse events (ie, liver, muscle, discontinuations due to flushing, gallbladder-related, cholecystectomy, fasting glucose changes, new-onset diabetes)."	( Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Adewale, AJ; Fazio, S; Guyton, JR; Polis, AB; Ryan, NW; Tershakovec, AM; Tomassini, JE, 2010)	0.61
" Overall, adverse events were similar in the 2 treatment groups."	( Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. Goldberg, AC; Jones, PH; Kelly, MT; Knapp, HR; Setze, CM; Sleep, DJ; Stolzenbach, JC, 2010)	0.59
" Incidences of adverse events or creatine kinase elevations were similar between groups."	( Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Betteridge, DJ; Brudi, P; Farnier, M; Guyton, JR; Johnson-Levonas, AO; Leiter, LA; Lin, J; Shah, A, 2011)	0.6
"Under standard clinical practice conditions, ezetimibe appears to be effective and safe for the control LDLc, thus making it possible to reach the therapeutic objectives proposed by the ATP-III in a high number of patients, especially when associated to statins."	( [Efficacy and safety of ezetimibe in vascular risk units]. Díaz Díaz, JL; Díaz Peromingo, JA; Martínez Ramonde, T; Pena Seijo, M; Pose Reino, A; Suárez Tembra, M, 2011)	0.94
" Adverse experiences were generally comparable among the groups."	( Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Bays, HE; Davidson, MH; Flaim, D; Jones-Burton, C; Lowe, RS; Massaad, R; Tershakovec, AM, 2011)	0.68
" Both monotherapy and combination therapy groups had similar incidences of all types of adverse events."	( Retrospective study on antihyperlipidemic efficacy and safety of simvastatin, ezetimibe and their combination in Korean adults. Bae, JW; Choi, CI; Jang, CG; Kim, MJ; Lee, SY; Lee, YH, 2011)	0.6
" The levels of LDL-C in the A+E group were significantly lower than those in the A group at follow-up, whereas there were no differences in major adverse cardiac events, in-stent restenosis, or in-stent % diameter stenosis (DS) between the groups."	( Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. Arimura, T; Ike, A; Iwata, A; Kawamura, A; Miura, S; Nishikawa, H; Saku, K; Sugihara, M, 2012)	0.62
" No treatment-related serious adverse events occurred."	( Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 stu Abrahamsen, TE; Desai, NR; Giugliano, RP; Hoffman, EB; Huang, F; Kohli, P; Liu, T; McDonald, ST; Mohanavelu, S; Rogers, WJ; Sabatine, MS; Scott, R; Somaratne, R; Wasserman, SM, 2012)	0.38
"63 hyperlipidemic patients with statin induced adverse effects were involved in the study."	( Effect of apolipoprotein E genotypes on the efficacy of ezetimibe monotherapy in patients with statin induced adverse effects. Balogh, I; Harangi, J; Harangi, M; Köbling, T; Márk, L; Paragh, G; Seres, I; Varga, J, 2013)	0.64
" Reports of adverse experiences were generally similar among groups."	( Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia. Averna, M; Bays, HE; Brudi, P; De Pellegrin, A; Farnier, M; Giezek, H; Lee, R; Lowe, RS; Majul, C; Muller-Wieland, D; Triscari, J, 2013)	0.7
" Safety of the combination was examined in terms of the type, onset, and severity of adverse drug reactions (ADRs)."	( Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study. Abe, K; Taneyama, T; Teramoto, T, 2013)	0.62
"Bezafibrate in combination with ezetimibe is safe and effective, and is potentially useful for comprehensive management of dyslipidemia."	( Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study. Abe, K; Taneyama, T; Teramoto, T, 2013)	0.9
" We aimed to compare the efficacy of and adverse effects from statin uptitration versus statin in combination with ezetimibe since only a few studies have addressed this question."	( Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Kumagai, H; Shuto, H; Suzuki, H; Watanabe, Y, 2013)	0.84
" The observation period was 1 year during which time patients were checked regularly in clinic for adverse effects as well as for usual laboratory examinations."	( Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Kumagai, H; Shuto, H; Suzuki, H; Watanabe, Y, 2013)	0.63
" No serious adverse effects such as rhabdomyolysis were noted in either group."	( Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Kumagai, H; Shuto, H; Suzuki, H; Watanabe, Y, 2013)	0.63
"When statin uptitration produces adverse effects such as myopathy, combination therapy with ezetimibe is recommended instead of statin alone."	( Comparative efficacy and adverse effects of the addition of ezetimibe to statin versus statin titration in chronic kidney disease patients. Kumagai, H; Shuto, H; Suzuki, H; Watanabe, Y, 2013)	0.85
" However, the ability to detect potentially beneficial changes in other lipoproteins such as lipoprotein (a), triglycerides, high-density lipoprotein cholesterol (HDL-C), and apolipoprotein (Apo) A1, and adverse events (AEs) was limited by sample sizes of individual trials."	( Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Albizem, M; Giugliano, RP; Kim, JB; Koren, MJ; Liu, T; Raal, FJ; Roth, EM; Sabatine, MS; Scott, R; Somaratne, R; Stein, EA; Sullivan, D; Wasserman, SM; Weiss, R; Yang, J, 2014)	0.4
" Adverse events (AEs) and serious AEs with evolocumab were reported in 56."	( Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Albizem, M; Giugliano, RP; Kim, JB; Koren, MJ; Liu, T; Raal, FJ; Roth, EM; Sabatine, MS; Scott, R; Somaratne, R; Stein, EA; Sullivan, D; Wasserman, SM; Weiss, R; Yang, J, 2014)	0.4
" Intolerance was defined as inability to take at least 2 different statins because of muscle-related adverse events (AEs), 1 at the lowest approved starting dose."	( Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. Baccara-Dinet, MT; Bruckert, E; Gipe, D; Guyton, JR; Jacobson, TA; Moriarty, PM; Thompson, PD, )	0.13
" This class side effect appears to be dose dependent, with more lipophilic statin (i."	( Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Macchi, C; Magni, P; Morlotti, B; Ruscica, M; Sirtori, CR, 2015)	0.42
"The incidence of adverse events was similar between ezetimibe-statin combination therapy and statin monotherapy; thus, we recommend combination therapy for patients with hypercholesterolaemia at high risk for cardiovascular and cerebrovascular disease."	( Safety of coadministration of ezetimibe and statins in patients with hypercholesterolaemia: a meta-analysis. Huang, W; Luo, L; Ren, F; Tang, L; Yuan, X; Zheng, Y; Zhu, H, 2015)	0.96
" Alirocumab was generally well tolerated, with no evidence of an excess of treatment-emergent adverse events."	( Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Blom, D; Cannon, CP; Cariou, B; Chaudhari, U; Colhoun, HM; Lorenzato, C; McKenney, JM; Pordy, R, 2015)	0.42
" Two authors independently selected trials fulfilling these criteria: RCTs comparing Ezetimibe±statin or another lipid-lowering drug against placebo, or against the same lipid-lowering drug at the same dosage, with a follow-up at least 24 weeks and one or more of these outcomes: all-cause mortality, cardiovascular (CV) mortality, stroke, myocardial infarction (MI), cancer, serious adverse events (SAEs); we assessed the risk of bias using the Cochrane checklist."	( Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. Battaggia, A; Donzelli, A; Font, M; Galvano, A; Molteni, D, 2015)	0.92
"The addition of ezetimibe to rosuvastatin appears to be safe in patients with HIV."	( Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Bennett, MT; Bondy, G; Frohlich, J; Johns, K; Saeedi, R, 2015)	1.03
" Treatment-emergent adverse events occurred in 56."	( Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial. Averna, M; Colhoun, HM; Donahue, S; Du, Y; Farnier, M; Hanotin, C; Jones, P; Severance, R; Steinhagen-Thiessen, E, 2016)	0.67
"Alirocumab produced greater LDL-C reductions than ezetimibe in statin-intolerant patients, with fewer skeletal-muscle adverse events vs atorvastatin."	( Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. Baccara-Dinet, MT; Bergeron, J; Bruckert, E; Cannon, CP; Du, Y; Gipe, DA; Guyton, JR; Jacobson, TA; Kopecky, SL; Moriarty, PM; Pordy, R; Thompson, PD; Zieve, FJ, )	0.66
"Ezetimibe and simvastatin treatment, either as a single pill or the combined use of the individual compounds, offers limited additional risk compared with simvastatin monotherapy and comprises a safe and efficient choice for dyslipidemia treatment in high-risk and diabetic patients."	( The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Elisaf, MS; Filippatos, TD; Kei, AA, 2016)	2.24
" Myotoxicity is a frequent side effect of statin therapy and one of the main causes of statin discontinuation, which limits effective treatment of patients at risk of or with cardiovascular disease."	( Statin-related myotoxicity. Fernandes, V; Pérez, A; Santos, MJ, 2016)	0.43
" Evolocumab was well tolerated, with balanced rates of adverse events leading to discontinuation of evolocumab vs."	( Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. Bridges, I; Dent, R; Djedjos, CS; Jacobson, TA; Miller, M; Preiss, D; Rosenson, RS, 2016)	0.43
" Fenofibrate use was associated with some changes in laboratory measurements, but there was no differential adverse effect between the combination therapy and fenofibrate monotherapy."	( Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study. Kono, S; Nakaya, N; Oikawa, S; Sasaki, J; Yamashita, S, 2017)	0.69
"The combination therapy with fenofibrate and ezetimibe substantially reduces concentrations of LDL cholesterol and triglycerides and is safe in a long-term treatment in Japanese patients with combined hyperlipidemia."	( Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study. Kono, S; Nakaya, N; Oikawa, S; Sasaki, J; Yamashita, S, 2017)	0.95
" Treatment-emergent adverse events occurred in 77."	( Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Baccara-Dinet, MT; Civeira, F; Farnier, M; Gaudet, D; Guyton, JR; Lecorps, G; Lepor, N; Manvelian, G; Stroes, E; Watts, GF, 2016)	0.43
"Previous individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall treatment-emergent adverse event (TEAE) rates comparable with controls."	( Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials. Bays, HE; Chaudhari, U; Jones, PH; Lorenzato, C; Miller, K; Pordy, R; Robinson, JG, 2016)	0.43
"To analyze the subsidized use and reported adverse events of ezetimibe, used to lower cholesterol, in Australia over the 11 years following its inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2004."	( Ezetimibe: Use, costs, and adverse events in Australia. David, MC; Hollingworth, SA; Martin, JH; Ostino, R; Tett, SE, 2017)	2.14
" Adverse event data were obtained from the Therapeutic Goods Administration."	( Ezetimibe: Use, costs, and adverse events in Australia. David, MC; Hollingworth, SA; Martin, JH; Ostino, R; Tett, SE, 2017)	1.9
" The major reported adverse events were musculoskeletal and connective tissue disorders and gastrointestinal disorders."	( Ezetimibe: Use, costs, and adverse events in Australia. David, MC; Hollingworth, SA; Martin, JH; Ostino, R; Tett, SE, 2017)	1.9
" All patients were assessed for adverse events (AEs), clinical laboratory data, and vital signs."	( A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE Ahn, JC; Bae, JH; Cha, DH; Cho, SK; Chung, WS; Han, KR; Hong, SJ; Hyon, MS; Jeon, DW; Jeong, HS; Kim, HS; Kim, SY; Kim, W; Kwan, J; Lee, HC; Rha, SW; Rhee, MY; Shin, JH; Sung, KC; Won, KH; Yoo, BS; Yoo, KD, 2018)	0.68
" There were no significant differences in the incidence of overall AEs, adverse drug reactions, and serious AEs; laboratory findings, including liver function test results and creatinine kinase levels, were comparable between groups."	( A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE Ahn, JC; Bae, JH; Cha, DH; Cho, SK; Chung, WS; Han, KR; Hong, SJ; Hyon, MS; Jeon, DW; Jeong, HS; Kim, HS; Kim, SY; Kim, W; Kwan, J; Lee, HC; Rha, SW; Rhee, MY; Shin, JH; Sung, KC; Won, KH; Yoo, BS; Yoo, KD, 2018)	0.68
" Safety parameters were assessed by adverse event reports and laboratory assessments throughout the study."	( Short-Term Efficacy and Safety of Adding Ezetimibe to Current Regimen of Lipid-Lowering Drugs in Human Immunodeficiency Virus-Infected Thai Patients Treated with Protease Inhibitors. Boonthos, K; Manosuthi, W; Pengsuparp, T; Puttilerpong, C, 2018)	0.75
" Bempedoic acid was well tolerated; rates of treatment-emergent adverse events, muscle-related adverse events, and discontinuations were similar in the bempedoic acid and placebo treatment groups."	( Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Ballantyne, CM; Banach, M; Hanselman, JC; Leiter, LA; Lepor, NE; Mancini, GBJ; Zhao, X, 2018)	0.74
"Recent studies have highlighted the possible risk of neuropsychiatric adverse effects during treatment with lipid-lowering medications."	( Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study. Alfadhel, M; Alghamdi, F; Alghamdi, J; Alghamdi, S; Matou-Nasri, S; Padmanabhan, S, 2018)	0.48
" No significant adverse effects were associated with ezetimibe treatment."	( Risk of Neuropsychiatric Adverse Effects of Lipid-Lowering Drugs: A Mendelian Randomization Study. Alfadhel, M; Alghamdi, F; Alghamdi, J; Alghamdi, S; Matou-Nasri, S; Padmanabhan, S, 2018)	0.73
"Due to the myopathic adverse events of statins, safer alternatives are being studied."	( Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials. Gan, X; He, C; Huang, R; Luo, S; Wang, X, )	0.13
"ETC-1002 is a safe and effective lipid-lowering agent and may be a suitable alternative in statin-intolerant pa-tients."	( Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials. Gan, X; He, C; Huang, R; Luo, S; Wang, X, )	0.13
" The primary endpoints included the incidence of adverse cardiovascular events and changed in blood lipids and high-sensitivity C-reactive protein (hs-CRP)."	( Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study. Huang, Z; Li, Q; Li, X; Ye, W; Zhang, Q, 2019)	0.82
"Statin/ezetimibe fixed-dose combination is often used as statin monotherapy; however, no study has analyzed its adverse effect (AE) signals."	( Comparison of signal detection between statin and statin/ezetimibe fixed-dose combination using the Korea Adverse Events Reporting System Database, 2005 - 2016 . Chun, Y; Ha, D; Lee, YJ; Shin, JY, 2019)	1.21
"We used data from the Korea Adverse Events Reporting System database from 2005 to 2016."	( Comparison of signal detection between statin and statin/ezetimibe fixed-dose combination using the Korea Adverse Events Reporting System Database, 2005 - 2016 . Chun, Y; Ha, D; Lee, YJ; Shin, JY, 2019)	0.76
" Treatment-emergent adverse events were similar between alirocumab (68."	( Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials. Deedwania, P; Elassal, J; Ferdinand, KC; Jacobson, TA; Koren, A; Thompson, D, )	0.13
" No significant difference was found in the incidence of laboratory-related adverse events (AEs) between statin combination therapy and monotherapy."	( The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis. Hu, H; Lin, S; Liu, T; Xu, H; Yang, J; Yao, Q; Yu, Y; Zhu, Y, 2020)	0.81
" Treatment-emergent adverse events occurred in 68."	( ODYSSEY EAST: Alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. Baccara-Dinet, MT; Chen, J; Chen, R; Chopra, VK; Han, Y; Huang, Z; Kuanprasert, S; Li, J; Ma, C; Ma, Y; Manvelian, G; Su, G; Yao, Z; Yuan, Z; Zhang, S; Zhao, Q, )	0.39
" However, the onset of adverse events associated with their use prevents to achieve the therapeutic targets recommended by the guidelines (GL) for the management of dyslipidemia."	( Effectiveness and Safety of Novel Nutraceutical Formulation Added to Ezetimibe in Statin-Intolerant Hypercholesterolemic Subjects with Moderate-to-High Cardiovascular Risk. Fratter, A; Lenti, S; Mazza, A; Nicoletti, M; Pellizzato, M; Rigatelli, G; Torin, G, 2021)	0.86
" It is still controversial whether lower LDL-C levels are associated with significant clinical adverse effects (e."	( How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Blumenthal, RS; Dhindsa, DS; Karagiannis, AD; Mehta, A; Orringer, CE; Sperling, LS; Stone, NJ; Virani, SS, 2021)	0.62
"00)], and reduced risk of myocardial infarction, cerebrovascular events, revascularization, and major adverse cardiovascular events (MACE)."	( Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. Alkhouli, M; Blaha, MJ; Blumenthal, RS; Kalra, A; Khan, MS; Khan, MU; Khan, MZ; Khan, SU; Michos, ED; Rashid, M; Virani, SS, 2022)	0.72
" We also compared safety based on the adverse events reported for the two groups."	( Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies. Choi, HD; Shin, KH, 2022)	0.98
" In terms of safety, there were no significant differences in treatment-related adverse events between the two treatments."	( Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies. Choi, HD; Shin, KH, 2022)	0.98
"Statin-ezetimibe combination therapy enhances levels of LDL-C and other lipids without increasing the risk of adverse events compared with statin monotherapy."	( Comparison of Efficacy and Safety of Statin-Ezetimibe Combination Therapy with Statin Monotherapy in Patients with Diabetes: A Meta-Analysis of Randomized Controlled Studies. Choi, HD; Shin, KH, 2022)	1.44
" Safety and tolerability were assessed by laboratory values and adverse events."	( Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. Ballantyne, CM; Banach, M; Bays, H; Bloedon, LT; Catapano, AL; Duell, PB; Goldberg, AC; Gotto, AM; Laufs, U; Leiter, LA; MacDougall, D; Mancini, GBJ; Ray, KK; Zhang, Y, )	0.13
" Thus, as an alternative to high-intensity statin monotherapy, moderate-intensity statin with ezetimibe combination therapy can lower LDL cholesterol concentrations effectively while reducing adverse effects."	( Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial. Ahn, CM; Cho, YH; Choi, D; Heo, JH; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Rha, SW; Yun, KH, 2022)	1.18
" Adverse events (AEs), clinical laboratory data, and vital signs were assessed in all patients."	( A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hyp Ahn, JC; Cha, DH; Cho, EJ; Cho, JM; Choi, CU; Choi, SY; Gwon, HC; Han, KH; Han, KR; Hong, SJ; Hong, YJ; Jeong, HS; Jeong, YH; Jo, SH; Kang, HJ; Kim, BK; Kim, SH; Kim, WS; Lee, SY; Park, TH; Woo, SI, 2022)	0.91
" There were no significant differences in the incidence of overall AEs and adverse drug reactions."	( A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hyp Ahn, JC; Cha, DH; Cho, EJ; Cho, JM; Choi, CU; Choi, SY; Gwon, HC; Han, KH; Han, KR; Hong, SJ; Hong, YJ; Jeong, HS; Jeong, YH; Jo, SH; Kang, HJ; Kim, BK; Kim, SH; Kim, WS; Lee, SY; Park, TH; Woo, SI, 2022)	0.91
" The incidence of adverse events and adverse drug reactions was not significantly different between the two groups receiving the fixed-dose combination and monotherapy."	( Efficacy and Safety of Pitavastatin/Ezetimibe Fixed-Dose Combination vs. Pitavastatin: Phase III, Double-Blind, Randomized Controlled Trial. Ako, J; Suganami, H; Tajima, S; Tanigawa, R; Tsujita, K; Yokote, K, 2023)	1.19
" The numbers of patients with adverse drug reactions (ADRs) were compared as safety variables."	( A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023)	1.1

Excerpt	Reference	Relevance
"The purpose of this study was to develop a population pharmacokinetic (PPK) model for ezetimibe that incorporates enterohepatic recirculation."	( A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Batra, VK; Ezzet, F; Kosoglou, T; Krishna, G; Statkevich, P; Wexler, DB, 2001)	0.75
" In Study 1, there were no indications of pharmacokinetic interactions between simvastatin and ezetimibe."	( Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Affrime, MB; Batra, VK; Cutler, DL; Kosoglou, T; Maxwell, SE; Mellars, L; Meyer, I; Patrick, JE; Statkevich, P; Veltri, EP; Yang, B; Zhu, Y, 2002)	0.76
" This study investigated the potential for pharmacodynamic and/or pharmacokinetic interactions between ezetimibe and lovastatin."	( Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Cutler, DL; Kosoglou, T; Maxwell, SE; Meyer, I; Musiol, B; Statkevich, P; Veltri, EP; Yang, B; Zhu, Y, 2004)	0.93
" The primary objectives of this study were to evaluate the pharmacodynamic effects and safety of the co-administration of ezetimibe and the new statin rosuvastatin."	( Pharmacodynamic interaction between ezetimibe and rosuvastatin. Boutros, T; Cutler, DL; Kosoglou, T; Maxwell, SE; Statkevich, P; Suresh, R; Tiessen, R; Yang, B; Zhu, Y, 2004)	0.81
" Blood samples were collected for ezetimibe and rosuvastatin pharmacokinetic evaluation prior to the first and last dose and at frequent intervals after the last dose (day 14) of study treatment."	( Pharmacodynamic interaction between ezetimibe and rosuvastatin. Boutros, T; Cutler, DL; Kosoglou, T; Maxwell, SE; Statkevich, P; Suresh, R; Tiessen, R; Yang, B; Zhu, Y, 2004)	0.88
" There was no significant pharmacokinetic drug interaction between ezetimibe and rosuvastatin."	( Pharmacodynamic interaction between ezetimibe and rosuvastatin. Boutros, T; Cutler, DL; Kosoglou, T; Maxwell, SE; Statkevich, P; Suresh, R; Tiessen, R; Yang, B; Zhu, Y, 2004)	0.83
" Pharmacokinetic parameters were assessed on day 14."	( Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Cutler, DL; Fruchart, JC; Guillaume, M; Kosoglou, T; Maxwell, SE; Pember, LJ; Reyderman, L; Statkevich, P; Veltri, EP, 2004)	0.56
"The primary pharmacodynamic parameter was percentage change from baseline in LDL-C concentration following co-administration of ezetimibe and fenofibrate vs either drug alone, or placebo."	( Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Cutler, DL; Fruchart, JC; Guillaume, M; Kosoglou, T; Maxwell, SE; Pember, LJ; Reyderman, L; Statkevich, P; Veltri, EP, 2004)	0.76
" In a separate pilot study, co-administration of ezetimibe and lovastatin resulted in a significant pharmacodynamic interaction, leading to an additive reduction in LDL-C."	( Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Boutros, T; Kosoglou, T; Reyderman, L; Seiberling, M; Statkevich, P, 2004)	0.85
" The point estimates based on the log-transformed Cmax and AUC values for lovastatin and beta-hydroxylovastatin were 113% and 119%, respectively, for co-administration of ezetimibe with lovastatin vs."	( Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Boutros, T; Kosoglou, T; Reyderman, L; Seiberling, M; Statkevich, P, 2004)	0.79
" Co-administration of ezetimibe and lovastatin is unlikely to cause a clinically significant pharmacokinetic drug interaction."	( Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers. Boutros, T; Kosoglou, T; Reyderman, L; Seiberling, M; Statkevich, P, 2004)	0.91
" The estimated terminal half-life of ezetimibe and ezetimibe-glucuronide is approximately 22 hours."	( Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Alton, KB; Bergman, AJ; Johnson-Levonas, AO; Kosoglou, T; Paolini, JF; Statkevich, P, 2005)	2.04
"The objective of this study was to evaluate the pharmacodynamic effects and safety of the co-administration of ezetimibe and fluvastatin in healthy hypercholesterolemic subjects at clinically-relevant doses and to evaluate the potential for a pharmacokinetic drug interaction between ezetimibe and fluvastatin."	( The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. Cutler, DL; Kosoglou, T; Maxwell, S; Reyderman, L; Statkevich, P, 2005)	0.77
" The apparent decrease in fluvastatin exposure on administration with ezetimibe was likely to be due to the parallel study design and two pharmacokinetic outliers and is considered of no clinical significance."	( The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe. Cutler, DL; Kosoglou, T; Maxwell, S; Reyderman, L; Statkevich, P, 2005)	0.79
"This study was conducted to evaluate the potential for pharmacokinetic interaction between fenofibrate and ezetimibe in healthy subjects."	( Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. Achari, R; Burt, DA; Chira, T; Edeki, T; Gustavson, LE; Kelly, MT; Rieser, MJ; Schweitzer, SM; Yannicelli, HD, 2006)	0.77
" The aim of this study was to characterize the pharmacokinetic interactions of mipomersen sodium with simvastatin and ezetimibe."	( Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Flaim, JD; Geary, RS; Riley, GC; Tribble, DL; vanVliet, AA; Wedel, MK; Yu, RZ, 2009)	0.75
" Mipomersen sodium pharmacokinetic profiles were assessed following the first dose (mipomersen sodium alone) and the last dose (mipomersen sodium in combination with simvastatin or ezetimibe)."	( Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Flaim, JD; Geary, RS; Riley, GC; Tribble, DL; vanVliet, AA; Wedel, MK; Yu, RZ, 2009)	0.73
"The area under the plasma concentration-time curve (AUC) from 0 to 24 hours (AUC(24)), maximum plasma concentration and apparent elimination half-life values of mipomersen sodium were similar when administered alone and in combination with oral simvastatin or oral ezetimibe."	( Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Flaim, JD; Geary, RS; Riley, GC; Tribble, DL; vanVliet, AA; Wedel, MK; Yu, RZ, 2009)	0.72
"These data provide evidence that mipomersen sodium exhibits no clinically relevant pharmacokinetic interactions with the disposition and clearance of simvastatin or ezetimibe, and vice versa."	( Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe. Flaim, JD; Geary, RS; Riley, GC; Tribble, DL; vanVliet, AA; Wedel, MK; Yu, RZ, 2009)	0.74
" Enzyme kinetic parameters (K(m) and V(max)) and pharmacokinetic properties of three probe drugs were compared using wild-type and humanized UGT1 mice that express the Gilbert's UGT1A128 allele [Tg(UGT1(A128)) Ugt1(-/-) mice]."	( A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation. Cai, H; Chen, S; Hotz, K; La Placa, DB; Nguyen, N; Peterkin, V; Stevens, JC; Tukey, RH; Yang, YS, 2010)	0.36
" Adverse pharmacokinetic interactions are hypothesized with sirolimus, which is a substrate of OATP1B1 and OATP1B3 and an inhibitor of ABCB1, OATP1B1, and OATP1B3 but not of ABCC2."	( Pharmacokinetic and pharmacodynamic interactions between the immunosuppressant sirolimus and the lipid-lowering drug ezetimibe in healthy volunteers. Engel, A; Hanke, U; Keiser, M; Lütjohann, D; Modess, C; Nassif, A; Oswald, S; Siegmund, W; Weitschies, W, 2010)	0.57
" Forty-three subjects among them participated in a pharmacokinetic study of ezetimibe."	( Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects. Bae, JW; Choi, CI; Chung, MW; Jang, CG; Lee, JH; Lee, SY, 2011)	0.83
" Besides the C(max) of unchanged ezetimibe, no significant difference was found in any other pharmacokinetic parameter of unchanged ezetimibe or ezetimibe-glucuronide in the three groups."	( Effects of UDP-glucuronosyltransferase polymorphisms on the pharmacokinetics of ezetimibe in healthy subjects. Bae, JW; Choi, CI; Chung, MW; Jang, CG; Lee, JH; Lee, SY, 2011)	0.88
"The goals of the current study were to develop and characterize a nanoemulsion of ezetimibe, evaluate its stability, lipid lowering and pharmacokinetic profile."	( Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment. Ali, J; Ali, M; Bali, V, 2011)	0.59
"This was an open-label, randomized, three-period, multiple-dose crossover study that assessed the potential for pharmacokinetic interaction between extended-release niacin and ezetimibe/simvastatin and their major metabolites."	( Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. Cutler, DL; Kim, KT; Kosoglou, T; Statkevich, P; Taggart, W; Triantafyllou, I; Xuan, F; Zhu, Y, 2011)	0.81
"There is a small pharmacokinetic drug interaction between ER niacin and ezetimibe/simvastatin and although this is not considered to be clinically significant, the concomitant use of these drugs should be appropriately monitored, especially during the niacin titration period."	( Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects. Cutler, DL; Kim, KT; Kosoglou, T; Statkevich, P; Taggart, W; Triantafyllou, I; Xuan, F; Zhu, Y, 2011)	0.85
" However, in the presence of raltegravir, ezetimibe AUC0-24 and Ctrough were significantly lower (>20%) and ezetimibe glucuronide Cmax was higher."	( Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. Armenis, K; Back, D; Boffito, M; Bonora, S; D'Avolio, A; Gazzard, B; Jackson, A; Moyle, G; Taylor, J; Watson, V, 2011)	0.84
" The purposes of this study were to develop a population pharmacodynamic (PPD) model to describe the time course for the LDL-C lowering effects of statins and assess the efficacy of combination therapy based on electronic medical records."	( Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records. Fukae, M; Gotanda, K; Hirakawa, M; Hirota, T; Ieiri, I; Kakara, M; Matsubayashi, S; Nomura, H; Shimomura, H, 2014)	0.4
" In addition, the established framework is expected to be applicable to other drugs without pharmacokinetic data in clinical practice."	( Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records. Fukae, M; Gotanda, K; Hirakawa, M; Hirota, T; Ieiri, I; Kakara, M; Matsubayashi, S; Nomura, H; Shimomura, H, 2014)	0.4
" The optimized nanocrystal formulations were evaluated for in-vitro solubility, dissolution, solid state characters and in-vivo pharmacodynamic performance."	( Preparation and pharmacodynamic assessment of ezetimibe nanocrystals: Effect of P-gp inhibitory stabilizer on particle size and oral absorption. Mishra, B; Srivalli, KMR, 2015)	0.68
" The method has been successfully applied in clinical pharmacokinetic study in the Indian population."	( Development and Validation of an LC-MS-MS Method for the Simultaneous Determination of Simvastatin, Simvastatin Acid and Ezetimibe in Human Plasma and Its Application to Pharmacokinetic Study in the Indian Population. Bonga, PB; Munaga, SB; Rao, VS; Sharma, HK; Valluru, RK, 2016)	0.64
" The aim of this study was to compare the pharmacokinetic (PK) profiles of an FDC tablet of rosuvastatin/ezetimibe and co-administration of rosuvastatin and ezetimibe as separate tablets in healthy Korean volunteers."	( Comparison of Pharmacokinetics and Safety of a Fixed-dose Combination of Rosuvastatin and Ezetimibe Versus Separate Tablets in Healthy Subjects. Chang, MJ; Jung, J; Kim, CO; Min, KL; Park, MS, 2017)	0.89
" However, the pharmacokinetic (PK) interaction was not clear by the coadministration of rosuvastatin and ezetimibe."	( Pharmacokinetic and pharmacodynamic interaction between ezetimibe and rosuvastatin in healthy male subjects. An, H; Kim, CH; Kim, SH; Shin, D, 2017)	0.92
"Ezetimibe is a potent cholesterol absorption inhibitor, with an erratic pharmacokinetic (PK) profile, attributed to an extensive enterohepatic recirculation (EHC)."	( On the population pharmacokinetics and the enterohepatic recirculation of total ezetimibe. Karalis, V; Soulele, K, 2019)	2.18
" Both drugs exhibit complex pharmacokinetic profiles attributed mainly to repetitive enterohepatic kinetics."	( Development of a joint population pharmacokinetic model of ezetimibe and its conjugated metabolite. Karalis, V; Soulele, K, 2019)	0.76
" However, the pharmacokinetic (PK) interaction among these therapeutic drugs has not been clearly reported."	( Pharmacokinetic Interaction Between Telmisartan and Rosuvastatin/Ezetimibe After Multiple Oral Administration in Healthy Subjects. Kang, SI; Kim, CH; Shin, D, 2021)	0.86
"To evaluate the pharmacokinetic interactions among rosuvastatin, ezetimibe, and telmisartan, a randomized, open-label, 3-period, 6-sequence crossover study was conducted in healthy subjects."	( Pharmacokinetic Interaction Among Ezetimibe, Rosuvastatin, and Telmisartan. Huh, KY; Jang, IJ; Kim, KT; Lee, S; Lee, SB; Lee, SW, 2021)	1.14
" Thus, the aim of this study is to assess the potential pharmacokinetic DDI between rosuvastatin and ezetimibe in a Chinese population."	( Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants. Abdel-Moneim, M; Hou, J; Hovsepian, L; Hu, C; Jia, C; Luan, Y; Wang, L; Wang, Q; Xie, F; Xie, X; Yang, N; Zhang, Z; Zhao, Z, 2023)	1.36
" The plasma concentrations of rosuvastatin and ezetimibe were determined, and the pharmacokinetic parameters were calculated."	( Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants. Abdel-Moneim, M; Hou, J; Hovsepian, L; Hu, C; Jia, C; Luan, Y; Wang, L; Wang, Q; Xie, F; Xie, X; Yang, N; Zhang, Z; Zhao, Z, 2023)	1.4
"Co-administration of rosuvastatin and ezetimibe showed no clinically significant pharmacokinetic interactions in a healthy Chinese population."	( Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants. Abdel-Moneim, M; Hou, J; Hovsepian, L; Hu, C; Jia, C; Luan, Y; Wang, L; Wang, Q; Xie, F; Xie, X; Yang, N; Zhang, Z; Zhao, Z, 2023)	1.42
" Information on the pharmacokinetic profiles of ezetimibe tablet in healthy Chinese volunteers are lacking, and regulatory requirements necessitate a bioequivalence study of ezetimibe tablet versus Ezetrol® in China."	( Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects. Cao, Y; Fu, Y; Gao, X; Jiang, X; Li, T; Li, X; Lin, P; Liu, Y; Ma, Y; Sun, F; Wang, C, 2023)	1.44

Excerpt	Reference	Relevance
" Therefore, we determined the effect of SCH 48461 and ezetimibe in combination with 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors in chow-fed dogs."	( The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. Alton, KB; Burrier, RE; Davis, HR; Pula, KK; Watkins, RW, 2001)	0.78
"The purpose of this study was to assess the efficacy and safety of ezetimibe administered with simvastatin in patients with primary hypercholesterolemia."	( Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. Bettis, R; Davidson, MH; LeBeaut, AP; Lipka, LJ; McGarry, T; Melani, L; Sun, S; Suresh, R; Veltri, EP, 2002)	1.99
"This multicenter, randomized, double-blind, placebo-controlled clinical study assessed the efficacy and safety of ezetimibe administered with lovastatin in primary hypercholesterolemia."	( Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Corbelli, J; Kerzner, B; LeBeaut, A; Lipka, LJ; Melani, L; Mukhopadhyay, P; Sharp, S; Suresh, R; Veltri, EP, 2003)	0.84
"To evaluate the efficacy and safety of ezetimibe 10 mg administered with pravastatin in patients with primary hypercholesterolemia."	( Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Hassman, D; LeBeaut, A; Lipetz, R; Lipka, L; Melani, L; Mills, R; Mukhopadhyay, P; Suresh, R; Veltri, E, 2003)	0.9
" Although statin therapy remains the mainstay of treatment for hyperlipidemia in the elderly, other therapies, including exercise training, plant stanols and sterols, soluble fiber, and drug combinations (especially ezetimibe, niacin, and/or fibrates alone or combined with statins) are also effective and important lipid therapies for the elderly population."	( Treatment of hyperlipidemia in elderly persons with exercise training, nonpharmacologic therapy, and drug combinations. Lavie, CJ, )	0.32
" Overall, ezetimibe has a favourable drug-drug interaction profile, as evidenced by the lack of clinically relevant interactions between ezetimibe and a variety of drugs commonly used in patients with hypercholesterolaemia."	( Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Alton, KB; Bergman, AJ; Johnson-Levonas, AO; Kosoglou, T; Paolini, JF; Statkevich, P, 2005)	2.17
"To report the case of a patient who underwent orthotopic heart transplant (OHT) and demonstrated a supratherapeutic response to ezetimibe when administered with cyclosporine."	( Supratherapeutic response to ezetimibe administered with cyclosporine. Burton, I; Koshman, SL; Lalonde, LD; Pearson, GJ; Tymchak, WJ, 2005)	0.83
"To assess whether treatment with insulin-sensitizing agents (ISAs) in combination with ezetimibe and valsartan have greater effect on hepatic fat content and lipid peroxidation compared to monotherapy in the methionine choline-deficient diet (MCDD) rat model of non-alcoholic fatty liver disease (NAFLD)."	( Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease. Assy, N; Bersudsky, I; Grozovski, M; Hussein, O; Szvalb, S, 2006)	0.8
"The primary aim of this study was to compare the effect of colesevelam HCl in combination with ezetimibe to ezetimibe monotherapy on low-density lipoprotein cholesterol (LDL-C) levels in subjects with primary hypercholesterolemia."	( Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Abby, S; Bays, H; Jones, M; Lai, YL; Rhyne, J, 2006)	0.79
" This study was designed to investigate the efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe 10 mg in patients at high risk of coronary heart disease."	( Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Ballantyne, CM; Duffield, E; Eber, B; Moccetti, T; Sosef, F; Vogt, A; Weiss, R, 2007)	0.78
" At present a drug combination comprising ezetimibe 10 mg and simvastatin in all doses (10, 20, 40 and 80 mg) is being introduced into our market under the company name Inegy."	( [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?]. Vaverková, H, 2007)	0.85
"This study was undertaken to investigate the effect of ezetimibe (10 mg/day) alone or in combination with atorvastatin (10 mg twice a week) on hypercholesterolemia in 56 high-risk patients intolerant to daily statin use."	( Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Athyros, VG; Kakafika, AI; Karagiannis, A; Koumaras, H; Mikhailidis, DP; Tziomalos, K, 2008)	0.93
"The aim of this study was to assess the effects of fluvastatin extended-release (XL) 80 mg/d administered alone or combined with ezetimibe 10 mg/d on plasma lipid levels and inflammatory parameters in patients with primary hypercholesterolemia."	( Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-labe Alvarez-Sala, LA; Cachofeiro, V; Gambus, G; Lahera, V; Masana, L; Moreno, MA; Pinilla, B; Pintó, X; Plana, N; Suarez, C; Trias, F, 2008)	0.78
"In this multicenter, randomized, open-label, parallel-group study, patients with hypercholesterolemia were randomized in a 1:1 ratio to receive fluvastatin XL 80 mg/d alone or in combination with ezetimibe 10 mg/d for 12 weeks."	( Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-labe Alvarez-Sala, LA; Cachofeiro, V; Gambus, G; Lahera, V; Masana, L; Moreno, MA; Pinilla, B; Pintó, X; Plana, N; Suarez, C; Trias, F, 2008)	0.76
"Fluvastatin XL in combination with ezetimibe was found to be well-tolerated and effective, allowing the majority (87%) of these patients with primary hypercholesterolemia to achieve current treatment goals, and reduced hs-CRP levels in patients at higher cardiovascular risk."	( Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-labe Alvarez-Sala, LA; Cachofeiro, V; Gambus, G; Lahera, V; Masana, L; Moreno, MA; Pinilla, B; Pintó, X; Plana, N; Suarez, C; Trias, F, 2008)	0.85
" We established whether ezetimibe combined with simvastatin differently influences post fat load lipid levels and lipoprotein composition as compared to simvastatin 80mg monotherapy in obese male metabolic syndrome patients."	( The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Dallinga-Thie, GM; Hajer, GR; van Vark-van der Zee, LC; Visseren, FL, 2009)	0.91
"Ezetimibe did not alter serum visfatin concentrations, either when administered as monotherapy or combined with a statin."	( Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Derdemezis, C; Elisaf, M; Filippatos, T; Mikhailidis, D; Tselepis, A, 2008)	2.18
"The aim of this study was to estimate the potential long-term impact on health status of prescribing ezetimibe in combination with statin therapy in patients with established CVD and evaluate its cost-effectiveness in a health economic model."	( Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data regis Ara, R; Chilcott, J; Duenas, A; Durrington, P; Paisley, S; Pandor, A; Tumur, I; Wilkinson, A; Williams, R, 2008)	0.81
"Multicentered double-blind, randomized, placebo-controlled, crossover study to determine the short-term safety, efficacy, and tolerability of ezetimibe in combination with ongoing statin therapy in HIV-infected adults with elevated low-density lipoprotein cholesterol (LDL-C)."	( Short-term ezetimibe is well tolerated and effective in combination with statin therapy to treat elevated LDL cholesterol in HIV-infected patients. Andersen, J; Busti, A; Chen, H; Chow, D; Glesby, MJ; Kohrs, S; Koletar, SL; Souza, S; Wu, J, 2009)	0.94
" We assessed the effects of rimonabant, alone and in combination with fenofibrate or ezetimibe, on adipokine levels in obese/overweight patients with dyslipidemia."	( Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study. Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A, 2010)	0.81
" A total of 84 patients were treated with either fluvastatin 80 mg (n = 28) alone or in combination with ezetimibe 10 mg (n = 56) for 12 weeks to determine the effects on lipids, apolipoproteins and LDL subfractions by equilibrium density gradient ultracentrifugation."	( Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. de Campo, A; März, W; Scharnagl, H; Schmölzer, I; Sourij, H; Stojakovic, T; Wascher, TC, 2010)	0.81
" This effect was offset when simvastatin was combined with ezetimibe (LDL-IVB +14."	( Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Berneis, K; Berthold, HK; Gouni-Berthold, I; Krone, W; Rizzo, M; Spinas, GA, 2010)	2.05
" We have shown in vitro that ezetimibe and tacrolimus may interact in competition for intestinal UGT1A1 and ABCB1 at concentrations reached in gut lumen after oral administration."	( Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Engel, A; Hanke, U; Keiser, M; Lütjohann, D; Modess, C; Nassif, A; Oswald, S; Runge, D; Siegmund, W; Ulrich, A; Weitschies, W, 2011)	0.88
"We compared the effect of simvastatin versus simvastatin combined with ezetimibe on hemostasis and inflammation after acute coronary events [acute coronary syndromes (ACS)]."	( Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. Machnik, A; Potaczek, DP; Tracz, W; Undas, A; Wypasek, E; Zmudka, K, 2011)	2.05
"Based on the data of Taiwan's NHIRD, our findings suggest that patients with ACS on ezetimibe combined with statins had a significantly lower risk of rehospitalization due to ACS, percutaneous transluminal coronary angioplasty, and revascularization than those on statins alone."	( Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in Taiwan. Bai, CH; Gau, CS; Hsiao, FY; Lin, CF; Shen, LJ; Wu, FL, 2011)	1
"The incidence of paradoxical HDL-C reductions was low in mixed dyslipidemic patients receiving FENO alone or combined with EZE or EZE/SIMVA."	( Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Shah, A, 2011)	0.57
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
"5 mg/day of rosuvastatin combined with 10 mg/day of ezetimibe (R2."	( Comparison of anti-inflammatory effects and high-density lipoprotein cholesterol levels between therapy with quadruple-dose rosuvastatin and rosuvastatin combined with ezetimibe. Iino, K; Ishida, M; Ito, H; Kosaka, T; Koyama, T; Nobori, K; Oguma, Y; Terata, Y; Watanabe, H; Yamazaki, D, 2013)	0.84
"The aim of this study was to observe the effects of atorvastatin combined with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia."	( Effects of atorvastatin in combination with ezetimibe on carotid atherosclerosis in elderly patients with hypercholesterolemia. Du, S; Han, YG; Li, L; Luo, P; Wang, GG; Wang, LX; Wu, SL; Zhu, HH, 2014)	0.89
" Fifty-one in each group were given placebo, ezetimibe 10mg combined with simvastatin 10mg (Vyto10), ezetimibe 10mg combined with simvastatin 20mg (Vyto20), or simvastatin 20mg alone (Simva20) daily for 2months."	( Vascular and metabolic effects of ezetimibe combined with simvastatin in patients with hypercholesterolemia. Han, SH; Hayashi, T; Kim, EY; Koh, KK; Lee, Y; Oh, PC; Park, YM; Sakuma, I; Shin, EK, 2015)	0.96
"To compare 2 doses of ETC-1002, alone or combined with ezetimibe 10 mg (EZE), vs EZE monotherapy for lowering low-density lipoprotein cholesterol (LDL-C)."	( Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. Ballantyne, CM; Hanselman, JC; MacDougall, DE; Margulies, JR; McKenney, JM; Newton, RS; Orloff, DG; Thompson, PD, )	0.63
" ETC-1002 alone or combined with EZE also reduced non-high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, LDL particle number, and high-sensitivity C-reactive protein compared with EZE alone."	( Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance. Ballantyne, CM; Hanselman, JC; MacDougall, DE; Margulies, JR; McKenney, JM; Newton, RS; Orloff, DG; Thompson, PD, )	0.38
"We sought to investigate whether treatment with ezetimibe in combination with statins improves coronary endothelial function in target vessels in coronary artery disease patients after coronary stenting."	( Ezetimibe in Combination With Statins Ameliorates Endothelial Dysfunction in Coronary Arteries After Stenting: The CuVIC Trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting), a Multicenter Randomize Egashira, K; Eshima, K; Higo, T; Hironaga, K; Ichi, I; Inoue, S; Kadokami, T; Katsuki, S; Kishimoto, J; Matoba, T; Miyata, K; Mukai, Y; Nakashiro, S; Oi, K; Sadamatsu, K; Satoh, S; Suematsu, N; Sunagawa, K; Takase, S; Takemoto, M; Todaka, K; Usui, M; Yamamoto, M, 2017)	2.15
"The aim of this study was to evaluate the efficacy of ezetimibe combined with atorvastatin in treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease (CHD)."	( Efficacy of ezetimibe combined with atorvastatin in the treatment of carotid artery plaque in patients with type 2 diabetes mellitus complicated with coronary heart disease. Ai, XB; Li, L; Wang, F; Wang, J; Yi, XL; Zou, YW, 2017)	1.08
" To explore the efficacy and safety of ezetimibe in combination with atorvastatin for the treatment of patients with T2DM and acute coronary syndrome (ACS)."	( Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study. Huang, Z; Li, Q; Li, X; Ye, W; Zhang, Q, 2019)	1.09
" Overall, ezetimibe and statin combination therapy significantly decreased LDL-C, non-HDL-C, and TC levels in patients with high cardiovascular risk, among which ezetimibe combined with atorvastatin had the best therapeutic effect."	( The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis. Hu, H; Lin, S; Liu, T; Xu, H; Yang, J; Yao, Q; Yu, Y; Zhu, Y, 2020)	1.21
"The results mentioned above suggested that pitavastatin combined with ezetimibe was an effective approach for STEMI patients with non-IRA disease undergoing primary PCI."	( Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarction Patients with Primary Percutaneous Coronary Intervention. Lei, LC; Li, GP; Peng, JJ; Ren, LH; Wang, ZY; Ye, HM; Zhao, B; Zhao, S, 2021)	1.15
" The present study aimed to compare mean LDL cholesterol reduction and its variability achieved with different doses of the three statins most frequently used in monotherapy or combined with ezetimibe in a real clinical setting."	( LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry. Bea, AM; Benaiges, D; Blanco-Vaca, F; Brea-Hernando, Á; Climent, E; Pedro-Botet, J; Perea, V; Pintó, X; Plana, N; Suárez-Tembra, M, 2022)	1.12
" As to combined treatment, the lowest and highest mean percentage LDL cholesterol reductions were obtained with simvastatin 10 mg combined with ezetimibe (50."	( LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry. Bea, AM; Benaiges, D; Blanco-Vaca, F; Brea-Hernando, Á; Climent, E; Pedro-Botet, J; Perea, V; Pintó, X; Plana, N; Suárez-Tembra, M, 2022)	1.13
"In a real clinical setting, rosuvastatin was superior to the other statins in lowering LDL cholesterol, both as monotherapy or combined with ezetimibe."	( LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry. Bea, AM; Benaiges, D; Blanco-Vaca, F; Brea-Hernando, Á; Climent, E; Pedro-Botet, J; Perea, V; Pintó, X; Plana, N; Suárez-Tembra, M, 2022)	1.13
"To assess the cost effectiveness of icosapent ethyl, fenofibrate, ezetimibe, evolocumab, and alirocumab in combination with statins compared to statin monotherapy for cardiovascular prevention from the perspective of UK's National Health Service."	( Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy. Boch, T; Michaeli, DT; Michaeli, JC; Michaeli, T, 2022)	1.2
"To analyze the significance of ezetimibe in combination with low- to moderate-intensity atorvastatin adjuvant aspirin therapy for cerebrovascular disease."	( Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease. Tang, X; Wang, L, 2022)	1.35
"Ezetimibe combined with medium- and low-intensity atorvastatin with aspirin in the treatment of cerebrovascular diseases can effectively improve the coagulation function of patients, reduce the level of inflammatory factors in patients, and improve the level of blood lipids in patients, with high safety and worthy of clinical application."	( Implications of Ezetimibe in Combination with Low- to Moderate-Intensity Atorvastatin Adjuvant Aspirin Therapy for Cerebrovascular Disease. Tang, X; Wang, L, 2022)	2.51
" However, the results of individual studies on the effect of statin therapy in combination with ezetimibe on C-reactive protein (CRP) and high-sensitivity CRP (hs-CRP) levels have not been clear."	( The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials. Arabi, SM; Bahrami, LS; Chambari, M; Hadi, V; Malek-Ahmadi, M; Rizzo, M; Sahebkar, A, 2022)	1.19
" Statin therapy in combination with ezetimibe significantly reduced the serum levels of hs-CRP (WMD - 0."	( The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials. Arabi, SM; Bahrami, LS; Chambari, M; Hadi, V; Malek-Ahmadi, M; Rizzo, M; Sahebkar, A, 2022)	1.25
"The current study showed that statin therapy in combination with ezetimibe could be effective in reducing the levels of hs-CRP and overall CRP."	( The effect of statin therapy in combination with ezetimibe on circulating C-reactive protein levels: a systematic review and meta-analysis of randomized controlled trials. Arabi, SM; Bahrami, LS; Chambari, M; Hadi, V; Malek-Ahmadi, M; Rizzo, M; Sahebkar, A, 2022)	1.21
"To investigate the application of atorvastatin (AT) combined with ezetimibe (EZ) in elderly patients with hypertension (HY) combined with type 2 diabetes mellitus (T2DM) and the significance analysis of changes in serum bilirubin levels during treatment."	( Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment. Du, M; Wang, Q; Wang, T; Zhu, S, 2023)	1.41
"One hundred and twelve elderly patients with HY combined with T2DM admitted to our hospital from September 2019 to March 2022 were selected and divided into a control group (AT) and a combined group (AT + EZ) according to the random number table method, with 56 cases in each group."	( Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment. Du, M; Wang, Q; Wang, T; Zhu, S, 2023)	1.17
"AT combined with EZ can effectively improve glucose, lipids, inflammation and upregulate serum bilirubin in patients with HY combined with T2DM."	( Application of Atorvastatin Combined with Ezetimibe in Elderly Patients with Hypertension Combined with T2DM and Analysis of Significance of Changes in Serum Bilirubin Levels During Treatment. Du, M; Wang, Q; Wang, T; Zhu, S, 2023)	1.17
" In total, we have retrospectively examined 1275 patients with CAD from January 2009 to April 2019 and divided them into two groups: intensive statin group and conventional-dose statins combined with ezetimibe group."	( Variability in Plasma Lipids Between Intensive Statin Therapy and Conventional-Dose Statins Combined with Ezetimibe Therapy in Patients with Coronary Atherosclerosis Disease. Chen, Z; Jin, J; Li, D; Li, Y; Liu, L; Liu, X; Shan, L; Wang, M; Xu, T; Zhang, W, 2023)	1.31
"The aim of this study was to explore the effect of Ezetimibe combined with Simvastatin in the treatment of coronary heart disease (CHD)."	( Effect of Ezetimibe combined with Simvastatin in the treatment of coronary heart disease: a retrospective analysis. Li, B; Li, Y; Liu, YQ; Peng, WZ; Wen, JK; Xu, ZS, 2023)	1.56

Excerpt	Reference	Relevance
" The intersubject coefficient of variation was 46% to 80% in the absorption rate constant, 27% in the distribution phase, and approximately 50% in the volume of distribution."	( A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Batra, VK; Ezzet, F; Kosoglou, T; Krishna, G; Statkevich, P; Wexler, DB, 2001)	0.53
" On average, about half of all cholesterol entering the intestine is absorbed, but the fractional absorption rate varies greatly among individuals."	( Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Turley, SD, 2004)	0.32
" The oral bioavailability of ezetimibe coadministered with gemfibrozil relative to each drug administered alone was evaluated with an analysis-of-variance model."	( Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Affrime, M; Batra, V; Boutros, T; Kosoglou, T; Maxwell, SE; Pember, L; Reyderman, L; Statkevich, P, 2004)	0.86
" Ezetimibe did not alter the bioavailability (based on AUC) of gemfibrozil."	( Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. Affrime, M; Batra, V; Boutros, T; Kosoglou, T; Maxwell, SE; Pember, L; Reyderman, L; Statkevich, P, 2004)	1.48
"Plant sterols are widely distributed in human diet but are poorly absorbed so that their plasma levels are very low."	( Effect of high plant sterol-enriched diet and cholesterol absorption inhibitor, SCH 58235, on plant sterol absorption and plasma concentrations in hypercholesterolemic wild-type Kyoto rats. Batta, AK; Bollineni, JS; Salen, G; Shefer, S; Xu, G, 2005)	0.33
" Although coadministration with gemfibrozil and fenofibrate increased the bioavailability of ezetimibe, the clinical significance is thought to be minor considering the relatively flat dose-response curve of ezetimibe and the lack of dose-related increase in adverse events."	( Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Alton, KB; Bergman, AJ; Johnson-Levonas, AO; Kosoglou, T; Paolini, JF; Statkevich, P, 2005)	1.99
" Studying the rate of absorption and synthesis has come only recently into the foreground of interest."	( [Change in the cholesterol metabolism associated with the combined inhibition of synthesis and absorption]. Márk, L; Paragh, G, 2007)	0.34
"Hypercholesterolemia is associated with decreased vascular nitric oxide bioavailability and deletion of endothelial nitric oxide synthase (eNOS) markedly accelerates atherosclerosis development in apolipoprotein E knockout (apoE ko) mice."	( Ezetimibe potently reduces vascular inflammation and arteriosclerosis in eNOS-deficient ApoE ko mice. Bauersachs, J; Ertl, G; Hu, K; Huang, PL; Kuhlencordt, PJ; Padmapriya, P; Rützel, S; Schäfer, A; Schödel, J, 2009)	1.8
"Self-nanoemulsifying granules (SNGs) were formulated with the objective of enhancing the bioavailability of the ezetimibe."	( Self-nanoemulsifying granules of ezetimibe: design, optimization and evaluation. Dixit, RP; Nagarsenker, MS, 2008)	0.84
"Self-nanoemulsifying granules were formulated with the objective of improving the bioavailability of the ezetimibe and simvastatin when administered together."	( Formulation and in vivo evaluation of self-nanoemulsifying granules for oral delivery of a combination of ezetimibe and simvastatin. Dixit, RP; Nagarsenker, MS, 2008)	0.77
" The formulation used for assessment of lipid lowering potential and bioavailability contained Capryol 90 (10%, v/v), Tween 20 (33."	( Study of surfactant combinations and development of a novel nanoemulsion for minimising variations in bioavailability of ezetimibe. Ali, J; Ali, M; Bali, V, 2010)	0.57
" The present study established nanoemulsion to be a possible alternative for minimizing variation in bioavailability of ezetimibe."	( Novel nanoemulsion for minimizing variations in bioavailability of ezetimibe. Ali, J; Ali, M; Bali, V, 2010)	0.81
"Ezetimibe ameliorated the status of metabolic syndrome and microalbuminuria, reduced inflammation and oxidative stress, and increased nitric oxide bioavailability in a LDL-chol reduction-dependent and -independent manner."	( Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia. Aihara, K; Akaike, M; Dagvasumberel, M; Hirata, Y; Ishikawa, K; Iwase, T; Koshiba, K; Kusunose, K; Matsumoto, T; Niki, T; Sata, M; Soeki, T; Sumitomo-Ueda, Y; Taketani, Y; Tomita, N; Wakatsuki, T; Yagi, S; Yamada, H; Yamaguchi, K; Yoshida, S, 2010)	3.25
"Carotenoid bioavailability is influenced by a number of factors including the presence of other carotenoids, which may enhance or inhibit the transport of one another by intestinal cells."	( Investigation of beta-carotene and lutein transport in Caco-2 cells: carotenoid-carotenoid interactions and transport inhibition by ezetimibe. Aisling, SA; O'Brien, NM; O'Sullivan, L, 2009)	0.56
" The formulation selected for bioavailability estimation contained Capryol 90 (10%, v/v), Crempophor EL (11."	( Nanocarrier for the enhanced bioavailability of a cardiovascular agent: in vitro, pharmacodynamic, pharmacokinetic and stability assessment. Ali, J; Ali, M; Bali, V, 2011)	0.37
" As ezetimibe is almost insoluble in water, its bioavailability is too low to be detected."	( Design and characterization of nanocrystal formulations containing ezetimibe. Gulsun, T; Gursoy, RN; Oner, L, 2011)	1.16
"The aim of this study was to investigate the bioavailability enhancement of the biopharmaceutics classification system class II compound ezetimibe loaded in ordered mesoporous silica (OMS) in dogs."	( Use of ordered mesoporous silica to enhance the oral bioavailability of ezetimibe in dogs. Daems, T; Eelen, S; Kiekens, F; Martens, J; Van Den Mooter, G; Verheyden, L, 2012)	0.81
"The aim of this work was to compare the intestinal absorption kinetics and the bioavailability of γ-tocotrienol (γ-T3) and α-tocopherol (α-Tph) administered separately as oil solutions to rats in vivo."	( Comparison of the intestinal absorption and bioavailability of γ-tocotrienol and α-tocopherol: in vitro, in situ and in vivo studies. Abuasal, BS; Kaddoumi, A; Qosa, H; Sylvester, PW, 2012)	0.38
" The studies, therefore, indicate the successful formulation development of self-nanoemulsifying systems with distinctly improved bioavailability potential of ezetimibe."	( Optimized self nano-emulsifying systems of ezetimibe with enhanced bioavailability potential using long chain and medium chain triglycerides. Bandyopadhyay, S; Katare, OP; Singh, B, 2012)	0.84
"The oral bioavailability of poorly water-soluble drugs (PWSD) is often significantly enhanced by coadministration with lipids in food or lipid-based oral formulations."	( Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation. Charman, WN; Porter, CJ; Quach, T; Trevaskis, NL; Tso, P; Yeap, YY, 2013)	0.39
"The purpose of this research was to evaluate the effect of the HPC (hydroxypropylcellulose) and Tween 80 on the physicochemical properties and oral bioavailability of ezetimibe-loaded solid dispersions."	( Effect of hydroxypropylcellulose and Tween 80 on physicochemical properties and bioavailability of ezetimibe-loaded solid dispersion. Choi, HG; Din, FU; Kim, DW; Kim, JO; Mustapha, O; Park, JH; Rashid, R; Yong, CS; Yousaf, AM, 2015)	0.83
"Drug nanocrystals have been widely accepted as potent formulations to overcome poor solubility, dissolution and bioavailability problems of hydrophobic drugs."	( Preparation and pharmacodynamic assessment of ezetimibe nanocrystals: Effect of P-gp inhibitory stabilizer on particle size and oral absorption. Mishra, B; Srivalli, KMR, 2015)	0.68
"The objective of this study was to compare the physicochemical characteristics, solubility, dissolution, and oral bioavailability of an ezetimibe-loaded solid self-nanoemulsifying drug delivery system (SNEDDS), surface modified solid dispersion (SMSD), and solvent evaporated solid dispersion (SESD) to identify the best drug delivery system with the highest oral bioavailability."	( Comparative study on solid self-nanoemulsifying drug delivery and solid dispersion system for enhanced solubility and bioavailability of ezetimibe. Choi, HG; Kim, DW; Kim, JO; Mustapha, O; Oh, YK; Park, JH; Rashid, R; Yong, CS; Youn, YS; Yousaf, AM, 2015)	0.82
" We also examined an approach to improve intestinal absorption of a poorly absorbed water-insoluble component, coenzyme Q10 (CoQ10), by this mechanism."	( An Approach to Improve Intestinal Absorption of Poorly Absorbed Water-Insoluble Components via Niemann-Pick C1-Like 1. Imai, M; Iseki, K; Noto, K; Sato, Y; Sugawara, M; Sumi, M; Takekawa, Y; Takekuma, Y; Yamaki, Y, 2016)	0.43
" The PK time course data were well described by a two compartment PK model with first order absorption, and covariates identified for PK parameters included weight on both clearance (CL) and central volume (V2), dose on CL, race on bioavailability (F), and age on V2."	( Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients. James, DE; Krueger, KA; Shen, T, 2017)	0.46
"We propose that the specific intestinal Niemann-Pick C1-like 1 protein inhibitor ezetimibe is a potential agent for preventing gallstone formation by reducing bioavailability of intestine- derived cholesterol to the liver for biliary secretion and desaturating bile through the inhibition of intestinal absorption of cholesterol."	( Effect of Inhibition of Intestinal Cholesterol Absorption on the Prevention of Cholesterol Gallstone Formation. Portincasa, P; Wang, DQ, 2017)	0.68
" There were no significant differences in the absorption rate of the drug, even at high concentrations on the apical side."	( Investigation of supersaturation and in vitro permeation of the poorly water soluble drug ezetimibe. Alhayali, A; Ehrhardt, C; Selo, MA; Velaga, S, 2018)	0.7
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"012mg/ml 23oC) and low oral bioavailability (about 35-65% for a once 10mg dose)."	( Dissolution rate enhancement of new co-crystals of ezetimibe with maleic acid and isonicotinamide. Kai, S; Li Na, D; Ling, F; Man, Z; Wen, L; Xiao-Hui, Z; Yan-Jie, H; Yu-Zhen, Y, 2019)	0.77
"Ezetimibe is a cholesterol-lowering agent with an oral bioavailability of 50% by virtue of its poor solubility and extensive hepatic and intestinal metabolism."	( Amorphous Solid Dispersion Based Oral Disintegrating Film of Ezetimibe: Development and Evaluation. Narayana, KA; Shrestha, S; Sudheer, P, 2021)	2.31
"The study aimed to overcome low bioavailability issues of ezetimibe by formulating an oral disintegrating film."	( Amorphous Solid Dispersion Based Oral Disintegrating Film of Ezetimibe: Development and Evaluation. Narayana, KA; Shrestha, S; Sudheer, P, 2021)	1.11
"The study revealed that the formulation approach could overcome the biopharmaceutical challenge of solubility as well as low bioavailability issues of ezetimibe."	( Amorphous Solid Dispersion Based Oral Disintegrating Film of Ezetimibe: Development and Evaluation. Narayana, KA; Shrestha, S; Sudheer, P, 2021)	1.06
" Eight different scenarios were performed with changes in the rate of absorption of EZE and EZEG."	( Investigation of the discriminatory ability of analytes for the bioequivalence assessment of ezetimibe: Parent drug, metabolite, total form, and combination of parent drug and total form. Hsieh, CM; Hsu, LF, 2022)	0.94
"Understanding the solid-state transitions of active pharmaceutical ingredients (APIs) is essential for quality control since differences in their forms affect the bioavailability of APIs."	( Study on Hydration and Dehydration of Ezetimibe by Terahertz Spectroscopy with Humidity-Controlled Measurements and Theoretical Analysis. Aiko, K; Davis, MP; Korter, TM; Mohara, M; Ono, T; Shimura, K, 2022)	0.99
"36 ng*h/mL), indicating improved oral bioavailability for eutectics."	( Development of ezetimibe eutectic with improved biopharmaceutical and mechanical properties to design an optimized oral solid dosage formulation. Ghosh, A; Gour, A; Kumari, N; Nandi, U; Pandey, N; Raj, A; Roy, P; Srividya, B, 2022)	1.07
" PK and bioavailability parameters were estimated via non-compartmental methods."	( Pharmacokinetics and bioequivalence of Ezetimibe tablet versus Ezetrol®:an open-label, randomized, two-sequence crossover study in healthy Chinese subjects. Cao, Y; Fu, Y; Gao, X; Jiang, X; Li, T; Li, X; Lin, P; Liu, Y; Ma, Y; Sun, F; Wang, C, 2023)	1.18

Excerpt	Relevance	Reference
" Additional dose-scheduling studies demonstrated that evening dosing was only slightly more effective than morning dosing, and that the drug could be taken with or without food without any impairment in efficacy."	( An investigative look: selective cholesterol absorption inhibitors--embarking on a new standard of care. Stein, EA, 2002)	0.31
" Optimum doses of statins, which have demonstrated undisputed efficacy in the treatment of hypercholesterolaemia in clinical trials, are seldom used; the inconvenience of dosage adjustments and safety concerns, particularly myalgia, may constitute obstacles to their optimal use for LDL-C reduction in clinical practice."	( Selective cholesterol absorption inhibition: a novel strategy in lipid-lowering management. Leitersdorf, E, 2002)	0.31
" To determine whether this class of intestinal cholesterol absorption inhibitors could discriminate between newly synthesized cholesterol in the intestine versus exogenously administered cholesterol, rats were intraduodenally dosed with (14)C-cholesterol and (3)H-mevalonate, and mesenteric lymph was analyzed for radiolabeled cholesterol and cholesteryl ester content."	( Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Compton, DS; Davis, HR; Farley, C; Hoos, LM; Smith-Torhan, A; van Heek, M, 2003)	1.76
" The maximum mean reduction of LDL cholesterol is approximately 20-25% in small studies at the maximal dose tested of 40 mg/day and the reduction is usually in the 16-20% range at the dosage of 10 mg/day."	( Ezetimibe. Brown, WV; Davis, W; Harris, M, 2003)	1.76
" Other possible roles for ezetimibe include its concurrent use with a statin to permit a lowering of statin dosage to avoid statin-related complications or its use as monotherapy to treat hypercholesterolemia when statin use cannot be tolerated or is contraindicated."	( Ezetimibe for management of hypercholesterolemia. Mauro, VF; Tuckerman, CE, 2003)	2.06
" Ezetimibe has a relatively flat dose-response curve and titration is not required."	( Hypolipidemic therapy and cholesterol absorption. Farmer, JA; Manhas, A, 2004)	1.23
" If the desired effect is not achieved with the starting dose of statins, a doubling of dosage only leads to 6% additional LDL-cholesterol level decrease."	( [New treatment option for decreasing blood cholesterol level--clinical significance of inhibition of both, cholesterol absorption and synthesis]. Czine, Z; Márk, L; Paragh, G, 2004)	0.32
" However, based on the established safety profile and flat dose-response of ezetimibe, this effect is not considered to be clinically significant."	( Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Cutler, DL; Fruchart, JC; Guillaume, M; Kosoglou, T; Maxwell, SE; Pember, LJ; Reyderman, L; Statkevich, P; Veltri, EP, 2004)	0.79
" 10/10 mg, 10/20 mg, 10/40 mg, and 10/80 mg) and hence, the dosage may be adjusted to suit the individual patient's needs."	( Ezetimibe/Simvastatin: a review of its use in the management of hypercholesterolemia. Murdoch, D; Scott, LJ, 2004)	1.77
" There are no clinically significant effects of age, sex or race on ezetimibe pharmacokinetics and no dosage adjustment is necessary in patients with mild hepatic impairment or mild-to-severe renal insufficiency."	( Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Alton, KB; Bergman, AJ; Johnson-Levonas, AO; Kosoglou, T; Paolini, JF; Statkevich, P, 2005)	2.01
" A rapid, specific reversed-phase HPLC method has been developed for assaying ezetimibe in pharmaceutical dosage forms."	( Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms. Chandrasekar, D; Diwan, PV; Kashyap, YV; Sistla, R; Tata, VS, 2005)	0.78
" The implications for chronic EZE dosing within the usual clinical paradigm of chronic CyA dosing have not been established; caution is recommended when using these agents concomitantly."	( Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. Bergman, AJ; Burke, J; Frick, G; Gottesdiener, K; Greenberg, HE; Johnson-Levonas, AO; Kosoglou, T; Kraft, WK; Larson, P; Murphy, G; Paolini, JF; Reyderman, L; Statkevich, P, 2006)	0.72
"This open-label, single-period study evaluated the single-dose pharmacokinetics of ezetimibe (EZE) 10 mg in the setting of steady-state cyclosporine (CyA) dosing in renal transplant patients."	( Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients. Bergman, AJ; Burke, J; Gottesdiener, K; Johnson-Levonas, AO; Kosoglou, T; Larson, P; Maxwell, SE; Murphy, G; Paolini, JF; Reyderman, L; Robson, R; Statkevich, P, 2006)	0.86
"The lowest and highest dosage strengths of EZE/SIMVA tablet were bioequivalent to the individual drug components administered together."	( Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects. Bergman, A; Gambale, J; Gottesdiener, K; Groff, M; Hreniuk, D; Johnson-Levonas, AO; Kosoglou, T; Lasseter, KC; Laurent, A; Liu, L; Matthews, N; Migoya, EM; Murphy, G; Musson, DG; Paolini, JF; Riffel, K; Roadcap, B; Statkevich, P; Valesky, R; Yi, B; Zhao, JJ, 2006)	0.65
" Blood samples were collected for up to 24 hours after dosing on study day 1 and up to 120 hours after dosing on study day 10 for determination of plasma concentrations of fenofibric acid, unconjugated (free) ezetimibe, and total (conjugated and unconjugated) ezetimibe using validated high-performance liquid chromatography methods with mass-spectrometric detection."	( Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. Achari, R; Burt, DA; Chira, T; Edeki, T; Gustavson, LE; Kelly, MT; Rieser, MJ; Schweitzer, SM; Yannicelli, HD, 2006)	0.75
"Ezetimibe added to atorvastatin therapy compared with treatment with the most common fixed atorvastatin daily dosage (10 mg) or with common atorvastatin titration strategies (up to 20 mg daily; up to 40 mg daily) resulted in cost per QALY estimates ranging from 25,344 to 44,332 Canadian dollars."	( Cost effectiveness of adding ezetimibe to atorvastatin therapy in patients not at cholesterol treatment goal in Canada. Alemao, E; Attard, C; Bourgault, C; Cook, J; Huse, D; Kohli, M; Lam, A; Marentette, M; Yin, D, 2006)	2.07
" The recommended dosage is 10 mg once daily; it is safe and well tolerated."	( Combination of statin and ezetimibe for the treatment of dyslipidemias and the prevention of coronary artery disease. Genest, J, 2006)	0.63
"We sought to test the platelet inhibitory and anti-inflammatory effects of a higher statin dosage compared with combined treatment with ezetimibe plus a low statin dose."	( Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? Fischer, S; Jaster, M; Martus, P; Morguet, AJ; Piorkowski, M; Rauch, U; Schultheiss, HP; Stellbaum, C, 2007)	0.9
" An excellent safety and tolerability profile combined with once-daily dosing make this attractive adjunct therapy for the treatment of hypercholesterolemia."	( Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Johnson, RR; Sweeney, ME, 2007)	1.78
" This has lead to a series of international and national recommendations for a further reduction in target values for LDL-cholesterol, which is often difficult to achieve with the usual dosage of statins."	( [Dual inhibition of cholesterol using the drug combination ezetimibe/simvastatin?]. Vaverková, H, 2007)	0.58
" The proposed method can be useful in the quality control of bulk manufacturing and pharmaceutical dosage forms."	( Stability-indicating reversed-phase liquid chromatographic method for simultaneous determination of simvastatin and ezetimibe from their combination drug products. Chaudhari, BG; Patel, NM; Shah, PB, )	0.34
" The proposed method can be useful in the quality control of bulk manufacturing and pharmaceutical dosage forms."	( Stability-indicating reversed-phase liquid chromatographic method for simultaneous determination of atorvastatin and ezetimibe from their combination drug products. Chaudhari, BG; Patel, LJ; Patel, NM; Patel, VP; Shah, PB, )	0.34
"A reversed-phase liquid chromatographic (LC) method was developed and validated for the simultaneous determination of ezetimibe and simvastatin in pharmaceutical dosage forms."	( Simultaneous liquid chromatographic determination of ezetimibe and simvastatin in pharmaceutical products. Barth, T; Dalmora, SL; Oliveira, PR; Todeschini, V, )	0.59
" The primary end-point for this analysis was the evaluation of the long-term safety and tolerability of EZE 10 mg monotherapy dosed daily for up to 24 months."	( Safety and efficacy of ezetimibe monotherapy in 1624 primary hypercholesterolaemic patients for up to 2 years. Dujovne, CA; Maccubbin, D; McCrary Sisk, C; Strony, J; Suresh, R; Veltri, E, 2008)	0.66
"Poor results from lipid-lowering therapy are mainly due to inadequate dosing and increased adverse effects with high-dose statin monotherapy or drug combinations."	( Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Fras, Z; Mikhailidis, DP, 2008)	0.72
"The authors conducted a prospective, controlled, open-label trial examining the effectiveness and safety of high-dose fluvastatin or a standard dosage of simvastatin plus ezetimibe, both with an intensive guideline-oriented cardiac rehabilitation program, in achieving the new ATP III LDL-C targets in patients with proven coronary artery disease."	( Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets. Abdel-Wahab, M; Geist, V; Herrmann, L; Khattab, AA; Liska, B; Richardt, G; Tölg, R; Westphal, R, 2008)	0.89
" The direct application of study observations to clinical practice is limited by patient selection criteria and dosage regime, which randomly applied relatively high doses rather than titration which often occurs in clinical practice."	( Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Bays, H; Capece, R; Liu, J; Sapre, A; Taggart, W; Tershakovec, A, 2008)	0.63
"The impact of the 2 ezetimibe dosing strategies on percent lowering of low-density lipoprotein cholesterol (LDL-C) and achievement of National Cholesterol Education Program Adult Treatment Panel III (ATP III) goals was assessed in all patients prescribed ezetimibe 5 or 10 mg."	( Ezetimibe 5 and 10 mg for lowering LDL-C: potential billion-dollar savings with improved tolerability. Agarwal, S; Baruch, L; Eng, C; Gupta, B; Lieberman-Blum, SS, 2008)	2.11
" The initial dose administered to patients in the extension was ezetimibe 10 mg coadministered with simvastatin 10 mg with the option to up-titrate statin dosage if LDL-C goals were not met."	( Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study. Hanson, ME; Strony, J; Veltri, EP; Yang, B, 2008)	0.86
"Ezetimibe is usually dosed daily, but its 22-hour elimination half-life permits significant cholesterol reduction with less frequent dosing."	( Effectiveness of thrice weekly ezetimibe. Seip, RL; Thompson, PD; Venero, CV; Venero, JV, 2008)	2.07
" The impact of the 2 ezetimibe dosing strategies on LDL and the achievement of the Adult Treatment Panel III LDL goal was evaluated."	( Effect on serum lipid levels of switching dose of ezetimibe from 10 to 5 mg. Agarwal, S; Baruch, L; Eng, C; Gupta, B; Haynos, A, 2009)	0.92
"In an open-label clinical trial, 54 hypercholesterolemic patients included in the study underwent 12 months of treatment with ezetimibe at a dosage of 10 mg/d."	( Ezetimibe effect on bone mineral density and markers of bone formation and resorption. Ayter, M; Ersoy, U; Gultekin Tirtil, F; Kucukkaya, B; Sertbas, Y, 2010)	2.01
"Two spectrophotometric methods are presented for the simultaneous determination of ezetimibe/simvastatin and ezetimibe/atorvastatin binary mixtures in combined pharmaceutical dosage forms without prior separation."	( Enhanced spectrophotometric determination of two antihyperlipidemic mixtures containing ezetimibe in pharmaceutical preparations. Barary, MA; El-Kimary, EI; Hassan, EM; Maher, HM; Youssef, RM, 2011)	0.82
"This paper describes validated HPLC and HPTLC methods for the simultaneous determination of rosuvastatin (ROS) and ezetimibe (EZE) in a combined tablet dosage form."	( Determination of rosuvastatin and ezetimibe in a combined tablet dosage form using high-performance column liquid chromatography and high-performance thin-layer chromatography. Ravi, TK; Varghese, SJ, )	0.62
"Simple, accurate, sensitive, and precise UV spectrophotometric, chemometric, and HPLC methods were developed for simultaneous determination of a two-component drug mixture of ezetimibe (EZ) and simvastatin (SM) in laboratory-prepared mixtures and a combined tablet dosage form."	( Quantitative analysis of the cholesterol-lowering drugs ezetimibe and simvastatin in pure powder, binary mixtures, and a combined dosage form by spectrophotometry, chemometry, and high-performance column liquid chromatography. Aboul Alamein, AM; Hegazy, MA; Lotfy, HM, )	0.57
" Simvastatin was discontinued and dosage of cholinesterase inhibitor was temporarily increased."	( Statin-associated myasthenic weakness. Pasutharnchat, N; Phanthumchinda, K, 2011)	0.37
" The incidence ofstatin-associated myasthenic weakness should be clearly investigated Challenge with other brands of statin or with reduced dosage is not beneficial in these patients."	( Statin-associated myasthenic weakness. Pasutharnchat, N; Phanthumchinda, K, 2011)	0.37
" Dalcetrapib did not change plasma (3)H-cholesterol level but increased (3)H-cholesterol in plasma HDL vs non-HDL, after oral dosing of labeled cholesterol."	( Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects. Blum, D; Chaput, E; Derks, M; Kallend, D; Niesor, EJ; Staempfli, A, 2011)	0.37
" The sinusoidal transporter Abcc3 was induced in MCD rats, which correlated with increased plasma concentrations of EZE-GLUC, regardless of dosing method."	( Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Canet, MJ; Cherrington, NJ; Fisher, CD; Hardwick, RN; Street, SM, 2012)	0.66
" We assessed the efficacy and safety of various doses and dosing intervals of REGN727, a monoclonal antibody to PCSK9, added to statins, to further lower LDL-C in patients with heterozygous familial hypercholesterolaemia."	( Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlle Bergeron, J; Dufour, R; Gaudet, D; Gipe, D; Pordy, R; Stein, EA; Weiss, R; Wu, R, 2012)	0.57
" At the end of the dosing interval at week 12, the mean LDL-C concentrations were reduced generally dose dependently by AMG 145 every 2 weeks (ranging from 41·8% to 66·1%; p<0·0001 for each dose vs placebo) and AMG 145 every 4 weeks (ranging from 41·8% to 50·3%; p<0·0001)."	( Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 stu Abrahamsen, TE; Desai, NR; Giugliano, RP; Hoffman, EB; Huang, F; Kohli, P; Liu, T; McDonald, ST; Mohanavelu, S; Rogers, WJ; Sabatine, MS; Scott, R; Somaratne, R; Wasserman, SM, 2012)	0.38
" Pharmacy data and drug dosage information were used to estimate a moving window of ezetimibe and statin exposure for each day of study follow-up."	( Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Ahmedani, BK; Canepa Escaro, F; Divine, G; Gamalski, S; Hayek, S; Lanfear, DE; Pladevall, M; Sattar, A; Wells, KE; Williams, LK, 2013)	1.02
" The validated LC/ESI-MS method can be used to study pharmacokinetics, bioavailability, and bioequivalence of combined dosage forms of ROS and EZE."	( Development and validation of a liquid chromatography/ mass spectrometry method for the simultaneous quantitation of rosuvastatin and ezetimibe in human plasma. Ravi, TK; Varghese, SJ, )	0.33
"To assess the lipid-lowering efficacy of ezetimibe in dyslipidemic cynomolgus monkeys comparing two dosing methods, and to evaluate PCSK9 plasma levels during dyslipidemia induction by feeding a high-fat/high-cholesterol diet (HFD), ezetimibe (Zetia(®), Ezetrol(®)) treatment, ezetimibe washout, and HFD washout."	( Inverse relationship between LDL cholesterol and PCSK9 plasma levels in dyslipidemic cynomolgus monkeys: effects of LDL lowering by ezetimibe in the absence of statins. Chia, SM; Davis, HR; Hentze, H; Jensen, KK; Johns, DG; Shaw, RJ; Shih, SJ; Wong, KK, 2013)	0.86
" No difference between 20-mg and 10-mg dosing was seen among patients not receiving statins."	( Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy. Ban, MR; DeGorter, MK; Hegele, RA; Kim, RB; Schwarz, UI; Tirona, RG; Ziada, A, 2013)	0.63
" Using a retrospective cohort design, we collected lipid profile data from patients who had been treated with hypolipidemic agents at a stable dosage for at least 12 weeks."	( Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease. Hamai, J; Kamiko, K; Kawasaki, S; Kondo, Y; Nezu, U; Shigematsu, E; Takahashi, M; Takano, T; Terauchi, Y; Yamada, M; Yamakawa, T; Yamazaki, S; Yoshii, T, 2014)	0.4
"In addition to LDL-C reduction, evolocumab, dosed either Q2W or Q4W, demonstrated significant and favourable changes in other atherogenic and anti-atherogenic lipoproteins, and was well tolerated over the 12-week treatment period."	( Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Albizem, M; Giugliano, RP; Kim, JB; Koren, MJ; Liu, T; Raal, FJ; Roth, EM; Sabatine, MS; Scott, R; Somaratne, R; Stein, EA; Sullivan, D; Wasserman, SM; Weiss, R; Yang, J, 2014)	0.4
" These data suggest that modeling of dose-response relationships may be useful in predicting clinical equivalence, lowering cost/timelines through effective powering of studies, and predicting the effectiveness of new dosage formulations without the need for additional clinical efficacy trials in regulatory settings."	( Prediction of clinical irrelevance of PK differences in atorvastatin using PK/PD models derived from literature-based meta-analyses. Adewale, A; Behm, MO; Kerbusch, T; Mandema, J; Vargo, R, 2014)	0.4
" Expected differences between FDC and the corresponding co-administered doses were predicted from a dose-response relationship model; sample size was estimated given the expected difference and equivalence margins (±4%)."	( Fixed-dose combination ezetimibe+atorvastatin lowers LDL-C equivalent to co-administered components in randomized trials: use of a dose-response model. Bays, HE; Chen, E; McPeters, G; Polis, AB; Tomassini, JE; Triscari, J, 2015)	0.73
"This paper describes a new RP-HPLC method for simultaneous quantification of these compounds in the bulk sample drug as well as in tablet dosage forms."	( New Validated RP-HPLC Analytical Method for Simultaneous Estimation of Atorvastatin and Ezetimibe in Bulk Samples as Well in Tablet Dosage Forms by Using PDA Detector. Debnath, M; Kumar, SA; Seshagiri Rao, JV, 2014)	0.62
" The dosage of atorvastatin will be increased by titration within the usual dose range with a treatment goal of lowering LDL-C below 70 mg/dL based on consecutive measures of LDL-C at follow-up visits."	( Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial. Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Ono, T; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T, 2015)	0.42
" Afterwards, clinicians have several options to treat dyslipidemia, including the use of a lower dose of the same statin, intermittent non-daily dosing of statin, initiation of a different statin, alone or in combination with nonstatin lipid-lowering agents, and substitution with red yeast rice."	( Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Macchi, C; Magni, P; Morlotti, B; Ruscica, M; Sirtori, CR, 2015)	0.42
" Thus, the management of patients intolerant to statins, particularly those at high or very high cardiovascular risk, involves alternative therapies, including the switch to another statin or the use of intermittent dosage statin regimens, as well as nonstatin lipid lowering drugs (ezetimibe and fibrates) or new hypolipidemic drugs such as PCSK9 monoclonal antibodies, the antisense oligonucleotide against the coding region of human apolipoprotein B mRNA (mipomersen), and microsomal triglyceride transfer protein inhibitor lomitapide."	( Statin intolerance: diagnosis and remedies. Catapano, AL; Pirillo, A, 2015)	0.59
" The proposed methods were successfully applied for the determination of the investigated drugs in pure form, dosage form and in synthetic mixtures with good recovery and the results obtained were favorably compared to those obtained with a reference method."	( Application of new spectrofluorometric techniques for determination of atorvastatin and ezetimibe in combined tablet dosage form. Ayad, MF; Magdy, N, 2015)	0.64
"Evolocumab (Repatha(®)) is a monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) that is administered subcutaneously at a dosage of 140 mg every 2 weeks or 420 mg once monthly."	( Evolocumab: A Review in Hyperlipidemia. Keating, GM, 2016)	0.43
" Every-4-weeks dosing of alirocumab may be appropriate for some patients in absence of background statin but is not yet approved."	( Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Brunet, A; Cannon, CP; DiCioccio, AT; Hanotin, C; Paehler, T; Pinquier, JL; Poitiers, F; Rey, J; Sasiela, WJ; Surks, HK, 2016)	0.43
" The dosage of atorvastatin was uptitrated with a treatment goal of lowering low-density lipoprotein cholesterol to below 70 mg/dl in both groups."	( Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial. Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T, 2016)	0.75
" Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately controlled hypercholesterolemia and not on statin (majority with statin-associated muscle symptoms), receiving treatment with fenofibrate, ezetimibe, or diet alone."	( Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. Baccara-Dinet, MT; Civeira, F; Farnier, M; Gaudet, D; Guyton, JR; Lecorps, G; Lepor, N; Manvelian, G; Stroes, E; Watts, GF, 2016)	0.61
" Identification of clinically significant covariates will support the design and dose selection for the pivotal registration studies, ensuring that patients are dosed appropriately."	( Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients. James, DE; Krueger, KA; Shen, T, 2017)	0.46
" In vivo, low continuous dosing of ezetimibe, delivered by food, or simvastatin, delivered via an osmotic pump had no effect on tumor growth compared to control mice."	( Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. Alfaqih, MA; Barry, WT; Dambal, SK; Dewhirst, MW; Freedland, AR; Freedland, SJ; Freeman, MR; Macias, E; Masko, EM; Muehlbauer, MJ; Newgard, CB; Phillips, TE; Pizzo, SV; Poulton, SH; Sanders, SE; Solomon, KR; Sun, S; Valilis, NA, 2017)	0.73
" Preventive effect of high-dose statin treatment is without doubt, although administration of such high dosage might require special precautions for patients with prior intracerebral hemorrhage and it also risks development of incident diabetes."	( [Lipids and cerebrovascular disease - New therapeutic options in lowering LDL-cholesterol]. Csécsei, P; Karádi, Z; Lovadi, E; Lovig, C; Szapáry, L, 2016)	0.43
" Finally, poor adherence was slightly more prevalent among patients treated with less effective statins, and at both low and maximal dosage regimens."	( Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care. Bellia, A; Cricelli, C; Cricelli, I; Della-Morte, D; Guglielmi, V; Lapi, F; Lauro, D; Medea, G; Parretti, D; Pecchioli, S; Sbraccia, P, 2017)	0.46
" Metformin hydrochloride (MTF), sitagliptin phosphate (SIT), simvastatin (SIM) and ezetimibe (EZB) were simultaneously determined with a simple reversed-phase LC method in which a SIT-SIM binary mixture, present in a dosage form brand, was considered central for its development."	( A Versatile Liquid Chromatographic Method for the Simultaneous Determination of Metformin, Sitagliptin, Simvastatin, and Ezetimibe in Different Dosage Forms. El-Zaher, AA; Elkady, EF; Elwy, HM; Saleh, MAEM, 2018)	0.91
" There is a clear dose-response effect of statin treatment on PCSK9 level, as increasing doses of statins also increase the level of circulating PCSK9."	( Lipid Lowering Therapy and Circulating PCSK9 Concentration. Nozue, T, 2017)	0.46
" Areas covered: The efficacy and safety of alirocumab has been initially evaluated in a comprehensive phase 3 program conducted in more than 6 000 patients with primary non-familial and heterozygous familial hypercholesterolemia: alirocumab reduced LDL-cholesterol up to 62% in phase 3 with every 2-week dosing compared with placebo, and up to 36% compared with ezetimibe, with an excellent safety and tolerability profile."	( Alirocumab for the treatment of hyperlipidemia in high-risk patients: an updated review. Farnier, M, 2017)	0.62
"Changes in low-density lipoprotein cholesterol (LDL-C) and other lipids from baseline to Week 24 were analysed (intention-to-treat) in four pools by alirocumab dosage (150 mg every 2 weeks [150] or 75 mg with possible increase to 150 mg every 2 weeks [75/150]), control (placebo/ezetimibe) and background statin usage (yes/no)."	( Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. Bujas-Bobanovic, M; Ganda, OP; Koren, A; Leiter, LA; Letierce, A; Mandel, J; Plutzky, J; Sanganalmath, SK, 2018)	0.66
" The increased dosage of rosuvastatin was also well tolerated in the combination treatment."	( Efficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia. Bae, JW; Han, SH; Hong, BK; Hong, SJ; Hwang, GS; Hyon, MS; Kim, JY; Kim, MK; Kim, SH; Kim, SW; Kim, W; Lee, SE; Park, CG; Park, JH; Rhee, MY; Shin, JH; Shin, SH; Son, JW; Sung, KC; Yoon, YE, 2018)	0.79
"In the prospective, randomized, controlled, multicenter PRECISE-IVUS trial, 246 patients undergoing intravascular ultrasound (IVUS)-guided PCI were randomly assigned to receive atorvastatin/ezetimibe combination or atorvastatin alone (the dosage of atorvastatin was up-titrated to achieve the level of low-density lipoprotein cholesterol < 70 mg/dL)."	( Impact of statin-ezetimibe combination on coronary atheroma plaque in patients with and without chronic kidney disease - Sub-analysis of PRECISE-IVUS trial. Fujimoto, K; Fujisue, K; Hokimoto, S; Ishihara, M; Izumiya, Y; Kaikita, K; Koide, S; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nagamatsu, S; Nakamura, S; Nakao, K; Ogawa, H; Oshima, S; Sakamoto, K; Shimomura, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamashita, T, 2018)	1.01
" The method is suitable for both drug substance and oral solid dosage form."	( Development of a Simple, Highly Selective RP-LC Method for the Quantification of Diastereomers and Other Related Substances of Ezetimibe Using Multivariate Analysis. Anireddy, JS; Balasubramanian, H; Kumar, RS; Rao, DV, 2019)	0.72
" The aim of this study was to evaluate the efficacy of adding ezetimibe to simvastatin, atorvastatin, or rosuvastatin monotherapy versus doubling the dosage or switching to a higher-potency statin in a population of patients with hypocholesterolemia at high risk of cardiovascular disease (CVD) and who had been previously treated with a statin."	( Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Ambegaonkar, B; Baxter, CA; Davies, G; Jansen, J; Lorenzi, M; Zoratti, MJ, 2019)	2.2
" Indeed, a significant number of patients resulted intolerants, especially when the dosage increased."	( Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. Costa, D; Napoli, C; Scognamiglio, M; Sorriento, A, 2019)	0.51
" To increase adherence and prevent worse outcomes, a combination therapy with lower dosage of statins and new lipid-lowering drugs may be used."	( An expert opinion paper on statin adherence and implementation of new lipid-lowering medications by the ESC Working Group on Cardiovascular Pharmacotherapy: Barriers to be overcome. Bilato, C; Coats, AJS; Drexel, H; Mollace, V; Perrone Filardi, P; Rosano, GMC; Spoletini, I, 2020)	0.56
" To achieve these goals, investigators used the statin and dosage of their choice and added ezetimibe as needed."	( Carotid Atherosclerosis Evolution When Targeting a Low-Density Lipoprotein Cholesterol Concentration <70 mg/dL After an Ischemic Stroke of Atherosclerotic Origin. Amarenco, P; Bruckert, E; Charles, H; Gabriel Steg, P; Giroud, M; Hobeanu, C; Labreuche, J; Lavallée, PC; Meseguer, E; Touboul, PJ; Vicaut, É, 2020)	0.78
" After a 5-week run-in period of treatment with atorvastatin 10 or 20 mg/d (cohorts A and B, respectively), or a bioequivalent dosage of another statin, patients were randomized in a 1:1 ratio within each cohort to receive EZ/AS 10/10 mg FDC (EZ10/AS10) or atorvastatin 20 mg (AS20), once daily (cohort A); or EZ/AS 10/20 mg FDC (EZ10/AS20) or atorvastatin 40 mg (AS40), once daily (cohort B)."	( Efficacy and Tolerability of Ezetimibe/Atorvastatin Fixed-dose Combination Versus Atorvastatin Monotherapy in Hypercholesterolemia: A Phase III, Randomized, Active-controlled Study in Chinese Patients. Chen, J; Ding, C; Ge, J; Li, Z; Liu, Y; Qian, J; Ren, X; Shi, M; Yang, P; Zhang, X, 2022)	1.01
" Additionally, ETZ exhibits poor mechanical properties, leading to difficulties in developing dosage forms through direct compression."	( Development of ezetimibe eutectic with improved biopharmaceutical and mechanical properties to design an optimized oral solid dosage formulation. Ghosh, A; Gour, A; Kumari, N; Nandi, U; Pandey, N; Raj, A; Roy, P; Srividya, B, 2022)	1.07

Role	Description
anticholesteremic drug	A substance used to lower plasma cholesterol levels.
antilipemic drug	A substance used to treat hyperlipidemia (an excess of lipids in the blood).
antimetabolite	A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
azetidines
organofluorine compound	An organofluorine compound is a compound containing at least one carbon-fluorine bond.
beta-lactam	A lactam in which the amide bond is contained within a four-membered ring, which includes the amide nitrogen and the carbonyl carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Drug induction of bile acid pathway	0	25

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	29.8493	0.0060	38.0041	19,952.5996	AID1159523
TDP1 protein	Homo sapiens (human)	Potency	33.4983	0.0008	11.3822	44.6684	AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	31.6180	0.0007	14.5928	83.7951	AID1259392
AR protein	Homo sapiens (human)	Potency	19.2880	0.0002	21.2231	8,912.5098	AID1259243; AID1259247; AID743035; AID743063
estrogen receptor 2 (ER beta)	Homo sapiens (human)	Potency	9.4392	0.0006	57.9133	22,387.1992	AID1259378
progesterone receptor	Homo sapiens (human)	Potency	25.1567	0.0004	17.9460	75.1148	AID1346784; AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	1.5651	0.0123	7.9835	43.2770	AID1645841
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	13.3332	0.0030	41.6115	22,387.1992	AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	27.1304	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptor	Homo sapiens (human)	Potency	29.8493	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	29.8493	0.0002	29.3054	16,493.5996	AID1259244
G	Vesicular stomatitis virus	Potency	8.2200	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	12.5046	0.0010	8.3798	61.1304	AID1645840
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	29.8470	0.0010	19.4141	70.9645	AID743191
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	21.5913	0.0007	23.0674	1,258.9301	AID743085; AID743122
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	22.3872	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	26.6032	0.0003	23.4451	159.6830	AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	25.1547	0.0006	27.2152	1,122.0200	AID743202; AID743219
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	13.5161	0.0079	8.2332	1,122.0200	AID2546; AID2551
neuropeptide S receptor isoform A	Homo sapiens (human)	Potency	5.0119	0.0158	12.3113	615.5000	AID1461
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	29.8493	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	8.2200	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	8.2200	0.0123	8.9648	39.8107	AID1645842
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	29.8493	0.0015	51.7393	15,848.9004	AID1259244
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	Potency	12.5893	0.0096	10.5250	35.4813	AID1479145
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	8.2200	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	8.2200	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	56.0000	0.1100	7.1903	10.0000	AID1473738
NPC1-like intracellular cholesterol transporter 1	Rattus norvegicus (Norway rat)	Ki	0.2000	0.1800	0.1900	0.2000	AID315718
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)	IC50 (µMol)	0.3700	0.3000	0.3233	0.3700	AID1872307
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
UDP-glucuronosyltransferase 1A1	Homo sapiens (human)	Km	64.0000	4.4900	6.5133	9.0000	AID624630
UDP-glucuronosyltransferase 1A3	Homo sapiens (human)	Km	42.0000	7.3400	7.3400	7.3400	AID624632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lipid metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
androgen metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
liver development	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
bilirubin conjugation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
acute-phase response	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to nutrient	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
steroid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
animal organ regeneration	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to lipopolysaccharide	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
retinoic acid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
response to starvation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
negative regulation of steroid metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
flavone metabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
flavonoid glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
biphenyl catabolic process	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to ethanol	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to glucocorticoid stimulus	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cellular response to estradiol stimulus	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
bile acid secretion	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
retinoic acid metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
flavonoid glucuronidation	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
xenobiotic glucuronidation	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
vitamin D3 metabolic process	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
sodium ion transport	Sodium/bile acid cotransporter	Homo sapiens (human)
response to organic cyclic compound	Sodium/bile acid cotransporter	Homo sapiens (human)
bile acid and bile salt transport	Sodium/bile acid cotransporter	Homo sapiens (human)
response to nutrient levels	Sodium/bile acid cotransporter	Homo sapiens (human)
bile acid signaling pathway	Sodium/bile acid cotransporter	Homo sapiens (human)
response to estrogen	Sodium/bile acid cotransporter	Homo sapiens (human)
response to ethanol	Sodium/bile acid cotransporter	Homo sapiens (human)
symbiont entry into host cell	Sodium/bile acid cotransporter	Homo sapiens (human)
transmembrane transport	Sodium/bile acid cotransporter	Homo sapiens (human)
cellular response to xenobiotic stimulus	Sodium/bile acid cotransporter	Homo sapiens (human)
regulation of bile acid secretion	Sodium/bile acid cotransporter	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cholesterol biosynthetic process	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
intestinal cholesterol absorption	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
cholesterol transport	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
lipoprotein metabolic process	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
vitamin E metabolic process	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
vitamin transport	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
cellular response to sterol depletion	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
cholesterol homeostasis	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
enzyme inhibitor activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
steroid binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
enzyme binding	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
protein homodimerization activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
protein heterodimerization activity	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
virus receptor activity	Sodium/bile acid cotransporter	Homo sapiens (human)
protein binding	Sodium/bile acid cotransporter	Homo sapiens (human)
bile acid:sodium symporter activity	Sodium/bile acid cotransporter	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
protein binding	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
vitamin E binding	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
cholesterol binding	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
small GTPase binding	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
myosin V binding	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
protein homodimerization activity	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
membrane	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
plasma membrane	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
perinuclear region of cytoplasm	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum chaperone complex	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
cytochrome complex	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A1	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
endoplasmic reticulum	UDP-glucuronosyltransferase 1A3	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Sodium/bile acid cotransporter	Homo sapiens (human)
basolateral plasma membrane	Sodium/bile acid cotransporter	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
plasma membrane	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
apical plasma membrane	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
cytoplasmic vesicle membrane	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
plasma membrane	NPC1-like intracellular cholesterol transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211319	Drug level in methionine and choline deficient fed Sprague-Dawley rat bile at 10 mg/kg, iv after 30 to 90 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1567204	Chaperone activity at GALNS p.R61W/p.W405_T406 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in p62 level at 0.001 to 0.01 uM measured after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1168723	Cytotoxicity against human HepG2 cells after 4 days by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID178717	Compound was tested for the change in serum cholesterol (SC) level in cholesterol fed rat	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	The discovery of ezetimibe: a view from outside the receptor.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1896147	Antiviral activity against hepatitis D virus infected in human Huh-7 cells overexpressing NTCP assessed as reduction in intracellular HDV RNA for 20 hrs followed by viral infection further compound washout and measured after 6 days post infection by RT-qP	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
AID1275465	Decrease in free fatty acid level in serum of cholesterol fed hamster model at 50 mg/kg/day, po administered for 7 days measured on day 7 post last dose	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.
AID24830	Percent negation of rise in total serum cholesterol relative to control-fed 0.5% cholesterol for 7 days, At a dose of 0.1 mg/kg/day	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211292	Drug metabolism in human intestinal microsomes assessed as UGT1A1-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 2% bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID289523	Decrease in LDL-cholesterol levels in high-cholesterol diet fed Wistar rat at 4 mg/kg/day	2007	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1	Ezetimibe analogs with a reorganized azetidinone ring: Design, synthesis, and evaluation of cholesterol absorption inhibitions.
AID1758168	Inhibition of PTL (unknown origin) at 50 uM relative to control	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1.
AID1567208	Chaperone activity at GALNS p.R61W/p.W405_T406 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in LC3B-2 level at 0.001 to 0.01 uM measured after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID624630	Drug glucuronidation reaction catalyzed by human recombinant UGT1A1	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID547673	Antidyslipidemic activity in cholesterol-fed rhesus monkey assessed as reduction in plasma cholesterol	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	2-Azetidinone--a new profile of various pharmacological activities.
AID548191	Inhibition of [3H]cholesterol absorption in C57BL/6 mouse plasma at 1 mg/kg, po after 1.5 hrs	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy.
AID24836	Percent negation of rise in total serum cholesterol relative to control-fed 0.5% cholesterol for 7 days, at a dose of 0.03 mg/kg/day	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID1599411	Antiviral activity against DENV2 New Guinea infected in human Huh7 cells assessed as reduction in viral yield after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Recent update on anti-dengue drug discovery.
AID1195465	Inhibition of [3H]cholesterol uptake in C57BL/6 mouse duodenum at 20 mg/kg/day, po for 2 days measured 4 hrs post last dose on day 2	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
AID624640	Drug glucuronidation reaction catalyzed by human recombinant UGT2B7	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1195467	Inhibition of [3H]cholesterol uptake in C57BL/6 mouse ileum at 20 mg/kg/day, po for 2 days measured 4 hrs post last dose on day 2	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
AID1389994	Antiinflammatory activity against mouse RAW264.7 cells assessed as decrease in cholesterol-methyl-beta-cyclodextrin-induced TNFalpha release at 30 uM relative to control	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1567190	Chaperone activity at GALNS p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in enzyme activity at 0.001 to 0.01 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate measured after 48 hrs by	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID86018	Compound was tested for percent reduction of liver cholesterol esters absorption in cholesterol fed hamster model at a dose of 3 mg/kg/day	1998	Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3	Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar.
AID1567199	Chaperone activity at GALNS p.R386C/p.F285 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as decrease in lysosomal mass measured after 48 hrs by LysoTracker Red DND-99/hoechst dye based fluorescence assay	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1211216	Unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 2% bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211221	Ratio of unbound intrinsic glucuronidation clearance in human kidney microsomes in presence of 2% bovine serum albumin to unbound intrinsic glucuronidation clearance in human kidney microsomes in absence of bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID89949	Compound was tested for the reduction in low density lipoprotein cholesterol	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	The discovery of ezetimibe: a view from outside the receptor.
AID1567206	Chaperone activity at GALNS p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in p62 level at 0.001 to 0.01 uM measured after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1567196	Chaperone activity at GALNS p.R61W/p.W405_T406 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as decrease in lysosomal mass measured after 48 hrs by LysoTracker Red DND-99/hoechst dye based fluorescence assay	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1567178	Inhibition of recombinant human GALNS expressed in Pichia pastoris at 10 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate measured after 18 hrs by fluorescence assay relative to control	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID315718	Displacement of [3H]ezetimibe-glucuronide from NPC1L1 in Sprague-Dawley rat brush border membrane	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption.
AID1195461	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
AID1211252	Drug metabolism in human intestinal microsomes assessed as UGT2B7-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 1% bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211201	Drug metabolism in human liver microsomes assessed as UGT1A1-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 2% bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1473762	Ratio of drug concentration at steady state in human at 10 mg, po after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1567188	Chaperone activity at GALNS p.R61W/p.W405_T406 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in enzyme activity at 0.001 to 0.01 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate meas	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1567189	Chaperone activity at GALNS p.R94C/p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in enzyme activity at 0.001 to 0.01 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate measured after 48	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID24838	The pharmacokinetics property percent negation of rise in liver cholesterol esters relative to control-fed 0.5% cholesterol for 7 days, At a dose of 0.03 mg/kg/day	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID1567191	Chaperone activity at GALNS p.R386C/p.F285 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in enzyme activity at 0.001 to 0.01 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate measured	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1211237	Fraction unbound in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID547674	Antidyslipidemic activity in cholesterol-fed hamster model assessed as reduction in liver cholesteryl esters	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	2-Azetidinone--a new profile of various pharmacological activities.
AID289522	Decrease in total cholesterol levels in high-cholesterol diet fed Wistar rat at 4 mg/kg/day	2007	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1	Ezetimibe analogs with a reorganized azetidinone ring: Design, synthesis, and evaluation of cholesterol absorption inhibitions.
AID547675	Antidyslipidemic activity in cholesterol-fed Dog assessed as reduction in plasma cholesterol level	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	2-Azetidinone--a new profile of various pharmacological activities.
AID422543	Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.03 mol fraction relative to cholate	2009	Journal of natural products, Jan, Volume: 72, Issue:1	Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1567213	Chaperone activity at GALNS p.R94C/p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as decrease in lysosomal mass at 0.001 uM measured after 72 hrs in presence of recombinant human GALNS expressed in Pichia pastoris by LysoTrac	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1567187	Chaperone activity at recombinant human GALNS expressed in HEK293 cells assessed as increase in GALNs level at 0.001 mM measured after 48 hrs by LysoTracker Green DND-26/DAPI staining based immunofluorescence assay	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1567185	Chaperone activity at recombinant human GALNS expressed in HEK293 cells assessed as increase in intracellular enzyme activity at 0.001 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate measured after 48 hrs by fluorescence assa	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1211225	Drug metabolism in human liver microsomes assessed as UGT1A1-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211194	Ratio of UGT1A1-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A1-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1567181	Chaperone activity at recombinant human GALNS expressed in Escherichia coli BL21 (DE3) assessed as increase in extracellular enzyme activity at 0.001 to 1 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate measured after 24 hrs	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID315720	Half life in rat hepatocytes	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption.
AID1211251	Unbound intrinsic glucuronidation clearance in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID315719	Inhibition of cholesterol absorption in chow fed hamster at 3 mg/kg, po	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1211272	Ratio of UGT1A1-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A1-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM in presence of 2% bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID374274	Hypocholesterolemic effect in high cholesterol-fed hamster assessed as reduction in plasma total cholesterol at 50 mg/kg, po for 7 days	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	2-Azetidinone derivatives: design, synthesis and evaluation of cholesterol absorption inhibitors.
AID59638	Compound was tested for the change in serum cholesterol (SC) levels in cholesterol fed dog	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	The discovery of ezetimibe: a view from outside the receptor.
AID1195464	Inhibition of [3H]cholesterol uptake in C57BL/6 mouse liver at 20 mg/kg/day, po for 2 days measured 4 hrs post last dose on day 2	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
AID1896146	Binding affinity to NTCP (unknown origin)	2022	Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19	Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
AID1599410	Antiviral activity against DENV1 infected in human Huh7 cells assessed as reduction in viral yield after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Recent update on anti-dengue drug discovery.
AID1211333	Drug level in methionine and choline deficient fed Sprague-Dawley rat plasma at 10 mg/kg, po after 120 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1275467	Increase in proportion of high density lipoprotein cholesterol to total cholesterol in serum of cholesterol fed hamster at 50 mg/kg/day, po administered for 7 days measured on day 7 post last dose	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.
AID1211334	Drug metabolism in methionine and choline deficient fed Sprague-Dawley rat plasma assessed as ezetimibe glucuronide formation at 10 mg/kg, po after 120 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1211340	Drug metabolism in methionine and choline deficient fed Sprague-Dawley rat plasma assessed as ezetimibe glucuronide formation at 10 mg/kg, iv after 120 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1211258	Ratio of UGT1A1-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A1-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM in presence of 2% bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211211	Unbound intrinsic glucuronidation clearance in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 2% bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1758176	Inhibition of PTL mRNA expression in human Caco-2 cells at 100 uM incubated for 24 hrs by qRT-PCR analysis	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211325	Drug level in methionine and choline deficient fed Sprague-Dawley rat urine at 10 mg/kg, iv after 120 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1168724	Inhibition of cholesterol uptake in MDCK2 cells at 20 to 100 uM after 1 hr by liquid scintillation counting	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors.
AID24833	Percent negation of rise in total serum cholesterol relative to control-fed 0.5% cholesterol for 7 days, At a dose of 1 mg/kg/day	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID1567211	Chaperone activity at GALNS p.R386C/p.F285 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in LC3B-2 level at 0.001 to 0.01 uM measured after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID182776	Compound was tested for cholesterol absorption inhibition in rats by bolus injection 1 mL) via the intestinal catheter into the small intestine, by cholesterol absorption assay	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1211336	Drug level in methionine and choline deficient fed Sprague-Dawley rat plasma at 10 mg/kg, iv after 40 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1168733	In vivo inhibition of acute [3H]cholesterol absorption in C57BL/6 mouse ileum at 10 mg/kg/day, po for 2 days before cholesterol administration measured 4 hrs post cholesterol administration relative to vehicle-treated control	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors.
AID422555	Antagonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to chenodeoxycholate	2009	Journal of natural products, Jan, Volume: 72, Issue:1	Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1567193	Chaperone activity at GALNS p.R94C/p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in protein expression at 0.001 to 0.01 uM after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID86158	Compound was tested for percent reduction of serum cholesterol absorption in cholesterol fed hamster model at a dose of 3 mg/kg/day	1998	Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3	Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar.
AID1211329	Effect on total bile acid levels in Sprague-Dawley rat nonalcoholic steatohepatitis model at 10 mg/kg, iv after 120 mins by spectrophotometry	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1758179	Inhibition of NPC1L1 expression in human Caco-2 cells at 0.1 to 100 uM incubated for 24 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1.
AID84698	Compound was tested for the change in liver cholesterol (CE) levels in hamster	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	The discovery of ezetimibe: a view from outside the receptor.
AID1567205	Chaperone activity at GALNS p.R94C/p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in p62 level at 0.001 to 0.01 uM measured after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211219	Ratio of unbound intrinsic glucuronidation clearance in human liver microsomes in presence of 2% bovine serum albumin to unbound intrinsic glucuronidation clearance in human liver microsomes in absence of bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1567210	Chaperone activity at GALNS p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in LC3B-2 level at 0.001 to 0.01 uM measured after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID374275	Hypocholesterolemic effect in high cholesterol-fed hamster assessed as increase in HDL-cholesterol at 50 mg/kg, po for 7 days	2009	European journal of medicinal chemistry, Apr, Volume: 44, Issue:4	2-Azetidinone derivatives: design, synthesis and evaluation of cholesterol absorption inhibitors.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211249	Unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase and 2% bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1389991	Inhibition of NPC1L1-mediated cholesterol-methyl-beta-cyclodextrin accumulation in mouse RAW264.7 cells incubated for 72 hrs by Oil Red O/hematoxyline staining based microscopic analysis	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1211326	Drug metabolism in methionine and choline deficient fed Sprague-Dawley rat urine assessed as ezetimibe glucuronide formation at 10 mg/kg, iv after 120 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1567180	Chaperone activity at recombinant human GALNS expressed in Escherichia coli BL21 (DE3) assessed as increase in intracellular enzyme activity at 0.001 to 1 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate measured after 24 hrs	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1567207	Chaperone activity at GALNS p.R386C/p.F285 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in p62 level at 0.001 to 0.01 uM measured after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1211187	Ratio of UGT1A1-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes to UGT1A1-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID711532	Inhibition of cholesterol absorption in syrian golden hamster	2011	Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8	Synopsis of some recent tactical application of bioisosteres in drug design.
AID1211265	Ratio of UGT1A1-mediated unbound intrinsic glucuronidation clearance in human intestinal microsomes to UGT1A1-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM in presence of 2% bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID422544	Reduction in human pancreatic recombinant 1B PLA2 activity expressed in Escherichia coli assessed as hydrolysis of 1,2-dimyristoyl-sn-3-glycerophosphocholine vesicles at 0.007 mol fraction relative to cholate	2009	Journal of natural products, Jan, Volume: 72, Issue:1	Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID1195459	Cytotoxicity against MDCK2 cells after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1168722	Cytotoxicity against MDCK2 cells after 4 days by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors.
AID1275466	Decrease in triglyceride level in serum of cholesterol fed hamster model at 50 mg/kg/day, po administered for 7 days measured on day 7 post last dose	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.
AID1211342	Drug level in methionine and choline deficient fed Sprague-Dawley rat bile at 10 mg/kg, po after 120 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1389993	Inhibition of NPC1L1-mediated cholesterol-methyl-beta-cyclodextrin accumulation in mouse RAW264.7 cells assessed as decrease in foam cell formation by measuring decrease in MDA level at 30 uM relative to control	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response.
AID422554	Agonist activity at human FXR transfected in human HuH7 cells co-transfected with human BSEP promoter reporter plasmid at 10 uM after 30 hrs by dual-luciferase reporter assay relative to control	2009	Journal of natural products, Jan, Volume: 72, Issue:1	Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID24840	The pharmacokinetics property percent negation of rise in liver cholesterol esters relative to control-fed 0.5% cholesterol for 7 days, At a dose of 0.3 mg/kg/day	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID24835	Percent negation of rise in total serum cholesterol relative to control-fed 0.5% cholesterol for 7 days, At a dose of 3 mg/kg/day	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID1168737	Inhibition of cholesterol uptake in MDCK2 cells expressing human NPC1L1 at 20 to 100 uM after 1 hr by liquid scintillation counting	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1567194	Chaperone activity at GALNS p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in protein expression at 0.001 to 0.01 uM after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID89950	Compound was tested for the reduction in total cholesterol	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	The discovery of ezetimibe: a view from outside the receptor.
AID89951	Compound was tested for the reduction in triglycerides	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	The discovery of ezetimibe: a view from outside the receptor.
AID1168735	In vivo inhibition of acute [3H]cholesterol absorption in C57BL/6 mouse liver at 10 mg/kg/day, po for 2 days before cholesterol administration measured 4 hrs post cholesterol administration relative to vehicle-treated control	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors.
AID1567184	Chaperone activity at recombinant human GALNS expressed in HEK293 cells assessed as increase in extracellular enzyme activity at 0.01 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate measured after 48 hrs by fluorescence assay	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1389987	Cytotoxicity against mouse RAW264.7 cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response.
AID1431667	Antagonist activity at Myc-tagged RXRalpha (unknown origin) expressed in human MCF-7 cells assessed as inhibition of 9-cis-RA induced receptor transactivation at 10 uM after 24 hrs by luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Virtual screening and experimental validation identify novel modulators of nuclear receptor RXRα from Drugbank database.
AID1211241	Fraction unbound in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1567214	Chaperone activity at GALNS p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as decrease in lysosomal mass at 0.001 uM measured after 72 hrs in presence of recombinant human GALNS expressed in Pichia pastoris by LysoTracker Red	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID86163	In vivo activity in a cholesterol-fed hamster assay was determined at 1 mg/kg/day	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis of iodinated biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors.
AID1567195	Chaperone activity at GALNS p.R386C/p.F285 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in protein expression at 0.001 to 0.01 uM after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID24831	Percent negation of rise in total serum cholesterol relative to control-fed 0.5% cholesterol for 7 days, At a dose of 0.3 mg/kg/day	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1567197	Chaperone activity at GALNS p.R94C/p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as decrease in lysosomal mass measured after 48 hrs by LysoTracker Red DND-99/hoechst dye based fluorescence assay	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID768314	Competitive binding affinity to human GFP-tagged NPC1L1 L1072T/L1168I mutant expressed in HEK293 cells assessed as localization to endoplasmic reticulum and plasma membrane at 0.01 to 10 uM after 24 hrs by fluorescence microscopic analysis in presence of	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Structure-activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect.
AID89948	Compound was tested for the reduction in high density lipoprotein cholesterol	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	The discovery of ezetimibe: a view from outside the receptor.
AID1567216	Chaperone activity at recombinant human GALNS expressed in Pichia pastoris assessed as increase in extracellular enzyme level by bioreactor-based assay	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1195469	Cytotoxicity against MDCK2 cells expressing human NPC1L1 dosed with micelles after 1 hr	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
AID1275458	Octanol-water partition coefficient, logP of the compound by HPLC analysis	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.
AID84866	Evaluated for its ability to reduce liver cholesterol esters(LCE) in cholesterol-fed hamsters.	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID1473761	Drug concentration at steady state in human at 10 mg, po after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1168731	In vivo inhibition of acute [3H]cholesterol absorption in C57BL/6 mouse jejunum at 10 mg/kg/day, po for 2 days before cholesterol administration measured 4 hrs post cholesterol administration relative to vehicle-treated control	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors.
AID1567220	Half life in po dosed human	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID126335	Compound was tested for the change in serum cholesterol (SC) levels in cholesterol fed monkey	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	The discovery of ezetimibe: a view from outside the receptor.
AID181919	Percent inhibition of 14C]cholesterol absorption into plasma using cholesterol absorption assay in rats at the dose of 10 ug/Kg	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors.
AID1389988	Inhibition of NPC1L1 in human Caco2 cells assessed as decrease in cholesterol uptake at 100 uM preincubated for 24 hrs followed by stigmosterol substrate addition measured after 24 hrs by HPLC method relative to control	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response.
AID1758178	Inhibition of PTL expression in human Caco-2 cells at 0.1 to 100 uM incubated for 24 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1.
AID1275464	Decrease in low density lipoprotein cholesterol level in serum of cholesterol fed hamster model at 50 mg/kg/day, po administered for 7 days measured on day 7 post last dose	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.
AID1567183	Chaperone activity at recombinant human GALNS expressed in HEK293 cells assessed as increase in intracellular enzyme activity at 0.01 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate measured after 48 hrs by fluorescence assay	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1567215	Chaperone activity at GALNS p.R386C/p.F285 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as decrease in lysosomal mass at 0.001 uM measured after 72 hrs in presence of recombinant human GALNS expressed in Pichia pastoris by	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1872307	Inhibition of NPC1L1 (unknown origin) assessed as inhibition of cholesterol cellular uptake by BCA colorimetric assay	2022	European journal of medicinal chemistry, Feb-15, Volume: 230	Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption.
AID1275461	Cytotoxicity against human GES-1 cells assessed as cell viability after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.
AID1168720	Cytotoxicity against MDCK2 cells expressing human NPC1L1 after 4 days by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors.
AID84707	Dose required to inhibit cholesterol absorption in cholesterol fed hamster model	1998	Bioorganic & medicinal chemistry letters, Feb-03, Volume: 8, Issue:3	Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: enhanced potency by modification of the sugar.
AID1211245	Unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211213	Unbound intrinsic glucuronidation clearance in human intestinal microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of UDP-glucuronosyltransferase	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1567192	Chaperone activity at GALNS p.R61W/p.W405_T406 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in protein expression at 0.001 to 0.01 uM after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID315721	Metabolic stability assessed as half life in rat liver microsomes	2008	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 18, Issue:2	Substituted oxazolidinones as novel NPC1L1 ligands for the inhibition of cholesterol absorption.
AID1275472	Toxicity in cholesterol fed hamster model assessed as decrease in body weight at 50 mg/kg/day, po administered for 7 days measured for 3 days during compound dosing	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.
AID1389992	Inhibition of NPC1L1-mediated cholesterol-methyl-beta-cyclodextrin accumulation in mouse RAW264.7 cells assessed as decrease in foam cell formation by measuring decrease in LDH level at 30 uM relative to control	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response.
AID1211232	Drug metabolism in human kidney microsomes assessed as UGT1A1-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1211320	Drug metabolism in methionine and choline deficient fed Sprague-Dawley rat bile assessed as ezetimibe glucuronide formation at 10 mg/kg, iv after 30 to 90 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1211339	Drug level in methionine and choline deficient fed Sprague-Dawley rat plasma at 10 mg/kg, iv after 120 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID181923	Percent inhibition of 14C]cholesterol absorption into plasma using cholesterol absorption assay in rats at the dose of 3 ug/Kg	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis of fluorescent biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors.
AID256344	Percent inhibition against cholesterol absorption in brush border membrane vesicle using rabbit small intestine at concentration of 6 uM	2005	Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19	Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption.
AID1567198	Chaperone activity at GALNS p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as decrease in lysosomal mass measured after 48 hrs by LysoTracker Red DND-99/hoechst dye based fluorescence assay	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1211322	Drug level in methionine and choline deficient fed Sprague-Dawley rat urine at 10 mg/kg, po after 120 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1211330	Drug level in methionine and choline deficient fed Sprague-Dawley rat plasma at 10 mg/kg, po after 40 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1389986	Cytotoxicity against HEK293 cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response.
AID84842	Effective dose required to produe activity in cholesterol hamster assay was determined	2002	Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3	Synthesis of iodinated biochemical tools related to the 2-azetidinone class of cholesterol absorption inhibitors.
AID1211180	Ratio of UGT1A1-mediated unbound intrinsic glucuronidation clearance in human kidney microsomes to UGT1A1-mediated unbound intrinsic glucuronidation clearance in human liver microsomes at 1 uM	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID768317	Binding affinity to human GFP-tagged NPC1L1 L1072T/L1168I mutant expressed in HEK293 cells assessed as localization to endoplasmic reticulum and plasma membrane at 10 uM after 24 hrs by fluorescence microscopic analysis	2013	Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17	Structure-activity relationship studies of Niemann-Pick type C1-like 1 (NPC1L1) ligands identified by screening assay monitoring pharmacological chaperone effect.
AID1758177	Inhibition of NPC1L1 mRNA expression in human Caco-2 cells at 100 uM incubated for 24 hrs by qRT-PCR analysis	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1.
AID1567186	Chaperone activity at recombinant human GALNS expressed in HEK293 cells assessed as increase in extracellular enzyme activity at 0.001 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate measured after 48 hrs by fluorescence assa	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1389995	Antiinflammatory activity against mouse RAW264.7 cells assessed as decrease in cholesterol-methyl-beta-cyclodextrin-induced ROS level at 30 uM relative to control	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response.
AID1211337	Drug metabolism in methionine and choline deficient fed Sprague-Dawley rat plasma assessed as ezetimibe glucuronide formation at 10 mg/kg, iv after 40 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1168727	In vivo inhibition of acute [3H]cholesterol absorption in C57BL/6 mouse plasma at 10 mg/kg/day, po for 2 days before cholesterol administration measured 4 hrs post cholesterol administration relative to vehicle-treated control	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID255693	Effective dose required for reduction of liver cholesterol ester using 7-day cholesterol-fed hamster model	2005	Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19	Synthesis and in vitro evaluation of inhibitors of intestinal cholesterol absorption.
AID1567182	Chaperone activity at recombinant human GALNS expressed in Pichia pastoris assessed as increase in extracellular enzyme activity at 0.001 uM using 4-methylumbelliferyl-beta-D-galactopyranoside-6-sulfate as substrate treated every 24 hrs for 96 hrs by fluo	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1567209	Chaperone activity at GALNS p.R94C/p.A393S mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as increase in LC3B-2 level at 0.001 to 0.01 uM measured after 48 hrs by Western blot analysis	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1275462	Cytotoxicity against human HEK293 cells assessed as cell viability after 48 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.
AID1567179	Stabilization of recombinant human GALNS expressed in Pichia pastoris assessed as melting temperature at 1 uM by SYPRO orange dye based fluorescence assay (Rvb = 62.8 degC)	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1211343	Drug metabolism in methionine and choline deficient fed Sprague-Dawley rat bile assessed as ezetimibe glucuronide formation at 10 mg/kg, po after 120 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1211323	Drug metabolism in methionine and choline deficient fed Sprague-Dawley rat urine assessed as ezetimibe glucuronide formation at 10 mg/kg, po after 120 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID1211208	Drug metabolism in human kidney microsomes assessed as UGT1A1-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 2% bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1195460	Cytotoxicity against MDCK2 cells expressing human NPC1L1 after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
AID1389989	Inhibition of NPC1L1 in mouse RAW264.7 cells assessed as decrease in choleserol-D7 absorption at 30 uM after 72 hrs by LC-MS/MS analysis relative to control	2018	Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8	Synthesis and evaluation of 1H-pyrrole-2,5-dione derivatives as cholesterol absorption inhibitors for suppressing the formation of foam cells and inflammatory response.
AID1195463	Inhibition of human NPC1L1 transfected in MDCK2 cells assessed as [3H]cholesterol uptake at 60 uM after 1 hr by liquid scintillation counting analysis	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
AID624632	Drug glucuronidation reaction catalyzed by human recombinant UGT1A3	2005	Pharmacology & therapeutics, Apr, Volume: 106, Issue:1	UDP-glucuronosyltransferases and clinical drug-drug interactions.
AID1599413	Antiviral activity against DENV2 H241 infected in human Huh7 cells assessed as reduction in viral yield after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Recent update on anti-dengue drug discovery.
AID1211244	Fraction unbound in human liver microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis in presence of 2% bovine serum albumin	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID24842	The pharmacokinetics property percent negation of rise in liver cholesterol esters relative to control-fed 0.5% cholesterol for 7 days, At a dose of 1 mg/kg/day	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID1599412	Antiviral activity against DENV3 infected in human Huh7 cells assessed as reduction in viral yield after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, Aug-15, Volume: 176	Recent update on anti-dengue drug discovery.
AID1567212	Chaperone activity at GALNS p.R61W/p.W405_T406 deletion mutant in mucopolysaccharidosis patient-derived fibroblasts assessed as decrease in lysosomal mass at 0.001 uM measured after 72 hrs in presence of recombinant human GALNS expressed in Pichia pastori	2019	Journal of medicinal chemistry, 07-11, Volume: 62, Issue:13	Identification of Ezetimibe and Pranlukast as Pharmacological Chaperones for the Treatment of the Rare Disease Mucopolysaccharidosis Type IVA.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1211173	Drug metabolism in human intestinal microsomes assessed as UGT1A1-mediated unbound intrinsic glucuronidation clearance at 1 uM after 30 to 60 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID24843	The pharmacokinetics property percent negation of rise in liver cholesterol esters relative to control-fed 0.5% cholesterol for 7 days, At a dose of 3 mg/kg/day	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID1473760	AUC in human at 10 mg, po after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1211328	Effect on total bile acid levels in Sprague-Dawley rat nonalcoholic steatohepatitis model at 10 mg/kg, po after 120 mins by spectrophotometry	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID24839	The pharmacokinetics property percent negation of rise in liver cholesterol esters relative to control-fed 0.5% cholesterol for 7 days, At a dose of 0.1 mg/kg/day	1998	Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6	Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
AID1195468	Cytotoxicity against MDCK2 cells dosed with micelles after 1 hr	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
AID548195	Inhibition of [3H]cholesterol absorption in C57BL/6 mouse plasma at 1 mg/kg, po after 5 hrs	2010	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 20, Issue:23	Spiroimidazolidinone NPC1L1 inhibitors. Part 2: structure-activity studies and in vivo efficacy.
AID1168729	In vivo inhibition of acute [3H]cholesterol absorption in C57BL/6 mouse duodenum at 10 mg/kg/day, po for 2 days before cholesterol administration measured 4 hrs post cholesterol administration relative to vehicle-treated control	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors.
AID1758174	Inhibition of NPC1L1 in human Caco-2 cells assessed as decrease in uptake of cholesterol-d6 at 50 uM by HPLC-MS analysis	2021	European journal of medicinal chemistry, Apr-15, Volume: 216	One-step modification to identify dual-inhibitors targeting both pancreatic triglyceride lipase and Niemann-Pick C1-like 1.
AID1211239	Fraction unbound in human kidney microsomes at 1 uM after 30 to 60 mins by LC-MS/MS analysis	2012	Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 40, Issue:4	Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin.
AID1275463	Decrease in total cholesterol level in serum of cholesterol fed hamster model at 50 mg/kg/day, po administered for 7 days measured on day 7 post last dose	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	Discovery of 2-azetidinone and 1H-pyrrole-2,5-dione derivatives containing sulfonamide group at the side chain as potential cholesterol absorption inhibitors.
AID1195466	Inhibition of [3H]cholesterol uptake in C57BL/6 mouse jejunum at 20 mg/kg/day, po for 2 days measured 4 hrs post last dose on day 2	2015	Bioorganic & medicinal chemistry, May-15, Volume: 23, Issue:10	Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors.
AID1211331	Drug metabolism in methionine and choline deficient fed Sprague-Dawley rat plasma assessed as ezetimibe glucuronide formation at 10 mg/kg, po after 40 mins by LC-MS/MS method	2012	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3	Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1346036	Human NPC1 like intracellular cholesterol transporter 1 (Patched family)	2005	Proceedings of the National Academy of Sciences of the United States of America, Jun-07, Volume: 102, Issue:23	The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	4 (0.17)	18.2507
2000's	697 (30.12)	29.6817
2010's	1185 (51.21)	24.3611
2020's	428 (18.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	563 (22.67%)	5.53%
Reviews	504 (20.29%)	6.00%
Case Studies	103 (4.15%)	4.05%
Observational	38 (1.53%)	0.25%
Other	1,276 (51.37%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (342)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Kidney Fat in Type 2 Diabetes & Diabetic Kidney Disease and the Effects of Ezetimibe: A Cross-Sectional Study and Randomized, Placebo-Controlled Trial [NCT04589351]	Phase 3	60 participants (Anticipated)	Interventional	2020-10-01	Active, not recruiting
Retrospective Observational Study of the Efficacy and Safety of Statin Monotherapy or Statins in Combination With Ezetimibe in Patients Receiving Lipid-lowering Therapy in Both Primary and Secondary Prevention of CVD [NCT04895098]		1,000 participants (Actual)	Observational	2021-06-23	Completed
A Single Center, Open Label, Randomized Study to Compare the Effect of Vytorin (Simvastatin/Ezetimibe) 10/20mg Versus Atorvastatin 20mg on ApoB/ApoA1 Ratio in Subjects With Diabetes [NCT01185236]	Phase 4	132 participants (Anticipated)	Interventional	2010-09-30	Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in [NCT00092638]	Phase 3	450 participants (Actual)	Interventional	2003-05-31	Completed
Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia [NCT00092560]	Phase 3	587 participants (Actual)	Interventional	2002-12-31	Completed
A Multicenter, Randomized, Double-Blind Study to Evaluate the Lipid-Altering Efficacy and Safety of the Ezetimibe/Simvastatin Combination Tablet Versus Rosuvastatin in Patients With Primary Hypercholesterolemia [NCT00090298]	Phase 3	2,815 participants (Actual)	Interventional	2004-04-30	Completed
Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients [NCT00654628]	Phase 4	173 participants (Actual)	Interventional	2007-08-01	Completed
A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe (+) Simvastatin Versus Atorvastatin in Patients With Primary Hypercholesterolemia [NCT00166504]	Phase 4	203 participants (Actual)	Interventional	2005-10-31	Completed
Non-Interventional Study On The Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia [NCT05798390]		0 participants (Actual)	Observational	2023-09-01	Withdrawn(stopped due to Due to patient availability)
Comparison of Efficacy and Safety of High-Intensity Statin and Ezetimibe Combination Versus StanDard carE in AsymptomatiC PatIentS wIth Presence of COroNary Artery CALCIUM (DECISION-CAL) [NCT05845424]	Phase 4	6,000 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia [NCT03510884]	Phase 3	153 participants (Actual)	Interventional	2018-05-31	Completed
Designated Drug Use Investigation (12 Weeks) of Zetia 10mg Tablets - A 12-Week Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy [NCT00704444]		11,332 participants (Actual)	Observational	2007-06-30	Completed
A Randomized, Double-blind, Active-controlled, Multicenter Phase3 Trial to Evaluate the Efficacy and Safety of Co-administrated Rosuvastatin/Ezetimibe and Telmisartan in Patients With Primary Hypercholesterolemia and Essential Hypertension [NCT03872232]	Phase 3	180 participants (Actual)	Interventional	2019-02-26	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Triplet Therapy With Bempedoic Acid (ETC 1002) 180 mg, Ezetimibe 10 mg, and Atorvastatin 20 mg in Patients With Elevated LDL C [NCT03051100]	Phase 2	63 participants (Actual)	Interventional	2017-01-19	Completed
A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 Mg + Ezetimibe 10 Mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated St [NCT03337308]	Phase 3	382 participants (Actual)	Interventional	2017-10-23	Completed
Analysis of Changes in Intestinal Flora of Hyperlipidemia by Ezetimibe and Orlistat. [NCT03884127]		58 participants (Anticipated)	Observational	2019-04-01	Not yet recruiting
Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry [NCT03110432]		1,713 participants (Actual)	Observational	2017-05-18	Active, not recruiting
A Phase 1 Feasibility Study of Cholesterol Metabolism Reprogramming (Evolocumab, Atorvastatin and Ezetimibe) in Combination With the Standard of Care in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma [NCT04862260]	Early Phase 1	12 participants (Anticipated)	Interventional	2021-10-04	Recruiting
A Multicentre, Open-Label, Observational Local Study to Evaluate the LDL-C Lowering Effect of Ezetimibe as Prescribed in Daily Routine Practice in the South African Population [NCT00457275]	Phase 3	440 participants	Interventional	2005-04-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in [NCT00092625]	Phase 3	442 participants (Actual)	Interventional	2003-03-31	Completed
A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo-Controlled Study Comparing the Efficacy, Safety, and Tolerability of Administration of Ezetimibe/Simvastatin Tablet 10/20 mg Versus Doubling the Dose of Simvastatin 20 mg [Simvastatin 40 mg] [NCT00423579]	Phase 4	120 participants (Actual)	Interventional	2006-07-01	Completed
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R207 (Rosuvastatin /Ezetimibe Combination) and Rosuvastatin Monotherapy in Patients With Primary Hypercholester [NCT02445352]	Phase 3	379 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C [NCT03001076]	Phase 3	269 participants (Actual)	Interventional	2016-11-29	Completed
A Randomized Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 + Ezetimibe 10 Fixed-Dose Combination Compared to Ezetimibe and Placebo In Subjects With T2DM and Elevated LDL-Cholesterol [NCT03531905]	Phase 2	242 participants (Actual)	Interventional	2018-05-09	Completed
Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D [NCT03105310]	Phase 2	20 participants (Anticipated)	Interventional	2016-01-31	Active, not recruiting
A Randomized, Open-label, Blinded Intravascular Ultrasound Analysis, Parallel Group, Multicenter Study to Evaluate the Effect of Praluent® (Alirocumab) on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercho [NCT02984982]	Phase 4	206 participants (Actual)	Interventional	2016-11-15	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target [NCT00092599]	Phase 3	410 participants (Actual)	Interventional	2003-02-28	Completed
A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin 10 mg/20 mg Fixed-Dose Combination Tablet Compared to Co-administration of Marketed Ezetimibe 10 mg and Atorvastatin [NCT01370590]	Phase 3	406 participants (Actual)	Interventional	2011-09-30	Completed
"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia" [NCT00092651]	Phase 3	1,398 participants (Actual)	Interventional	2002-09-30	Completed
Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients With Mixed Hyperlipidemia [NCT00092573]	Phase 3	576 participants (Actual)	Interventional	2003-04-30	Completed
Ezetimibe Phase IV Clinical Study in Patients With Hypercholesterolemia [NCT00871351]	Phase 4	125 participants (Actual)	Interventional	2009-02-01	Completed
Evaluate The Lipid-Lowering Efficacy and Safety of Vytorin in Comparison With Atorvastatin in Hypercholesterolaemic Patients With Coronary Artery Disease [NCT00442897]	Phase 4	229 participants (Actual)	Interventional	2006-09-30	Completed
A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe in Healthy Male Subjects [NCT02127320]	Phase 1	24 participants (Actual)	Interventional	2014-06-30	Completed
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 Study [NCT05266586]	Phase 2	119 participants (Actual)	Interventional	2022-03-09	Completed
Efficacy, Safety, and Tolerability of Ezetimibe in Coadministration With Simvastatin in the Therapy of Adolescents With Heterozygous Familial Hypercholesterolemia [NCT00129402]	Phase 3	248 participants (Actual)	Interventional	2005-08-31	Completed
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial) (Phase 3, Protocol No. P05522) [NCT00867165]	Phase 3	138 participants (Actual)	Interventional	2009-05-21	Completed
Early Alirocumab to Reduce LDL-C in Myocardial Infarction [NCT03750760]	Phase 4	0 participants (Actual)	Interventional	2020-01-31	Withdrawn(stopped due to Changes in funding decision)
Same Lipid Lowering by Atorvastatin Versus Atorvastatin Plus Ezetimibe on Coronary Plaque Progression [NCT01086020]	Phase 4	400 participants (Anticipated)	Interventional	2010-01-31	Recruiting
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Ezetimibe + Simvastatin on Clinical Outcomes in Patients With Aortic Stenosis [NCT00092677]	Phase 3	1,873 participants (Actual)	Interventional	2001-01-31	Completed
Assessment of Sterol Metabolism in Sitosterolemia: A Pilot Study of Patients Treated With Ezetimibe [NCT01584206]		8 participants (Actual)	Interventional	2012-04-30	Completed
Synergistic Effect of Simvastatin and Ezetimibe on Lipid and Pro-inflammatory Profiles in Pre-diabetic Subjects [NCT01103648]		50 participants (Actual)	Interventional	2005-06-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Effects of Ezetimibe on the Postprandial Lipoprotein Response in Patients With Primary Hypercholesterolemia [NCT00101439]	Phase 3	58 participants (Actual)	Interventional	2005-11-10	Completed
Effect of High-intensity Statin With Ezetimibe COmbination theRapy Versus High-intensity sTatin Monotherapy After Percutaneous Coronary Intervention With Drug-eluting Stents; the ESCORT Trial [NCT05782777]		4,310 participants (Anticipated)	Interventional	2023-03-31	Not yet recruiting
Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of CKD-391 in Healthy Male Subjects [NCT02461004]	Phase 1	52 participants (Actual)	Interventional	2015-07-31	Completed
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia [NCT03288038]	Phase 3	382 participants (Actual)	Interventional	2014-10-13	Completed
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Factorial Design, Phase III Clinical Trial To Evaluate the Efficacy and Safety of Atorvastatin+Ezetimibe Combination Therapy and Atorvastatin Monotherapy in Patients With Primary [NCT02451098]	Phase 3	385 participants (Actual)	Interventional	2015-03-31	Completed
A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid/Ezetimibe Fix [NCT05103254]		20 participants (Anticipated)	Observational	2021-09-01	Recruiting
Comparison of High-dose Rosuvastatin Versus Low-dose Rosuvastatin Plus Ezetimibe on Carotid Plaque Inflammation in Patients With Acute Coronary Syndrome [NCT04056169]	Phase 4	50 participants (Actual)	Interventional	2017-06-29	Completed
A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease [NCT03434613]	Phase 4	64 participants (Actual)	Interventional	2018-05-14	Completed
A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conv [NCT02476006]	Phase 3	998 participants (Actual)	Interventional	2015-06-23	Completed
A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin Versus Switch [NCT00862251]	Phase 3	808 participants (Actual)	Interventional	2009-04-30	Completed
A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart Disease [NCT00409773]	Phase 3	1,143 participants (Actual)	Interventional	2007-01-31	Completed
A Multicenter Prospective Randomized-controlled Interventional Study to Evaluate the Effect of High Dose Rosuvastatin Versus High Dose Rosuvastatin and Ezetimibe in Acute Ischemic Stroke Patients [NCT05884502]	Phase 4	330 participants (Anticipated)	Interventional	2022-09-01	Recruiting
A Phase III Efficacy And Safety Study of Ezetimibe (SCH58235) 10 mg in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial Hypercholesterolemia [NCT03884452]	Phase 3	50 participants (Actual)	Interventional	2000-05-03	Completed
Long-Term, Safety and Tolerability Study of SCH 58235 or Placebo in Addition to Atorvastatin in Subjects With Primary Hypercholesterolemia [NCT03882892]	Phase 3	400 participants (Anticipated)	Interventional	2001-02-02	Completed
Lipid-lowering Regimes Improve Oxidative Stress, Tryptophan Degradation in Hypercholesterolemia Chronic Kidney Disease Patients [NCT03543774]	Phase 4	30 participants (Anticipated)	Interventional	2018-06-15	Recruiting
A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Japanese Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related [NCT02634580]	Phase 3	61 participants (Actual)	Interventional	2016-02-27	Completed
A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Drug-drug Interaction Between LGEV1801 and LGEV1802 in Healthy Korean Male Volunteers [NCT03532854]	Phase 1	42 participants (Actual)	Interventional	2018-05-28	Completed
A Phase III, Open-label, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Rosuvastatin Monotherapy [NCT02748057]	Phase 3	135 participants (Actual)	Interventional	2016-05-18	Completed
Estudo clínico Randomizado, Controlado e Duplo-cego do Impacto da inibição de um Transportador de Membrana do Colesterol na absorção da Vitamina D [NCT02234544]	Phase 4	52 participants (Actual)	Interventional	2014-10-31	Completed
A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea [NCT00496730]	Phase 3	256 participants (Actual)	Interventional	2007-07-31	Completed
A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia [NCT01763866]	Phase 3	2,067 participants (Actual)	Interventional	2013-01-15	Completed
A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: [NCT00202878]	Phase 3	18,144 participants (Actual)	Interventional	2005-10-17	Completed
SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI® (Fixed Dose Combination [NCT05546398]		500 participants (Actual)	Observational	2022-04-22	Completed
The Effect of Simvastatin on Bone Density in Postmenopausal Women With Type 2 Diabetes: a Double-blind, Randomized Active-comparator (Ezetimibe) Controlled Clinical Trial [NCT05613400]	Phase 4	240 participants (Anticipated)	Interventional	2022-04-13	Enrolling by invitation
A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Hypercholesterolemia [NCT00092690]	Phase 3	1,902 participants (Actual)	Interventional	2003-06-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target [NCT00092612]	Phase 3	372 participants (Actual)	Interventional	2003-05-31	Completed
Drugs in Breast Milk [NCT05543122]		304 participants (Anticipated)	Observational	2022-03-09	Recruiting
Effects of High-dose StAtin Versus Low-dose Statin Plus Ezetimibe on Statin-Associated Muscle Symptoms & on Reaching Target LDL-C Levels Among Elderly Patients With Atherosclerotic Cardiovascular Disease [NCT04826354]	Phase 4	582 participants (Actual)	Interventional	2021-08-11	Completed
CKD-391 in Healthy Volunteers to Investigate the Pharmacokinetic Drug Interaction Between Atorvastatin an Ezetimibe After Oral Administration [NCT02288338]	Phase 1	36 participants (Actual)	Interventional	2014-11-30	Completed
A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers [NCT02289430]	Phase 1	59 participants (Actual)	Interventional	2014-12-31	Completed
A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less [NCT01763827]	Phase 3	615 participants (Actual)	Interventional	2013-01-21	Completed
A Randomized, Placebo- and Ezetimibe-controlled, Dose-ranging Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Hypercholesterolemic Subjects With a 10-year Framingham Risk Score of 10% or Less [NCT01375777]	Phase 2	411 participants (Actual)	Interventional	2011-07-06	Completed
A Randomized Double-blinded, Double Dummy, Active-controlled, Parallel Design, Phase 3 Clinical Trial to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolem [NCT04669041]	Phase 3	305 participants (Actual)	Interventional	2020-12-08	Completed
Study on the Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy Subjects [NCT05681247]	Phase 1	59 participants (Actual)	Interventional	2017-12-17	Completed
The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes [NCT01384058]	Phase 4	41 participants (Actual)	Interventional	2007-11-30	Completed
An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase [NCT02890992]	Phase 2	42 participants (Actual)	Interventional	2016-09-15	Completed
A MC, DB, Rand, Study to Evaluate Efficacy, Safety and Tolerability of Eze/Simva 10/40 mg, Atorva 40 mg, Rosuva 10 mg in Achieving LDL-C <2 mmol/l in Pts With CVD...on Simva 40 mg With LDL-C ³2 mmol/l [NCT00462748]	Phase 3	786 participants (Actual)	Interventional	2007-03-31	Completed
A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg When Added to Atorvastatin 10 mg Versus Titration to Atorvastatin 20 mg and to 40 mg in Elderly Patients With Hypercholesterolemia [NCT00418834]	Phase 3	1,053 participants (Actual)	Interventional	2007-01-31	Completed
Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of CKD-391 in Healthy Male Subjects [NCT02501200]	Phase 1	46 participants (Actual)	Interventional	2015-08-31	Completed
An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia [NCT03510715]	Phase 3	18 participants (Actual)	Interventional	2018-08-31	Completed
"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Factorial Design Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet in Patients With Primary Hypercholesterolemia" [NCT00092664]	Phase 3	1,104 participants (Actual)	Interventional	2003-01-31	Completed
A Multi-center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg/Day When Added to Ongoing Therapy With a Statin Versus Statin Therapy Alone, in Patients With Hypercholestero [NCT00092586]	Phase 3	2,904 participants (Actual)	Interventional	2002-09-30	Completed
A Multicenter Study to Assess the Cholesterol Lowering Level of Switching to an Investigational Drug Compared to Doubling the Dose of an Investigational Drug in Patients With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease [NCT00090168]	Phase 3	435 participants (Actual)	Interventional	2004-01-27	Completed
Intravascular Ultrasound Evaluation of the Intervention Effect of Simvastatin Combined With Ezetimibe on Coronary Borderline Lesion in Patients With Stable Angina Pectoris and Diabetes Mellitus Compared With Simvastatin Alone [NCT03771053]		240 participants (Anticipated)	Interventional	2018-01-01	Recruiting
Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects [NCT00621699]	Phase 1	24 participants (Actual)	Interventional	2007-09-30	Completed
Efficacy of Ezetimibe/Simvastatin 10/20 mg and MK0524A (1-2 g/Day) in Patients With Mixed Hyperlipidemia and Two or More Risk Factors to Cardiovascular Disease. [NCT00738985]	Phase 4	0 participants (Actual)	Interventional	2009-11-30	Withdrawn(stopped due to The study was cancelled due to budget limitations)
Observational Study of Approaches to Lipid-lowering Therapy in Russian Patients With Coronary Heart Disease (<>) [NCT00730132]		712 participants (Actual)	Observational	2008-01-31	Completed
A Randomized, Open-Labeled, Parallel Group Comparison Study to Evaluate the Efficacy, Safety of Ezetimibe Alone Versus Statin in the Treatment of Hypercholesterolemia [NCT00753883]	Phase 4	40 participants (Actual)	Interventional	2006-07-31	Completed
Efficacy and Safety of Combination Therapy of Moderate-intensity Statin and Ezetimibe Compared to High-intensity Statin: Study Protocol for a Randomized Controlled Trial [NCT04080310]	Phase 4	270 participants (Actual)	Interventional	2018-03-15	Completed
Comparison of Low-Intensity Statin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus in Prediabetic Patients With Atherosclerotic Cardiovascular Disease [NCT05579626]		4,000 participants (Anticipated)	Interventional	2023-03-14	Recruiting
A Multicenter, Randomized, Open-labeled, Parallel Group Comparison Study to Evaluate the Efficacy, Safety and Tolerability of Ezetimibe Added to Ongoing Statin Therapy Versus Doubling the Dose of Ongoing Statin in the Treatment of Hypercholesterolemia. [NCT00652327]	Phase 4	83 participants (Actual)	Interventional	2005-12-31	Completed
Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk [NCT00814723]	Phase 4	90 participants (Actual)	Interventional	2005-09-30	Completed
Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients Receiving Protease Inhibitors: a Randomized, Prospective, Controlled Pilot Study. [NCT00843661]	Phase 4	60 participants (Anticipated)	Interventional	2009-03-31	Recruiting
A Multicenter, Randomized, Parallel Groups, Placebo-Controlled Study Comparing the Efficacy, Safety, and Tolerability of the Daily Co-Administration of Ezetimibe 10 mg or Ezetimibe Placebo to Ongoing Treatment With Atorvastatin 10 mg in Subjects With Prim [NCT00202904]	Phase 4	81 participants (Actual)	Interventional	2005-05-31	Completed
Te Influence of Ezetimibe on Gallbladder Function [NCT00634140]		0 participants (Actual)	Interventional	2009-08-31	Withdrawn(stopped due to Study was never initiated due to lack of funding support.)
A Randomized, Double-blind, Multi-center Clinical Trial to Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin Combination Tablets and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets [NCT03847506]	Phase 4	127 participants (Actual)	Interventional	2018-07-05	Completed
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combo Tab Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg in Patients With Primary High Cholesterol and High Cardiovascular [NCT00479713]	Phase 3	618 participants (Actual)	Interventional	2007-02-01	Completed
Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty - The REMEDY Study [NCT02205775]	Phase 3	280 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to difficult recruitment)
A Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Effects of Ezetimibe on the Plasma Appearance of 7-Ketocholesterol After an Oral Bolus in Patients With Primary Hypercholesterolemia [NCT00794677]	Phase 4	26 participants (Actual)	Interventional	2006-06-30	Completed
Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Ezetimibe Among Filipino Patients [NCT00704535]		4,105 participants (Actual)	Observational	2006-03-31	Completed
A Phase 3, Double-Blind Efficacy and Safety Study of Ezetimibe (SCH 58235) 10 mg in Addition to Atorvastatin Compared to Placebo in Subjects With Primary Hypercholesterolemia (Protocol P00692) [NCT03867110]	Phase 3	628 participants (Actual)	Interventional	2000-03-06	Completed
A Multicenter, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 mg In Subjects With Prim [NCT00651404]	Phase 3	137 participants (Actual)	Interventional	2004-01-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Co-administered With Existing Simvastatin 10mg or 20mg in Attaining Low-Density Lipoprotein Cholesterol Targ [NCT00651014]	Phase 4	82 participants (Actual)	Interventional	2004-01-31	Terminated(stopped due to slow subject recruitment and lack of medical and scientific merit due to change in new standard of therapy during that same period.)
A Randomized Open Label Trial to Assess the Effect of Plant Sterols Associated With Ezetimibe in LDL-cholesterol Levels in Coronary Patients Previously on Statin Therapy [NCT02089867]	Phase 2/Phase 3	47 participants (Actual)	Interventional	2006-10-31	Completed
Ezetimibe Reverse Cholesterol Transport (RCT) Pilot Study [NCT00701727]	Phase 4	31 participants (Actual)	Interventional	2008-06-30	Completed
The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients [NCT02103049]	Phase 4	80 participants (Actual)	Interventional	2014-04-30	Completed
Ezetimibe for Patients With Chronic Hepatitis D [NCT03099278]	Phase 2	20 participants (Anticipated)	Interventional	2017-01-31	Recruiting
A Pilot Study of the Effect of Ezetimibe in Patients With Chronic Hepatitis C Infection [NCT02126137]	Phase 1	20 participants (Anticipated)	Interventional	2013-10-31	Recruiting
A Randomized, Double-Blind, Active-Controlled, Multicenter, Crossover Study to Evaluate the Efficacy of Ezetimibe/Atorvastatin 10 mg/40 mg Fixed-Dose Combination Tablet Compared to Co-Administration of Marketed Ezetimibe 10 mg and Atorvastatin 40 mg in Pa [NCT01370603]	Phase 3	328 participants (Actual)	Interventional	2011-09-30	Completed
Antilipidemic Ezetimibe Induces Regression of Endometriotic Explants in a Rat Model of Endometriosis [NCT04844996]	Early Phase 1	18 participants (Actual)	Interventional	2019-09-01	Completed
[NCT02251847]	Phase 3	400 participants (Anticipated)	Interventional	2014-07-31	Recruiting
Ezetimibe/Simvastatin and Rosuvastatin for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy: a Randomized, Double Blinded, Placebo Controlled Clinical Trial [NCT02129231]	Phase 2	74 participants (Actual)	Interventional	2012-02-29	Completed
Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome [NCT00988364]	Phase 4	30 participants (Actual)	Interventional	2007-03-31	Completed
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed Dose Combination Daily on Top of Maximally Tolerated Lipid-Modifying Therapy in Participants With Heterozygous Familial Hyp [NCT06005597]	Phase 3	400 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Effect of Ezetimibe on Oxidized LDL Cholesterol [NCT01008345]	Phase 4	100 participants (Actual)	Interventional	2008-09-30	Completed
Plaque REgression With Cholesterol Absorption Inhibitor or Synthesis Inhibitor Evaluated by IntraVascular UltraSound [NCT01043380]	Phase 4	245 participants (Actual)	Interventional	2010-01-31	Completed
Open-label, Long-term Study of Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors [NCT00654095]	Phase 3	146 participants (Actual)	Interventional	2007-12-01	Completed
Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects [NCT00376246]	Phase 4	28 participants (Actual)	Interventional	2006-09-30	Completed
A Prospective, Non-Intervention, Multi-Center Observational Study to Evaluate the Efficacy and Safety of CREZET Tablet in Patients With Dyslipidemia [NCT05889143]		15,000 participants (Anticipated)	Observational	2023-05-24	Recruiting
Evaluating the Anti-Proliferative Effects of Atorvastatin on the Endometrium of Endometrial Cancer Patients: A Pre-Operative Window Study [NCT02767362]	Early Phase 1	24 participants (Actual)	Interventional	2015-11-30	Completed
Additive Effect of Ezetimibe Upon Simvastatin Treatment on Systemic Inflammatory Activity and Endothelial Function During Myocardial Infarction [NCT00905905]	Phase 4	40 participants (Anticipated)	Interventional	2009-05-31	Completed
Orient Pharma Co., Ltd. [NCT04643093]	Phase 3	390 participants (Actual)	Interventional	2020-08-01	Completed
[NCT02749994]	Phase 3	396 participants (Actual)	Interventional	2016-04-30	Completed
A Multicenter., Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at Moderately High Risk for CHD Not Adequately Controlled on Atorvastatin 20 Mg [NCT00276458]	Phase 3	196 participants (Actual)	Interventional	2006-02-28	Completed
Post - Marketing Surveillance of the Safety, Tolerability and Efficacy of Vytorin (Ezetimibe + Simvastatin) Tablet Among Filipino Patients [NCT00909389]		4,748 participants (Actual)	Observational	2006-11-30	Completed
A 6wk Open-Label, Randomised, Multicentre, Phase IIIb, Parallel Group Study to Compare the Safety & Efficacy of Rosuvastatin 40mg in Comb.With Ezetimibe 10mg in Subjects With Hypercholesterolaemia & CHD or Atherosclerosis or a CHD Risk Equiv. (10 yr Risk [NCT00653445]	Phase 3	0 participants	Interventional	2004-06-30	Completed
Cholesterol Lowering Via Bempedoic Acid/Ezetimibe, an ACL-Inhibiting Regimen in Acute Coronary Syndrome (CLEAR ACS) Study [NCT05263778]	Phase 4	500 participants (Anticipated)	Interventional	2022-03-31	Not yet recruiting
A Multicenter, Double-blind, Randomized, Active-controlled Parallel Groups Study Comparing The Efficacy and Safety of The Daily Co-Administration of Ezetimibe 10 mg With Simvastatin 20 mg Vs Simvastatin Or Ezetimibe Alone in Subjects With Primary Hypercho [NCT00650819]	Phase 3	240 participants (Actual)	Interventional	2004-06-01	Completed
A Multicenter, Randomized, Double-blind, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypercholesterolemia [NCT00110435]	Phase 3	1,229 participants (Actual)	Interventional	2005-05-31	Completed
A Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Fenofibrate Coadministration in Patients With Mixed Hyperlipidemia [NCT00093899]	Phase 3	611 participants (Actual)	Interventional	2004-11-30	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia - 1 Year Open-Label Extension [NCT00092807]	Phase 3	37 participants (Actual)	Interventional	2001-02-12	Completed
[NCT00681525]	Phase 1	18 participants (Actual)	Interventional	2008-04-30	Completed
Goal Achievement of A1c and LDL in a Randomized Trial Comparing Colesevelam vs. Ezetimibe as Add-on to Baseline Statin Therapy: The GOAL-RCT Trial [NCT02682680]	Phase 4	200 participants (Actual)	Interventional	2016-01-11	Completed
[NCT00972829]	Phase 4	30 participants (Anticipated)	Interventional	2009-09-30	Recruiting
A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD [NCT00525824]	Phase 3	1,743 participants (Actual)	Interventional	2007-08-31	Completed
A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono) [NCT05763875]	Phase 3	300 participants (Anticipated)	Interventional	2023-03-15	Recruiting
[NCT00810303]	Phase 1	12 participants (Actual)	Interventional	2009-03-31	Completed
Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy in Reduction of Progression of Atherosclerosis Among Patients With Systemic Lupus Erythematosus: A Randomized Single-Blind Trial [NCT02548936]	Early Phase 1	30 participants (Actual)	Interventional	2015-04-30	Enrolling by invitation
Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects [NCT00621101]	Phase 1	24 participants (Actual)	Interventional	2007-04-30	Completed
Effects of Ezetimibe in Association With Statins on Postprandial Lipemia in Type 2 Diabetic Patients [NCT00699023]	Phase 4	13 participants (Anticipated)	Interventional	2008-06-30	Completed
Randomized Trial of Ezetimibe Versus nutraCeuticals in Statin-intoLerant patIents Treated With PercutaneouS Coronary Intervention [NCT01490229]	Phase 4	100 participants (Anticipated)	Interventional	2013-01-31	Recruiting
INdians Followed for INtensive Lipid Lowering Treatment and Its safetY: To Assess The Safety And Effectiveness Of Ezetimibe Co-Administered With Any Statin Compared To Doubling Of Current Statin Daily Dose In South Asian Canadians [NCT00664469]	Phase 3	64 participants (Actual)	Interventional	2007-08-31	Terminated(stopped due to Poor enrollment)
Transplantation Using Hepatitis C Positive Donors to Hepatitis C Negative Recipients: A Safety Trial [NCT04017338]	Phase 3	40 participants (Anticipated)	Interventional	2018-08-06	Recruiting
Effects of Simvastatin Versus Simvastatin Combined With Ezetimibe on Blood Coagulation in Patients With Acute Coronary Events: Relationship With Cholesterol-Lowering and Anti-Inflammatory Properties [NCT00725829]		100 participants (Anticipated)	Interventional	2008-06-30	Recruiting
Regulation of Cholesterol Absorption: LDL Cholesterol Response to a Combination of Phytosterols and Ezetimibe (Phyto-3) [NCT00863265]	Early Phase 1	22 participants (Actual)	Interventional	2009-06-30	Completed
Evaluation of the Pharmacokinetics and Safety of Raltegravir and Ezetimibe When Co-administered to Male and Female Healthy Volunteers [NCT00772551]	Phase 1	26 participants (Actual)	Interventional	2008-06-30	Completed
SCH 58235: A Multicentre, Randomised, Parallel Group, Placebo-Controlled Study Comparing the Efficacy, Safety, And Tolerability of the Daily Co-Administration of Ezetimibe 10 mg With Atorvastatin 10 mg vs. Ezetimibe Placebo With Atorvastatin 10 mg in Untr [NCT00653796]	Phase 4	148 participants (Actual)	Interventional	2003-09-01	Completed
Evaluation of Long-term Lipid-lowering Therapy on Myocardial Electrical Heterogeneity, Myocardial Deformation, Arterial Stiffness and Quality of Life in Patients With Primary STEMI/NSTEMI With Coronavirus Infection COVID-19 [NCT04900155]		45 participants (Actual)	Interventional	2020-11-20	Active, not recruiting
Assessment of the Effects of Long-term Lipid-lowering Therapy on Parameters of Electrical Myocardial Heterogeneity, Myocardial Deformation Characteristics, Vascular Rigidity, and Quality of Life in Patients With Primary STEMI or NSTEMI [NCT04347434]	Phase 4	300 participants (Anticipated)	Interventional	2020-02-12	Recruiting
The Effect of Usual Dose Rosuvastatin Plue Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque: A Randomized Controlled Trial [NCT03169985]	Phase 4	280 participants (Anticipated)	Interventional	2017-07-12	Recruiting
A Retrospective Survey to Evaluate the Effectiveness and Safety of Dual Inhibition Lipid-lowering Regimen in the Treatment of Dyslipidemic Patients in Normal Practice [NCT00726856]		1,200 participants (Anticipated)	Observational	2007-05-31	Completed
A Multicenter, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Simvastatin 20 Mg In Subjects With Prima [NCT00651274]	Phase 4	144 participants (Actual)	Interventional	2003-04-01	Completed
A Randomized, Double-Blind, Active Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination BMS-201038 (AEGR-733) and Ezetimibe vs. Monotherapy in Subjects With Moderate Hypercholesterolemia [NCT00405067]	Phase 2	60 participants (Actual)	Interventional	2006-05-31	Completed
A Multi-center, Randomized, Double-Blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWJ1451 in Patients With Hypertension and Dyslipidemia [NCT04161001]	Phase 3	237 participants (Anticipated)	Interventional	2019-11-20	Recruiting
The Impact of the Time of Drug Administration on the Effectiveness of Combined Treatment of Hypercholesterolemia With ROSuvastatin and EZEtimibe (ROSEZE) - A Single-center, Crossover, Open-label Study [NCT02772640]	Phase 4	83 participants (Actual)	Interventional	2016-03-31	Completed
Retrospective Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin / Ezetimibe as a Treatment for Patients With Dyslipidaemia in Usual Medical Practice. [NCT04862962]		120 participants (Actual)	Observational	2021-09-30	Completed
Vytorin on Carotid Intima-media Thickness and Overall Rigidity [NCT00738296]	Phase 4	90 participants (Actual)	Interventional	2005-04-30	Completed
A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients With or Without Statin Intolerance [NCT01941836]	Phase 2	349 participants (Actual)	Interventional	2013-09-30	Completed
The Effect Of Ezetimibe In Addition To Optimal Cholesterol-Lowering Statin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction - Assessed By Optical Coherence Tomography And Intravascular Ultrasound. [NCT01385631]	Phase 4	87 participants (Actual)	Interventional	2011-06-30	Completed
A Phase II, Fixed-sequenced, Open- Label, Research Study to Assess Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Therapies in Healthy Volunteers [NCT00359281]	Phase 2	125 participants (Actual)	Interventional	2006-03-31	Completed
A Randomized, Double-blinded, Multi-center, Phase III Study to Compare The Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia [NCT04074551]	Phase 3	145 participants (Actual)	Interventional	2019-07-16	Completed
Evaluation of Potential for Pharmacokinetic Drug Interaction Between SCH 58235 and Pitavastatin [NCT00653913]	Phase 1	18 participants (Actual)	Interventional	2004-03-31	Completed
SCH 465981: Assessment of Bi-Directional Interaction Between Components of Vytorin® (Ezetimibe and Simvastatin) and Niaspan® (Niacin Extended-Release Tablets) in Healthy Subjects [NCT00652431]	Phase 1	18 participants (Actual)	Interventional	2007-05-31	Completed
A Double-Blind, Randomized, Multicenter, Active-Comparative, 12-Week Study to Assess the Efficacy and Safety of the Drug in Conjunction With Another Drug in Korean Patients With Primary Hypercholesterolemia [NCT00157911]	Phase 3	136 participants (Actual)	Interventional	2002-12-31	Completed
An Open-Label, Multicenter Study to Assess the Efficacy of Switching to a Combination Tablet Ezetimibe/Simvastatin 10mg/40mg, Compared to Doubling the Dose of Statin in Patients Hospitalized With a Coronary Event [NCT00132717]	Phase 3	450 participants (Actual)	Interventional	2005-01-01	Completed
Effects on Atherosclerosis Regression of Ezetimibe Monotherapy or Ezetimibe Plus Simvastatin Combination Therapy: Evaluation by Fluorodeoxyglucose Positron Emission Tomography [NCT00926055]		0 participants (Actual)	Interventional	2011-09-30	Withdrawn
Prospective Evaluation of LDL Levels in Patients Converted From Zetia (Ezetimibe)10 mg to 5 mg [NCT00762229]		39 participants (Actual)	Interventional	2007-07-31	Completed
"An Open-Label, Randomized, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of Switching to Rosuvastatin 10 mg Daily Versus Atorvastatin 10 mg Daily With Ezetimibe 10 mg Daily Versus Doubling the Dose of Atorvastatin to 20 mg Daily in [NCT00651378]	Phase 4	87 participants (Actual)	Interventional	2004-09-01	Terminated(stopped due to Slow enrollment [HIGH SCREEN FAILURE RATE])
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to An Ongoing Regimen of Ezetimibe 10 mg in Patients Homozygous Sitosterolemia [NCT00092898]	Phase 3	30 participants (Actual)	Interventional	2004-10-31	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK0653 When Added to Current Regimen in Patients With Homozygous Sitosterolemia [NCT00092820]	Phase 3	58 participants (Actual)	Interventional	2001-02-12	Completed
A Pilot Study of the Safety, Efficacy, and Tolerability of Ezetimibe (Zetia) in Combination With Statin Therapy for the Treatment of Elevated LDL Cholesterol in HIV-Infected Subjects [NCT00099684]		44 participants (Actual)	Interventional	2005-11-30	Completed
An Open-label Exploratory Study of the Pharmacokinetic Interaction of CXA-10 Administered to Steady State With Pravastatin and Vytorin® (Simvastatin and Ezetimibe) in Healthy Males [NCT02547402]	Phase 1	10 participants (Actual)	Interventional	2015-12-31	Completed
Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels [NCT00955227]		60 participants (Actual)	Interventional	2009-07-31	Completed
[NCT00548145]		38 participants (Actual)	Interventional	2007-11-30	Terminated
[NCT02942602]		58 participants (Actual)	Interventional	2014-04-03	Completed
Efficacy and Safety Study of Fluvastatin and Ezetimibe Combined Versus Fluvastatin Alone [NCT00171288]	Phase 3	83 participants (Actual)	Interventional	2003-08-31	Completed
A Randomized Trial of the Long-term Clinical Effects of Raising HDL Cholesterol With Extended Release Niacin/Laropiprant [NCT00461630]	Phase 3	25,673 participants (Actual)	Interventional	2007-01-31	Completed
A Single Center, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 Mg In Subjects With Pr [NCT00319449]	Phase 4	22 participants (Actual)	Interventional	2005-09-30	Completed
A Multicenter, Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at High Risk for CHD Not Adequately Controlled on Atorvastatin 40 Mg [NCT00276484]	Phase 3	579 participants (Actual)	Interventional	2006-02-28	Completed
A Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Groups Study Comparing the Efficacy and Safety of Vytorin Versus Placebo in Subjects With Primary Hypercholesterolemia [NCT00413972]	Phase 3	392 participants (Actual)	Interventional	2006-04-30	Completed
Assessment of the Effects of Ezetimibe on Coronary Plaque Volume in Patients With Acute Coronary Syndrome [NCT01068093]	Phase 4	120 participants (Anticipated)	Interventional	2010-10-31	Recruiting
A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing the Efficacy, Safety, and Tolerability of Co-administration of Ezetimibe 10 mg With Ongoing Treatment With Simvastatin 20 mg Versus Doubling the Dose of Simvastati [NCT00423488]	Phase 3	93 participants (Actual)	Interventional	2005-07-12	Completed
Platelet Function in Diabetic Patients With and Without Renal Impairment, and the Effects of Lipid Lowering Treatment [NCT01035320]	Phase 4	39 participants (Actual)	Interventional	2006-01-31	Completed
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction [NCT00203476]	Phase 4	30 participants (Actual)	Interventional	2005-05-31	Completed
Moderate-intensity Rosuvastatin Plus Ezetimibe Versus High-intensity Rosuvastatin for Target LDL-C Goal Achievement in Patients With Recent Ischemic Stroke: a Randomized Clinical Trial [NCT03993236]	Phase 4	584 participants (Anticipated)	Interventional	2019-09-09	Recruiting
A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia [NCT05930028]	Phase 3	156 participants (Anticipated)	Interventional	2023-07-13	Recruiting
A Phase III, Randomized, Active Comparator-controlled, Clinical Trial to Study the Efficacy and Safety of MK-0653H in Japanese Patients With Hypercholesterolemia. [NCT02741245]	Phase 3	321 participants (Actual)	Interventional	2016-06-09	Completed
A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis [NCT01950884]	Phase 4	45 participants (Anticipated)	Interventional	2013-10-31	Enrolling by invitation
Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial [NCT04626973]		3,048 participants (Anticipated)	Interventional	2021-01-15	Recruiting
To Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia [NCT04584736]	Phase 3	283 participants (Actual)	Interventional	2019-06-11	Completed
A Randomized, Double Blind, Parallel, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A in Patient With Primary Hypercholesterolemia or Mixed Dyslipidemia [NCT05970679]	Phase 3	252 participants (Actual)	Interventional	2022-08-17	Completed
A Clinical Trial to Compare the Pharmacokinetics and Safety of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe in Healthy Male Volunteers [NCT02029625]	Phase 1	41 participants (Actual)	Interventional	2014-02-28	Completed
Clinical Comparison of Low-dose Rosuvastatin Plus Ezetimibe Combination Therapy and High-dose Rosuvastatin Monotherapy in Patients With Minimal to Intermediate Coronary Artery Disease Without Percutaneous Coronary Intervention : A Prospective, Multicenter [NCT06186037]	Phase 4	6,356 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
A Randomized, Double-Blinded Study of Simvastatin 20 mg/Day Versus Vytorin 10/20 in Subjects With Lipid Profiles Not Meeting Current NCEP Guidelines, Following a Low-Carbohydrate Diet [NCT00566267]	Phase 2/Phase 3	58 participants (Actual)	Interventional	2006-04-30	Completed
Reverse Cholesterol Transport in Humans [NCT01603758]	Phase 1	132 participants (Actual)	Interventional	2014-01-31	Completed
Impact of Combined Ezetimibe and Atorvastatin Therapy on Coronary Thin-cap Fibroatheroma As Assessed by Optical Coherence Tomography [NCT02588235]	Phase 4	100 participants (Anticipated)	Interventional	2015-10-31	Recruiting
Open-label, Long-term Study of Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase Inhibitors [NCT00653523]	Phase 3	151 participants (Actual)	Interventional	2007-12-01	Completed
A Randomized, Single-dose, Open, Crossover Clinical Trial to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone in Healthy Male Volunteers [NCT02730689]	Phase 1	66 participants (Actual)	Interventional	2014-12-31	Completed
A Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg and Lapaquistat Acetate 100 mg Administered in Combination With Ezetimibe 10 mg vs Ezetimibe 10 mg in Su [NCT00268697]	Phase 3	1,267 participants (Actual)	Interventional	2005-10-31	Completed
Effect of Diabetes Mellitus on Cholesterol Absorption, Synthesis and Statin Efficacy [NCT00879710]		57 participants (Actual)	Interventional	2008-08-31	Completed
In Silico Non Interventional Secondary Use of Data Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease [NCT05974345]		204,691 participants (Actual)	Observational	2023-11-03	Active, not recruiting
Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) [NCT02768545]	Phase 4	12 participants (Anticipated)	Interventional	2013-06-30	Recruiting
A Study to Evaluate the Definitive Bioequivalence of SCH 900068 With Marketed Products (Protocol No. P07551) [NCT01236430]	Phase 1	200 participants (Actual)	Interventional	2011-02-28	Completed
A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe (+) Simvastatin Versus Atorvastatin in Hypercholesterolemic Patients With Diabetes Mellitus or Metabolic Syndrome [NCT00157924]	Phase 4	190 participants (Actual)	Interventional	2005-11-30	Completed
Risk Reduction in Coronary Heart Disease - a Prospective Randomized Study [NCT00679237]		1,600 participants (Actual)	Interventional	2007-09-30	Completed
A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to [NCT01154036]	Phase 3	1,547 participants (Actual)	Interventional	2010-07-31	Completed
A Prospective, Randomized Study to Determine the Effect of Ezetimibe in Addition to Rosuvastatin on Lipids in Participants With the Hypercholesterolemia Associated With HIV Antiretroviral Therapy [NCT00908011]		43 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized, Double-blind, Active-controlled, Multicenter Phase III Trial to Evaluate the Efficacy and Safety of Co-administrated AD-2071 and AD-2073 in Patients With Primary Hypercholesterolemia and Essential Hypertension [NCT04158076]	Phase 3	131 participants (Actual)	Interventional	2020-01-23	Completed
Designated Drug Use Investigation (Long-Term Administration) of Zetia 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy [NCT00705211]		1,794 participants (Actual)	Observational	2007-06-30	Completed
A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Ezetimibe Treatment in Patients With Primary Hypercholesterolemia [NCT00677248]	Phase 2	120 participants (Anticipated)	Interventional	2008-04-30	Completed
Randomized Comparison of the CHOlesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant patientS - The CHOLESS Trial [NCT01807078]	Phase 4	200 participants (Anticipated)	Interventional	2014-01-31	Not yet recruiting
Phase IV Study for Efficacy and Safety of Evolocumab Added to Ezetimibe (Standard of Care) in High Cardiovascular Risk Haemodialized Statin Intolerant Patients With Hypercholesterolemia [NCT04659525]	Phase 4	50 participants (Anticipated)	Interventional	2020-11-01	Recruiting
Long-Term, Open-Label, Safety and Tolerability Study of SCH 58235 in Addition to Atorvastatin or Simvastatin in the Therapy of Homozygous Familial Hypercholesterolemia [NCT03885921]	Phase 3	44 participants (Actual)	Interventional	2000-10-25	Completed
A Multicenter, Randomized, Double-blind, Active-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia [NCT04659070]	Phase 3	156 participants (Anticipated)	Interventional	2020-07-15	Recruiting
Rho-kinase in Patients With Atherosclerosis: Effects of Statins A Randomized Clinical Trial Comparing Ezetimibe/Simvastatin and Simvastatin [NCT00560170]	Phase 4	40 participants (Actual)	Interventional	2007-09-30	Completed
A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia [NCT01644474]	Phase 3	103 participants (Actual)	Interventional	2012-07-31	Completed
[NCT01857843]	Phase 4	160 participants (Actual)	Interventional	2009-11-30	Completed
Long-Term, Open-Label, Safety and Tolerability Study of Ezetimibe (SCH 58235) in Addition to Atorvastatin in Subjects With Coronary Heart Disease or Multiple Risk Factors and With Primary Hypercholesterolemia Not Controlled by a Starting Dose (10 mg) of A [NCT03882996]	Phase 3	432 participants (Actual)	Interventional	2000-10-06	Completed
Austrian Cholesterol Screening And Treatment II (ACT II) [NCT01381679]		1,682 participants (Actual)	Observational	2009-05-31	Completed
Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients. [NCT00738972]	Phase 3	12 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to Study terminated early due to sample size, not possible to perform further statistical analysis.)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Low Doses of the MTP-Inhibitor AEGR-733 on Hepatic Fat Accumulation as Measured by Magnetic Resonance Spectroscopy [NCT00559962]	Phase 2	260 participants (Actual)	Interventional	2007-10-31	Completed
Phase 4 Study on Effect of Ezetimibe on Platelet Aggregation and LDL Tendency to Peroxidation In Hypercholesterolemic Patients on Simvastatin [NCT00466401]	Phase 4	20 participants	Interventional	2005-02-28	Completed
A Multicenter, Open Labeled, Cross-Over Designed Prospective Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis [NCT00433823]	Phase 4	0 participants	Interventional	2007-01-31	Recruiting
"Ezetimibe Utilization Early After Acute Myocardial Infarction. EzAMI Trial" [NCT04701242]		500 participants (Anticipated)	Interventional	2021-03-24	Recruiting
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Ezetimibe-Calibrated, Multicenter Study Evaluating the Safety and Efficacy of Four Doses and Two Dose-Regimens of AVE5530 Over 4 Weeks in Patients With Mild to Moderate Primary Hypercholestero [NCT00440154]	Phase 2	206 participants (Actual)	Interventional	2007-02-28	Completed
A Multi-center, Randomized, Open-label, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of EzetimiBe/Rosuvastatin Diabetic Dislipidemia With Hypertriglyceridaemia [NCT04700436]	Phase 4	240 participants (Anticipated)	Interventional	2020-01-03	Recruiting
Effects of Ezetimibe Add-On to Statin Therapy on Adipokine Production in Obese and Metabolic Syndrome Patients With Atherosclerosis [NCT00485121]		50 participants (Anticipated)	Interventional	2007-04-30	Completed
A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Administrated AD-221 and AD-221A in Patients With Primary Hypercholesterolemia [NCT05131997]	Phase 3	290 participants (Actual)	Interventional	2021-11-16	Completed
An Open-Label Postmarking Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid and Ezetimibe in the Breast Milk of Healthy Lactating Women Administered Therapeutic Doses of Bempedoic Acid or Bempedoic Acid/Ezetimibe [NCT06021951]	Phase 4	16 participants (Anticipated)	Interventional	2023-08-04	Recruiting
Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol) [NCT03277079]	Phase 4	100 participants (Anticipated)	Interventional	2017-10-01	Not yet recruiting
Phase IV Study for Efficacy and Safety of Evolocumab Added to Ezetimibe (Standard of Care) in High Cardiovascular Risk Haemodialized Statin Intolerant Patients With Hypercholesterolemia [NCT04397653]	Phase 4	50 participants (Anticipated)	Interventional	2020-05-04	Recruiting
A Phase III Double-Blind Efficacy and Safety of Ezetimibe (SCH 58235) 10 MG in Addition to Atorvastatin in Subjects With Coronary Heart Disease or Multiple Cardiovascular Risk Factors and With Primary Hypercholesterolemia Not Controlled by a Starting Dose [NCT03867318]	Phase 3	621 participants (Actual)	Interventional	2000-04-24	Completed
SCH 058235: Assessment of a Multiple-Dose Drug Interaction Between Ezetimibe and Rosuvastatin in Healthy Hypercholesterolemic Subjects [NCT00651144]	Phase 1	40 participants (Actual)	Interventional	2003-03-31	Completed
A Study to Assess Adding Ezetimibe 30 mg to Ongoing Treatment With Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia [NCT00099996]	Phase 3	3 participants	Interventional	2004-12-31	Completed
The Comparison of the Efficacy of Ezetimibe and Fenofibrate Versus Atorvastatin Alone in the Lowering of LDL Cholesterol [NCT00299884]		45 participants (Actual)	Observational	2005-01-31	Completed
A Randomized, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor [NCT01375764]	Phase 2	160 participants (Actual)	Interventional	2011-07-28	Completed
Silent Cerebrovascular Lesion and Cognitive Decline Prevention in Atrial Fibrillation by Intensive Cholesterol Lowering in Elderly Patients [NCT00449410]	Phase 4	35 participants	Interventional	2005-05-31	Completed
Genetic Determinanats of Cardiovascular Risk Factors: Comparison of Efficacy and Safety of Ezetimibe or Statin Monotherapy to Co-Administration of Both [NCT00461968]		240 participants	Interventional	2005-02-28	Completed
A Randomized, Prospective, Double-Blind Study to Evaluate the Effects on Lipid Profile of Combined Ezetimibe and Simvastatin Therapy as Compared to Simvastatin Alone in People With Type 2 Diabetes [NCT00157482]	Phase 2	108 participants	Interventional	2005-01-31	Completed
Clinical Trial of Zocor and Vytorin in Adolescents With Type 1 Diabetes [NCT00477204]	Phase 2	9 participants (Actual)	Interventional	2007-05-31	Completed
A Prospective Randomized Open Label Blinded Endpoint Multicenter Study in Patients With Coronary Artery Disease to Assess the LDL Lowering Effect of Switching to Ezetimibe (+) Simvastatin for Cholesterol Lowering, Compared the Dose of the Statin Used. [NCT00166530]	Phase 4	367 participants (Actual)	Interventional	2005-11-30	Completed
"Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention (The ELIMIT Trial)" [NCT00687076]	Phase 4	102 participants (Actual)	Interventional	2004-04-30	Completed
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin [NCT01218204]	Phase 2	287 participants (Actual)	Interventional	2010-09-14	Completed
Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe [NCT00475826]		0 participants	Interventional	2007-04-30	Recruiting
Comparison of the Effect on Endothelial Function of Statin Therapy in High Dose Versus Low Dose Combined With Ezetimibe [NCT01241097]		60 participants (Anticipated)	Interventional	2010-03-31	Recruiting
A Double-blinded, Placebo-controlled Randomized Trial Assessing the Extent to Which Consumption of Two Different Amounts of a Non-Pharmaceutical Food Supplement Can Improve Cardiovascular Health [NCT01890889]		150 participants (Anticipated)	Interventional	2013-07-31	Recruiting
ARBITER 6: ARterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6 - HDL and LDL Treatment Strategies in Atherosclerosis (HALTS) [NCT00397657]	Phase 4	400 participants (Anticipated)	Interventional	2006-11-30	Terminated(stopped due to Independent steering committee has stopped the trial based on results of a prespecified, blinded interim analysis. It was not stopped due to safety concerns.)
Effect of Early Initiation of Evolocumab and Combination Lipid-lowering Agent on Lipid Profiles Changes in Patients With Acute Coronary Syndrome Undergoing percuTAneous coronaRy Intervention: a Prospective, Randomized Controlled Trial [NCT05661552]	Phase 4	102 participants (Anticipated)	Interventional	2022-12-01	Recruiting
A RANDOMIZED, BALANCED, OPEN LABEL, CROSSOVER, TWO PERIOD, TWO TREATMENT, TWO SEQUENCE, SINGLE DOSE, BIOEQUIVALENCE STUDY OF ACOTRAL® EZETIMIBE 10 MG TABLETS CONTAINING EZETIMIBE MANUFACTURED BY LABORATORIOS PHOENIX S.A.I.C.F, ARGENTINA AND ZETIA® EZETIMI [NCT01597700]	Phase 1	52 participants (Actual)	Interventional	2012-01-13	Completed
Comparison of Antiplatelet and Anti-inflammatory Effects of High Dose Statin Monotherapy Versus Moderate Dose Statin Plus Ezetimibe [NCT00474123]		78 participants (Actual)	Interventional	2006-01-31	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate SCH-58235 in Homozygous Sitosterolemia [NCT00045812]	Phase 2	5 participants	Interventional	2001-03-31	Completed
Comparative Efficacy Evaluation of Lipid Levels When Treated With Niaspan and Statin or Other Lipid-Modifying Therapies [NCT00079638]	Phase 4	300 participants	Interventional	2004-04-30	Completed
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of WelChol® in Combination With Zetia® Compared to Zetia® Alone in Patients With Primary Hypercholesterolemia [NCT00185107]	Phase 4	45 participants	Interventional	2005-03-31	Completed
The Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial Dysfunction in Patients With the Metabolic Syndrome. [NCT00189085]	Phase 4	20 participants	Interventional	2004-12-31	Completed
A Multicenter, Randomized, Double-Blind, Prospective, Parallel Study to Compare the Safety and Efficacy of Fenofibrate or Ezetimibe as Add-On Therapy to Atorvastatin in Subjects With Combined Hyperlipidemia, Typical of the Metabolic Syndrome [NCT00195793]	Phase 3	174 participants (Actual)	Interventional	2004-08-31	Completed
CHORD1 - CHOlesterol Lowering and Residual Risk in Diabetes, Type 1 [NCT05641753]	Phase 4	125 participants (Anticipated)	Interventional	2022-12-06	Recruiting
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons in Men With Stable Coronary Heart Disease. [NCT00481351]	Phase 4	25 participants (Actual)	Interventional	2007-06-30	Completed
A Multicenter, Open-label, 6 Week Study to Evaluate the Efficacy and Safety of Algorithm Based Intensive Treatment With Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Patients. [NCT01587235]	Phase 4	0 participants (Actual)	Interventional	2013-03-31	Withdrawn
A Multicenter, Open Study To Evaluate The Efficacy Of Ezetimibe 10 Mg Added On Statin Therapy, In Reducing LDL Cholesterol To Target Levels In Patients After Acute Coronary Syndrome [NCT00652717]	Phase 4	280 participants (Actual)	Interventional	2005-02-01	Completed
Ezetimibe Added to Statin Therapy [NCT00395473]	Phase 3	141 participants (Actual)	Interventional	2005-03-31	Completed
An Open-Label, Worldwide, Treatment Use Study to Provide Ezetimibe 10 Mg/Day to Patients With Homozygous Familial Hypercholesterolemia or Homozygous Sitosterolemia [NCT00092833]	Phase 3	49 participants (Actual)	Interventional	2002-07-31	Terminated
Randomized Parallel Group Trial Of The Efficacy And Safety Of Ezetimibe With A Statin Versus Statin Dose Doubling In Patients With Persistent Primary Hypercholesterolemia [NCT00652847]	Phase 4	1,140 participants (Actual)	Interventional	2005-05-31	Completed
A Randomized, Double-Blind, Placebo-Controlled,4-Period, Crossover Study to Evaluate the Effects of Ezetimibe and Simvastatin, Coadministered and Alone, on Intestinal Absorption of Cholesterol [NCT00652301]	Phase 3	40 participants (Actual)	Interventional	2003-07-31	Completed
A Comparison of Treatment With Ezetimibe (SCH 58235) and Simvastatin Coadministration Versus Simvastatin in Attaining the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Coronary Heart Disease (CHD) or CHD Risk Equivalent Str [NCT00551447]	Phase 3	616 participants (Actual)	Interventional	2002-01-31	Completed
A Double-Blind, Multicenter Study to Assess the LDL-C Lowering of Combination Tablets Ezetimibe/Simvastatin (10mg/20mg) and Ezetimibe/Simvastatin (10mg/40mg) Compared to Atorvastatin 20mg in Patients With Type II Diabetes. [NCT00541697]	Phase 3	648 participants (Actual)	Interventional	2005-01-19	Completed
Compare Ezetimibe 10mg and Simvastatin 40mg vs Atorvastatin 80mg Daily in Subjects With Cardiovascular Heart Disease and/or Diabetes Mellitus With Uncontrolled Lipids on Statin Therapy [NCT00395603]	Phase 3	550 participants (Anticipated)	Interventional	2006-09-30	Terminated(stopped due to This study was terminated early due to poor recruitment.)
Ezetimibe Together With Any Statin Cholesterol Enhancement [NCT00328523]	Phase 3	1,496 participants (Actual)	Interventional	2004-06-30	Completed
Multicenter,Double Blind,Randomized, 2-period, Crossover Study to Compare Ezetimibe/Simvastatin (10mg/10 mg) Combination Tablet Versus Simvastatin 80mg Tablet on Postprandial Arterial Endothelial Function in Patients With Metabolic Syndrome [NCT00817843]	Phase 4	100 participants (Actual)	Interventional	2009-04-30	Completed
The Effects of Ezetimibe/Simvastatin Versus Simvastatin Alone on Platelet and Inflammatory Biomarkers in Patients With the Metabolic Syndrome [NCT00819403]	Phase 4	15 participants (Actual)	Interventional	2009-01-31	Completed
A Randomized, Partial Blind, 3 Parallel Groups Study of the Pharmacodynamic Profile of SAR236553 (REGN727) Administered as Multiple Subcutaneous Doses, Either Alone or on Top of Ezetimibe or Fenofibrate Administered as Multiple Oral Doses in Healthy Subje [NCT01723735]	Phase 1	79 participants (Actual)	Interventional	2012-11-30	Completed
Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study [NCT01849068]	Phase 3	20 participants (Actual)	Interventional	2013-06-30	Completed
Phase 0 Trial of Presurgical Cholesterol-lowering on Prostate Cancer Cell Growth [NCT02534376]	Early Phase 1	63 participants (Actual)	Interventional	2015-09-30	Completed
Phase 3, Open-Label, Multi-Center, Double-Blind, Randomized, Parallel Group Study Efficacy and Safety of Fixed Combination Torcetrapib/Atorvastatin, Administered Once Daily (QD) Compared to Fixed Combination Ezetimibe/Simvastatin for 6 Weeks in Subjects W [NCT00267267]	Phase 3	1,784 participants	Interventional	2006-01-31	Terminated
A Phase 2 ,Multicentre, Randomised, Double Blind Double Simulation, Placebo and Positive Controlled Study to Evaluate the Efficacy and Safety of HSK31679 in Patients With Hypercholesterolemia With Non-alcoholic Fatty Liver Disease [NCT05795517]	Phase 2	200 participants (Anticipated)	Interventional	2023-04-26	Active, not recruiting
Effect of PCSK9 Inhibitors on Calcific Aortic Valve Disease: a Prospective Randomized Controlled Trial [NCT04968509]	Phase 3	160 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
A Double-Blind Efficacy and Safety Study of Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia [NCT02260648]	Phase 3	149 participants (Actual)	Interventional	2015-01-31	Terminated(stopped due to Study termination due to insufficient efficacy.)
Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis [NCT01766713]	Phase 2	50 participants (Actual)	Interventional	2013-01-31	Completed
A Randomized, Double-Blind Study of the Efficacy and Safety of Alirocumab Added on to Atorvastatin Versus Ezetimibe Added on to Atorvastatin Versus Atorvastatin Dose Increase Versus Switch to Rosuvastatin in Patients Who Are Not Controlled on Atorvastatin [NCT01730040]	Phase 3	355 participants (Actual)	Interventional	2012-10-31	Completed
Atorvastatin vs. Atorvastatin/Ezetimibe in Patients With Hypo-response to Initial Dose Statin Therapy [NCT00965055]	Phase 3	2 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to The study was terminated due to inability to recruit subjects. A total of 2/100 anticipated were radomized.)
Examination of the Effect of Ezetimibe on Glucose Metabolism - Randomized, Double-blind, Placebo-controlled Study in Type 2 Diabetes Mellitus Patients With Hypercholesterolemia - Phase 4, Protocol No. 367 (Also Known as SCH 58235, P06541) [NCT01611883]	Phase 4	152 participants (Actual)	Interventional	2012-07-02	Completed
A Phase III, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy and Safety of MK-0653C in Japanese Patients With Hypercholesterolemia [NCT02550288]	Phase 3	309 participants (Actual)	Interventional	2015-09-29	Completed
A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia at Risk for Coronary Heart Disease [NCT00783263]	Phase 3	440 participants (Actual)	Interventional	2008-11-30	Completed
A Randomized comparaTive Study Of Rosuvastatin/Ezetimibe 20/10mg and Atorvastatin/Ezetimibe 40/10mg in Patients With Coronary Artery Drug eLuting stEnt Implantation Requiring High-dose stAtin/Ezetimibe combiNaTion Therapy: TOLERANT Trial [NCT05910476]	Phase 4	200 participants (Anticipated)	Interventional	2023-05-03	Recruiting
A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe in Participants With Mild Dyslipidemia [NCT04770389]	Phase 2	112 participants (Actual)	Interventional	2021-02-23	Completed
Effect of Combination Ezetimibe and High-Dose Simvastatin vs Simvastatin Alone on the Atherosclerotic Process in Subjects With Heterozygous Familial Hypercholesterolemia (The ENHANCE Trial) [NCT00552097]	Phase 3	720 participants (Actual)	Interventional	2002-06-01	Completed
Study of Heart and Renal Protection (SHARP): The Effects of Lowering LDL-cholesterol With Simvastatin 20mg Plus Ezetimibe 10mg in Patients With Chronic Kidney Disease: a Randomized Placebo-controlled Trial [NCT00125593]	Phase 4	9,438 participants (Actual)	Interventional	2003-06-30	Completed
Study of no Pharmacokinetic Interaction Between Rosuvastatin 20 mg and Ezetimibe 10 mg, Open Design, Randomized, Single Dose, 3x6, Crossove, Healthy Volunteers in Fasting, in Fixed Combination Against Individuals Components Managed [NCT04895059]	Phase 1	36 participants (Actual)	Interventional	2017-04-30	Completed
RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial) [NCT03044665]		3,780 participants (Anticipated)	Interventional	2017-03-15	Recruiting
Real World Data Observational Study to Evaluate the Management Status of Dyslipidemia Following Administration of Statin and Ezetimibe Complex Treatment Patient in the Medical Situation by Classification of Medical Institutions in KOREA [NCT05614765]		18,000 participants (Anticipated)	Observational	2022-07-08	Recruiting
A Multicenter Clinical Trial to Compare the Efficacy and Safety Between Rosuvastatin/Ezetimibe Combination and Monotherapy of Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia [NCT03217409]	Phase 4	85 participants (Actual)	Interventional	2017-08-10	Completed
A Randomised, Double-Blind Study Comparing the Efficacy and Safety of 145 mg Fenofibrate, 10 mg Ezetimibe and Their Combination in Patients With Type IIb Dyslipidemia and Features of the Metabolic Syndrome [NCT00349284]	Phase 3	181 participants	Interventional	2005-01-31	Completed
Effects of Ezetimibe and Simvastatin on LDL Receptor Protein Expression and on LDL Receptor and HMG-CoA Reductase mRNA Expression in Mononuclear Cells: a Randomized Controlled Study in Healthy Men [NCT00317993]	Phase 4	60 participants	Interventional	2004-04-30	Completed
A Randomized, Double-Blind, Active-Controlled Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk and Not Adequately Controlled With Atorvastatin: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin Versus [NCT00782184]	Phase 3	250 participants (Actual)	Interventional	2008-11-30	Completed
A Double-blind, Randomized, Placebo-controlled, Multicenter Phase II Study of AK102 in the Treatment of Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular Disease [NCT04358432]	Phase 2	262 participants (Actual)	Interventional	2020-05-13	Completed
A 16-week Multicenter, 2-period Study to Investigate the Effect of the Combination of Fluvastatin ER 80mg and Fenofibrate 200mg on HDL-C in Comparison to the Combination of Simvastatin 20mg and Ezetimibe 10mg in Patients With Metabolic Syndrome [NCT00385658]	Phase 4	75 participants (Actual)	Interventional	2006-08-31	Completed
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of AK102 in Patients With Heterozygous Familial Hypercholesterolemia [NCT04173793]	Phase 2	109 participants (Actual)	Interventional	2019-11-18	Completed
A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy [NCT01644188]	Phase 3	720 participants (Actual)	Interventional	2012-08-31	Completed
A Phase 2 Study to Evaluate the Safety and Efficacy of PCSK9 Inhibitor AK102 in Patients With Homozygous Familial Hypercholesterolemia (HoFH) [NCT03933293]	Phase 2	10 participants (Actual)	Interventional	2019-05-13	Completed
Intensive Lipid-lowering Therapy for Early Achievement of Guideline-recommended LDL Cholesterol Levels in Patients With ST-elevation Myocardial Infarctions [NCT05587621]		1,000 participants (Anticipated)	Observational [Patient Registry]	2022-08-23	Recruiting
Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C [NCT02971033]	Phase 2	2 participants (Actual)	Interventional	2018-04-16	Terminated(stopped due to Study Funding ended)
CHOlesterol Lowering and Residual Risk in Type 2 Diabetes [NCT04369664]	Phase 4	151 participants (Actual)	Interventional	2020-08-12	Completed
A Double-Blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Long-Term Tolerability and Durable Efficacy of AMG 145 (Evolocumab) on LDL-C in Hyperlipidemic Subjects [NCT01516879]	Phase 3	905 participants (Actual)	Interventional	2012-01-05	Completed
Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes. [NCT03204799]		150 participants (Anticipated)	Observational	2016-12-17	Recruiting
Bioequivalence of Ezetimibe Tablets in Healthy Subjects: A Single-dose and Two-period Crossover Study [NCT04814589]	Phase 1	96 participants (Anticipated)	Interventional	2021-03-13	Recruiting
A Phase 2 Double Blind, Parallel Group, Placebo Controlled, Randomized, Dose Ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Twice Monthly Subcutaneous Doses In Hypercholesterolemic Japanese Subjects Who Are Receivin [NCT02055976]	Phase 2	218 participants (Actual)	Interventional	2014-03-31	Completed
A Long-term Study to Evaluate the Efficacy and Safety of AK102 in Combination With Lipid-lowering Therapy in Patients With Hypercholesterolemia [NCT04173403]	Phase 2	796 participants (Actual)	Interventional	2019-11-04	Completed
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally [NCT02642159]	Phase 4	413 participants (Actual)	Interventional	2016-03-15	Completed
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety, and Tolerability of SCH 58235 When Added to Ongoing Therapy With an HMG-CoA Reductase Inhibitor (Statin) in Patients With Primary Hyperchole [NCT03882905]	Phase 3	769 participants (Actual)	Interventional	2001-01-31	Completed
A Multicenter, Double-Blind, Randomized Study to Evaluate the Lipid-Altering Efficacy, Safety, and Tolerability of Ezetimibe Coadministered With Simvastatin Versus Simvastatin Monotherapy in African-American Subjects With Primary Hypercholesterolemia [NCT00650663]	Phase 4	247 participants (Actual)	Interventional	2003-10-01	Completed
Comparison of Effects of Simvastatin Versus Ezetimibe on Intracellular Lipid and Inflammation in Obese Subjects [NCT04638400]	Phase 4	10 participants (Actual)	Interventional	2017-05-01	Terminated(stopped due to Lack of recruitment- Fellow responsible for study graduated)
Phase III, Multicenter, Randomized, Open-label, Comparative Study to Evaluate Efficacy and Safety of Rosuvastatin + Ezetimibe Versus Simvastatin + Ezetimibe in High Risk Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia [NCT01420549]	Phase 3	129 participants (Actual)	Interventional	2013-03-31	Completed
Open Label Study Evaluating The Use Of Combination Therapy Of Ezetimibe And Statins In Patients With Dyslipidemia In Colombia [NCT00651963]	Phase 4	80 participants (Actual)	Interventional	2004-09-30	Completed
Investigate the Effect of Ezetimibe, Simvastatin, and Omega 3- Fatty Acids on Dyslipidemia Patients: a Pharmacokinetics Based Study [NCT05080140]		3 participants (Anticipated)	Observational	2019-06-01	Active, not recruiting
A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia [NCT01890967]	Phase 2	527 participants (Actual)	Interventional	2013-06-30	Completed
Effect Of Ezetimibe Coadministration With Simvastatin In A Middle Eastern Population: A Prospective, Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial [NCT00652444]	Phase 4	120 participants (Actual)	Interventional	2003-09-30	Completed
A Multicenter, Double-Blind, Randomized, Parallel Group, 28-Week Study to Evaluate the Efficacy and Safety of Ezetimibe and Simvastatin Co-administration Versus Atorvastatin in Patients With Hypercholesteremia [NCT00092716]	Phase 3	655 participants (Actual)	Interventional	2002-05-31	Completed
A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor [NCT01763905]	Phase 3	307 participants (Actual)	Interventional	2013-01-24	Completed
A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin Versus Ezetimibe Added-on to Rosuvastatin Versus Rosuvastatin Dose Increase in Patients Who Are Not Controlled on Rosuvastatin [NCT01730053]	Phase 3	305 participants (Actual)	Interventional	2012-11-30	Completed
The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study [NCT02227784]	Phase 3	366 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Study termination due to program termination.)
Observational Study Evaluating the LDL-C Lowering Effects of Ezetimibe With a Statin as Prescribed in Daily Routine Practice in an Indonesian Population [NCT00705081]		453 participants (Actual)	Observational	2006-01-31	Completed
THE EFFECT OF SIMVASTATIN VERSUS COMBINED SIMVASTATIN/EZETIMIBE TREATMENT ON THE CONCENTRATION OF SMALL DENSE LOW-DENSITY LIPOPROTEIN PARTICLES IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA [NCT00932620]	Phase 4	100 participants (Actual)	Interventional	2009-06-30	Completed
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of Ezetimibe Plus Simvastatin Compared With Simvastatin Alone on Flow-Mediated Brachial Artery Vasoactivity in Subjects With Primary Hypercholesterolemia (The EFFECTS Trial) [NCT00651391]	Phase 3	28 participants (Actual)	Interventional	2003-10-01	Terminated(stopped due to Slow enrollment)
A Multicenter, Randomized, Parallel Groups, Placebo-controlled Study Comparing the Efficacy, Safety, and Tolerability of the Daily Coadministration of Ezetimibe 10 mg With Atorvastatin 10 mg in Untreated Subjects With Primary Hypercholesterolemia and Coro [NCT00650689]	Phase 3	122 participants (Actual)	Interventional	2003-05-31	Completed
Comprehensive Magnetic Resonance of Peripheral Arterial Disease [NCT00587678]		85 participants (Actual)	Interventional	2006-01-31	Completed
An Open-Label, 2-Period, Crossover Study to Determine the Effect of Multiple Oral Doses of Ezetimibe 20 mg on the Pharmacokinetics of a Single Oral Dose of Cyclosporine in Young, Healthy, Normal, Male and Female Subjects [NCT00653276]	Phase 1	13 participants (Actual)	Interventional	2003-11-30	Completed
Vytorin As Strategy To Reduce Dislipidemia In Adults [NCT00651560]	Phase 3	167 participants (Actual)	Interventional	2005-11-01	Completed
A Randomized, Double-Blind, Parallel, Multicenter Study to Evaluate the Efficacy and Safety of Simvastatin Monotherapy Compared With Simvastatin Plus Ezetimibe (SCH 58235) in Type 2 Diabetic Patients Treated With Thiazolidinediones [NCT00551876]	Phase 3	214 participants (Actual)	Interventional	2001-12-31	Completed
A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of ABT-335 in Combination With Atorvastatin and Ezetimibe to Atorvastatin in Combination With Ezetimibe in Subjects With Combined (Atherogenic) Dyslipidemia [NCT00639158]	Phase 3	543 participants (Actual)	Interventional	2008-02-29	Completed
Effect of Atorvastatin and Omega 3 Combination Therapy on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes and Combined Dyslipidemia [NCT05365438]	Phase 4	105 participants (Anticipated)	Interventional	2022-10-01	Recruiting
Non-interventional Study on the Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (MILOS) [NCT04579367]		5,000 participants (Anticipated)	Observational	2021-01-15	Recruiting
A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Ther [NCT02715726]	Phase 3	615 participants (Actual)	Interventional	2016-07-27	Completed
A Multicenter, Randomized, Double-Blind, Parallel, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at High or Moderately High Risk for Coronary [NCT00535405]	Phase 3	1,289 participants (Actual)	Interventional	2007-11-30	Completed
Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia [NCT00271817]	Phase 3	1,220 participants (Actual)	Interventional	2005-12-31	Completed
INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in Patients With Stable Cardiovascular Disease (INTENSITY-HIGH) [NCT03355027]		60 participants (Actual)	Interventional	2017-11-30	Active, not recruiting
A Prospective, Multicenter, Randomized, Open-label Trial to Compare Low-dose ROSUvastatin Plus eZETimibe Versus High-dose Rosuvastatin in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention [NCT04499859]	Phase 4	3,548 participants (Anticipated)	Interventional	2020-10-01	Recruiting
A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Eff [NCT01984424]	Phase 3	511 participants (Actual)	Interventional	2013-12-10	Completed
SCH 58235: A Multicenter, Randomised, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, and Tolerability Of The Daily Co-Administration of Ezetimibe 10 mg With Simvastatin 20 mg vs Ezetimibe Placebo With Simvastatin 20 mg in Untrea [NCT00653835]	Phase 4	153 participants (Actual)	Interventional	2003-09-01	Completed
"An Open Label, One-sequence, 3-period Study to Evaluate Drug-drug Interactions and Safety Between BR1017-1 and BR1017-2 in Healthy Volunteers" [NCT05372380]	Phase 1	32 participants (Actual)	Interventional	2022-05-09	Completed
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins [NCT01709513]	Phase 3	314 participants (Actual)	Interventional	2012-09-30	Completed
Study of Lipoprotein Subfractions, Inflammation, Oxidative Stress and Endothelial Function After Treatment With Simvastatin and Ezetimibe Administered Alone and in Combination in Hyperlipidemic Patients [NCT02304926]		42 participants (Actual)	Interventional	2009-01-31	Completed
The Effect of Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD [NCT02244944]	Phase 2	2 participants (Actual)	Interventional	2014-09-30	Terminated(stopped due to Failure to recruit)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00092677 (19) [back to overview]	Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events)
NCT00092677 (19) [back to overview]	Incident Cancer
NCT00092677 (19) [back to overview]	Nonfatal Myocardial Infarction (MI)
NCT00092677 (19) [back to overview]	Nonhemorrhagic Stroke
NCT00092677 (19) [back to overview]	Percutaneous Coronary Intervention (PCI)
NCT00092677 (19) [back to overview]	Percent Change in Time Weighted Average Triglycerides From Baseline to End of Follow-up
NCT00092677 (19) [back to overview]	Percent Change in Time Weighted Average Total Cholesterol From Baseline to End of Follow-up
NCT00092677 (19) [back to overview]	Percent Change in Time Weighted Average Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to End of Follow-up
NCT00092677 (19) [back to overview]	Percent Change in Time Weighted Average High-density Lipoprotein Cholesterol (HDL-C) From Baseline to End of Follow-up
NCT00092677 (19) [back to overview]	Aortic Valve Replacement (AVR)
NCT00092677 (19) [back to overview]	Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events)
NCT00092677 (19) [back to overview]	Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events)
NCT00092677 (19) [back to overview]	Cardiovascular Death
NCT00092677 (19) [back to overview]	Change From Baseline in Peak Transaortic Jet Velocity
NCT00092677 (19) [back to overview]	Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS)
NCT00092677 (19) [back to overview]	Hospitalization for Unstable Angina
NCT00092677 (19) [back to overview]	Death Due to Cancer
NCT00092677 (19) [back to overview]	Death (Any Cause)
NCT00092677 (19) [back to overview]	Coronary Artery Bypass Grafting (CABG)
NCT00101439 (2) [back to overview]	Total Cholesterol Concentration of Chylomicron-remnant (Sf 60-400) Subfractions After a Cholesterol-Rich Test Meal
NCT00101439 (2) [back to overview]	Total Cholesterol Concentration of Chylomicron (Sf≥400) Fractions After a Cholesterol-Rich Test Meal
NCT00125593 (7) [back to overview]	Major Vascular Events Analyzed Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo
NCT00125593 (7) [back to overview]	Major Vascular Events Analyzed Amongst Patients Initially Randomized to Simvastatin Plus Ezetimibe Versus Placebo (Original Protocol-defined Primary Outcome)
NCT00125593 (7) [back to overview]	Non-hemorrhagic Stroke Among All of Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo
NCT00125593 (7) [back to overview]	Key Outcome as Per Statistical Analysis Plan = Major Atherosclerotic Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo
NCT00125593 (7) [back to overview]	Coronary or Non-coronary Revascularization Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo
NCT00125593 (7) [back to overview]	End-stage Renal Disease Among All Patients Not on Dialysis at the Time of Randomization to Simvastatin Plus Ezetimibe Versus Placebo
NCT00125593 (7) [back to overview]	Major Coronary Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo
NCT00129402 (6) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC)
NCT00129402 (6) [back to overview]	Percent Change From Baseline in Non High-density Lipoprotein Cholesterol (Non HDL-C)
NCT00129402 (6) [back to overview]	Percent Change From Baseline in Triglycerides (TG)
NCT00129402 (6) [back to overview]	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
NCT00129402 (6) [back to overview]	Percent Change From Baseline in Apolipoprotein B (Apo B)
NCT00129402 (6) [back to overview]	Percent Change From Baseline in HDL-C
NCT00166504 (1) [back to overview]	LDL-C Lowering Efficacy
NCT00202878 (4) [back to overview]	Time to First Occurrence of CV Death, Nonfatal MI, UA With Hospitalization, All Revascularization Occurring ≥30 Days After Randomization, and Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)
NCT00202878 (4) [back to overview]	Time to First Occurrence of Death From Any Cause, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)
NCT00202878 (4) [back to overview]	Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)
NCT00202878 (4) [back to overview]	Time to First Occurrence of Coronary Heart Disease (CHD) Death, Non-fatal MI, or Urgent Coronary Revascularization With PCI or CABG ≥ 30 Days After Randomization (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)
NCT00203476 (4) [back to overview]	LFT Elevation
NCT00203476 (4) [back to overview]	LDL Goal Attainment
NCT00203476 (4) [back to overview]	Incidents of Rhabdomyolysis
NCT00203476 (4) [back to overview]	Change in HDL From Baseline to 12 Weeks.
NCT00271817 (10) [back to overview]	Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
NCT00271817 (10) [back to overview]	Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
NCT00271817 (10) [back to overview]	Percent Change From Baseline in Triglycerides (TG)
NCT00271817 (10) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
NCT00271817 (10) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
NCT00271817 (10) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
NCT00271817 (10) [back to overview]	Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
NCT00271817 (10) [back to overview]	Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)
NCT00271817 (10) [back to overview]	Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)
NCT00271817 (10) [back to overview]	Percent Change From Baseline in Triglycerides (TG)
NCT00276458 (14) [back to overview]	Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6
NCT00276458 (14) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
NCT00276458 (14) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 6
NCT00276458 (14) [back to overview]	Percent Change From Baseline in Apolipoprotein B: Apolipoprotein A-I Ratio at Week 6
NCT00276458 (14) [back to overview]	Percent Change From Baseline in C-Reactive Protein (CRP) at Week 6
NCT00276458 (14) [back to overview]	Number of Participants Who Attained Target LDL-C <100 mg/dL at Week 6
NCT00276458 (14) [back to overview]	Percent Change in High Density Lipoprotein -Cholesterol (HDL-C)at Week 6
NCT00276458 (14) [back to overview]	Percent Change in C-Reactive Protein (CRP) at Week 6
NCT00276458 (14) [back to overview]	Percent Change From Baseline in Total-Cholesterol:High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
NCT00276458 (14) [back to overview]	Percent Change in Apolipoprotein A-I at Week 6
NCT00276458 (14) [back to overview]	Percent Change From Baseline in Triglycerides (TG) at Week 6
NCT00276458 (14) [back to overview]	Percent Change From Baseline in Total-Cholesterol at Week 6
NCT00276458 (14) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
NCT00276458 (14) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in Apolipoprotein B (Apo B)
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in Apolipoprotein A-I (Apo A-I)
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in Apolipoprotein B:Apolipoprotein A-I (Apo B:Apo A-I) Ratio
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in C Reactive Protein (CRP)
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (Non-HDL-C:HDL-C) Ratio
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in Total-Cholesterol
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in Triglycerides (TG)
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C)
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in Low-Density Lipoprotein-Cholesterol:High-Density Lipoprotein-Cholesterol (LDL-C:HDL-C) Ratio
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in Low-Density Lipoprotein (LDL)-C
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in High-Density Lipoprotein Cholesterol (HDL-C)
NCT00276484 (13) [back to overview]	Percent Change From Baseline to Week 6 in Total-Cholesterol (TC):High-Density Lipoprotein Cholesterol (HDL-C) Ratio
NCT00276484 (13) [back to overview]	Number of Patients Who Attained Target Low-Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 6
NCT00319449 (3) [back to overview]	Number of Participants Who Achieve the Target LDL-C Concentration of < 3.3 mmol/L (130 mg/dL)
NCT00319449 (3) [back to overview]	High Density Lipoprotein-cholesterol (HDL-C), Total Cholesterol and Triglycerides at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg
NCT00319449 (3) [back to overview]	Low Density Lipoprotein-cholesterol (LDL-C) at Baseline and After 6 Weeks of Treatment With Ezetimibe 10 mg Added to Atorvastatin 10 mg Versus Placebo Added to Atorvastatin 10 mg
NCT00359281 (11) [back to overview]	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
NCT00359281 (11) [back to overview]	AUC0-t Rosuvastatin (Lomitapide 60 mg)
NCT00359281 (11) [back to overview]	AUC0-t Atorvastatin Acid (Lomitapide 60 mg)
NCT00359281 (11) [back to overview]	AUC0-t Fenofibric Acid
NCT00359281 (11) [back to overview]	AUC0-t Nicotinic Acid
NCT00359281 (11) [back to overview]	AUC0-t Nicotinuric Acid
NCT00359281 (11) [back to overview]	AUC0-t Rosuvastatin (Lomitapide 10 mg)
NCT00359281 (11) [back to overview]	AUC0-t Simvastatin
NCT00359281 (11) [back to overview]	AUC0-t Simvastatin Acid
NCT00359281 (11) [back to overview]	AUC0-t Total Ezetimibe
NCT00359281 (11) [back to overview]	Area Under Concentration-time Curve From 0 to Last Measureable Concentration (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg)
NCT00376246 (2) [back to overview]	Percent Change in Flow Mediated Dilation
NCT00376246 (2) [back to overview]	Lipid Profile- Change in LDL(Low Density Lipoprotein)
NCT00405067 (10) [back to overview]	Percent Change in Apolipoprotein A1 (Apo A1) at 12 Weeks as Compared to Baseline
NCT00405067 (10) [back to overview]	Percent Change in Apolipoprotein B (Apo B) at 12 Weeks as Compared to Baseline
NCT00405067 (10) [back to overview]	Percent Change in Body Weight at 12 Weeks as Compared to Baseline
NCT00405067 (10) [back to overview]	Percent Change in HDL-C at 12 Weeks Compared to Baseline
NCT00405067 (10) [back to overview]	Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) at 12 Weeks as Compared to Baseline
NCT00405067 (10) [back to overview]	Percent Change in LDL-C at 12 Weeks Therapy Compared to Baseline Between Treatments
NCT00405067 (10) [back to overview]	Percent Change in Lipoprotein(a)[Lp(a)]at 12 Weeks as Compared to Baseline
NCT00405067 (10) [back to overview]	Percent Change in Tryglycerides (TGs) at 12 Weeks Compared to Baseline
NCT00405067 (10) [back to overview]	Percent of Change at 12 Weeks Therapy Compared to Baseline Between Treatments for the Following Parameters: Total Cholesterol (TC)
NCT00405067 (10) [back to overview]	Percent Change in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at 12 Weeks as Compared to Baseline.
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (LDL-C: HDL-C) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients With Atherosclerotic Vascular Disease (AVD)
NCT00409773 (15) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Triglyceride (TG) (mg/dL) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients Without Atherosclerotic Vascular Disease (AVD)
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Total-Cholesterol: High Density Lipoprotein-Cholesterol (Total-C:HDL- C) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Total Cholesterol(mg/dL) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (Non-HDL-C:HDL-C) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in High-Sensitivity C-reactive (Hs-CRP) (mg/dL) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Apolipoprotein-B: Apolipoprotein-A1 (Apo-B:Apo-A1) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Apolipoprotein-A1 (Apo-A1) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Apolipoprotein- B (Apo-B) at Week 6
NCT00409773 (15) [back to overview]	Percent Change From Baseline in Non- High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6
NCT00413972 (1) [back to overview]	Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint After 8 Weeks of Treatment
NCT00418834 (28) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6
NCT00418834 (28) [back to overview]	Percent Change From Baseline in LDL-C at Week 6
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Ratio of Highly Selective C-Reactive Protein (Hs-CRP) at Week 6
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC) at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC) at Week 6
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC): High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Triglycerides (TG) at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Triglycerides (TG) at Week 6
NCT00418834 (28) [back to overview]	Number of Patients Who Achieved LDL-C <100 mg/dL for Patients Without Atherosclerotic Vascular Disease (AVD) and LDL-C <70 mg/dL for Patients With Atherosclerotic Vascular Disease (AVD) at Week 6
NCT00418834 (28) [back to overview]	Number of Patients Who Achieved LDL-C<100 mg/dL for Patients Without AVD and LDL-C<70 mg/dL for Patients With AVD at Week 12
NCT00418834 (28) [back to overview]	Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 12
NCT00418834 (28) [back to overview]	Number of Patients Who Achieved Low Density Lipoprotein Cholesterol (LDL-C) <70 mg/dL at Week 6
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Apo Lipoprotein A-I (Apo A-I) at Week 6
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 12
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Apo Lipoprotein B (Apo B) at Week 6
NCT00418834 (28) [back to overview]	Percent Change From Baseline in Apo Lipoprotein B (Apo B):Apo Lipoprotein A-I (Apo A-I) Ratio at Week 6
NCT00423488 (1) [back to overview]	Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment
NCT00423579 (1) [back to overview]	Change in Low-density-lipoprotein Cholesterol (LDL-C) at 6 Weeks
NCT00442897 (2) [back to overview]	Number of Participants Reaching the LDL-C (Low Density Lipoprotein-Cholesterol) Goal (< 100 mg/dl) After 6 Weeks of Treatment
NCT00442897 (2) [back to overview]	Number of Participants Reaching the LDL-C Goal (< 100 mg/dl) After 12 Weeks of Treatment
NCT00461630 (5) [back to overview]	Stroke
NCT00461630 (5) [back to overview]	Coronary or Non-coronary Revascularisation
NCT00461630 (5) [back to overview]	Major Coronary Events
NCT00461630 (5) [back to overview]	Major Vascular Event
NCT00461630 (5) [back to overview]	Mortality
NCT00462748 (1) [back to overview]	Percentage of Patients Achieving a Target of Fasting LDL-C of <2mmol/l at Study End
NCT00474123 (10) [back to overview]	Interleukin-6
NCT00474123 (10) [back to overview]	Monocyte Chemoattractant Protein (MCP)-1
NCT00474123 (10) [back to overview]	Oxidized Low-Density Lipoprotein Cholesterol
NCT00474123 (10) [back to overview]	Platelet Function Analyzer [PFA]-100
NCT00474123 (10) [back to overview]	Soluble CD40 Ligand
NCT00474123 (10) [back to overview]	Soluble Intercellular Adhesion Molecule (sICAM)-1
NCT00474123 (10) [back to overview]	C-reactive Protein
NCT00474123 (10) [back to overview]	Endothelial Progenitor Cells
NCT00474123 (10) [back to overview]	Triglyceride
NCT00474123 (10) [back to overview]	LDL Cholesterol
NCT00477204 (1) [back to overview]	Change in LDL-c From Baseline to 6 Months in Subjects With Type 1 Diabetes Taking Vytorin or Zocor.
NCT00479713 (10) [back to overview]	Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein-Cholesterol (Non-HDL-C)
NCT00479713 (10) [back to overview]	Percent Change From Baseline in High-sensitivity C (Hs-C) Reactive Protein
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Triglycerides.
NCT00479713 (10) [back to overview]	The Percentage of Participants Achieving Designated Low Density Lipoprotein-Cholesterol (LDL-C) Levels After 6 Weeks of Treatment
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Apolipoprotein B
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-Cholesterol (HDL-C) Ratio
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C)/High Density Lipoprotein-Cholesterol (HDL-C) Ratio
NCT00479713 (10) [back to overview]	Percent Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C)
NCT00479713 (10) [back to overview]	Percent Change From Baseline in Total Cholesterol
NCT00481351 (5) [back to overview]	CPK
NCT00481351 (5) [back to overview]	High Density Lipoprotein
NCT00481351 (5) [back to overview]	Low Density Lipoprotein
NCT00481351 (5) [back to overview]	Total Cholesterol
NCT00481351 (5) [back to overview]	Alanine Aminotransferase
NCT00496730 (3) [back to overview]	Change in Lower Density Lipoprotein Cholesterol From Baseline After 8 Weeks.
NCT00496730 (3) [back to overview]	Mean Percent Change of Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline After 8 Weeks.
NCT00496730 (3) [back to overview]	Number of Patients Attaining LDL-C Goal After 8 Weeks Treatment.
NCT00525824 (13) [back to overview]	Percent Change in Apolipoprotein A1 (ApoA-1) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in Apolipoprotein B (ApoB) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in ApoB/ApoA-1 After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in Triglycerides (TG) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in Total Cholesterol (TC) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in TC/HDL-C After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in Non-high-density Lipoprotein Cholesterol (nonHDL-C) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in Non-HDL-C/HDL-C After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in LDL-C/HDL-C After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in LDL-C After 6 Weeks Monotherapy
NCT00525824 (13) [back to overview]	Percent Change in High-sensitivity C-reactive Protein (Hs-CRP) After 6 Weeks Combination Treatment
NCT00525824 (13) [back to overview]	Percent Change in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks Combination Treatment
NCT00535405 (6) [back to overview]	Percentage of Patients Who Achieved LDL-C <100 mg/dL at Week 12
NCT00535405 (6) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 12
NCT00535405 (6) [back to overview]	Percentage of Patients Who Achieved LDL-C <70 mg/dL at Week 12
NCT00535405 (6) [back to overview]	Percentage of Patients Without Atherosclerosis Vascular Disease (AVD) Who Achieved LDL-C <100 mg/dL or Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12
NCT00535405 (6) [back to overview]	Percentage of Patients With High Risk for CHD Who Achieved LDL-C <70 mg/dL at Week 12
NCT00535405 (6) [back to overview]	Percentage of Patients With AVD Who Achieved LDL-C <70 mg/dL at Week 12
NCT00548145 (1) [back to overview]	Alzheimer's Disease Assessment Scale-cognitive Component-Japanese Version(ADAS-Jcog)
NCT00559962 (1) [back to overview]	Absolute Change From Baseline in Percent Hepatic Fat
NCT00587678 (11) [back to overview]	Plaque Volume
NCT00587678 (11) [back to overview]	Triglycerides
NCT00587678 (11) [back to overview]	V02 - Maximal Oxygen Consumption
NCT00587678 (11) [back to overview]	Total Cholesterol
NCT00587678 (11) [back to overview]	6-minute Walk Distance
NCT00587678 (11) [back to overview]	High Density Lipoprotein Cholesterol
NCT00587678 (11) [back to overview]	Log Treadmill Exercise Time
NCT00587678 (11) [back to overview]	Low Density Lipoprotein Cholesterol
NCT00587678 (11) [back to overview]	Magnetic Resonance Angiographic Index
NCT00587678 (11) [back to overview]	Perfusion Index
NCT00587678 (11) [back to overview]	Phosphocreatine Recovery Time Constant - the Time it Takes for Phosphocreatine Levels to Recover to Plateau.
NCT00639158 (8) [back to overview]	Mean Percent Change in Apolipoprotein AI (apoAI) From Baseline to Final Visit
NCT00639158 (8) [back to overview]	Mean Percent Change in Apolipoprotein B (apoB) From Baseline to Final Visit
NCT00639158 (8) [back to overview]	Mean Percent Change in Apolipoprotein CIII (apoCIII) From Baseline to Final Visit
NCT00639158 (8) [back to overview]	Mean Percent Change in High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Final Visit
NCT00639158 (8) [back to overview]	Mean Percent Change in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) From Baseline to Final Visit
NCT00639158 (8) [back to overview]	Median Percent Change in High-Sensitivity C-Reactive Protein (hsCRP) From Baseline to Final Visit
NCT00639158 (8) [back to overview]	Median Percent Change in Triglycerides From Baseline to Final Visit
NCT00639158 (8) [back to overview]	Mean Percent Change in Very Low-Density Lipoprotein Cholesterol (VLDL-C) From Baseline to Final Visit
NCT00652327 (1) [back to overview]	Percentage Change in Low Density Lipoprotein-Cholesterol (LDL-C) From Baseline at Study Endpoint, After 8 Weeks of Treatment
NCT00653523 (1) [back to overview]	Number of Participants With Adverse Events and Adverse Reactions
NCT00654095 (1) [back to overview]	Number of Participants With Adverse Events and Adverse Reactions
NCT00654628 (12) [back to overview]	Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
NCT00654628 (12) [back to overview]	Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 12
NCT00654628 (12) [back to overview]	Mean Percent Change From Baseline of High Density Lipoprotein-C (HDL-C) at Week 6
NCT00654628 (12) [back to overview]	Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12
NCT00654628 (12) [back to overview]	Mean Percent Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
NCT00654628 (12) [back to overview]	Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 12
NCT00654628 (12) [back to overview]	Mean Percent Change From Baseline of Total-Cholesterol (TC) at Week 6
NCT00654628 (12) [back to overview]	Mean Percent Change of Triglycerides From Baseline at Week 12
NCT00654628 (12) [back to overview]	Mean Percent Change of Triglycerides From Baseline at Week 6
NCT00654628 (12) [back to overview]	The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 12-week Treatment.
NCT00654628 (12) [back to overview]	The Percentage of Participants Achieving Low Density Lipoprotein-C (LDL-C) Treatment Goal After 6-week Treatment.
NCT00654628 (12) [back to overview]	Mean Change From Baseline of Low Density Lipoprotein-Cholesterol (LDL-C) at Week 12
NCT00687076 (2) [back to overview]	Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic Resonance Imaging (MRI) to Examine the Femoral Artery for Progression of Atherosclerosis
NCT00687076 (2) [back to overview]	Change in Total Cholesterol (mg/dl) From Baseline to Month 12
NCT00701727 (7) [back to overview]	Change From Baseline in Total Cholesterol, From Fasting Plasma Samples
NCT00701727 (7) [back to overview]	Low-density Lipoprotein (LDL);
NCT00701727 (7) [back to overview]	Cholesterol Efflux Rate (Ra Cholesterol)
NCT00701727 (7) [back to overview]	de Novo Cholesterol Synthesis (DNC)
NCT00701727 (7) [back to overview]	Fecal Excretion of Plasma-derived Cholesterol
NCT00701727 (7) [back to overview]	High-density Lipoprotein (HDL)
NCT00701727 (7) [back to overview]	Triglycerides (TG)
NCT00704535 (8) [back to overview]	Safety as Measured by Number of Subjects With at Least One Adverse Event
NCT00704535 (8) [back to overview]	To Evaluate the Efficacy of Ezetimibe in Lowering Serum Cholesterol Levels 28 Days After Visit 1 (Baseline)
NCT00704535 (8) [back to overview]	Safety as Measured by Adverse Event Relatedness to Study Drug as Reported by the Investigator.
NCT00704535 (8) [back to overview]	Safety as Measured by Severity of Adverse Events as Determined by the Investigator
NCT00704535 (8) [back to overview]	Safety as Measured by Dose Adjustment Upon Incidence of an Adverse Event
NCT00704535 (8) [back to overview]	Safety as Measured by Outcome of Adverse Events
NCT00704535 (8) [back to overview]	Tolerability as Measured by Subject Self-assessment
NCT00704535 (8) [back to overview]	Safety as Measured by Number and Type of Adverse Events.
NCT00705081 (3) [back to overview]	Number of Participants Reporting Adverse Events
NCT00705081 (3) [back to overview]	Intensity of Adverse Events Reported
NCT00705081 (3) [back to overview]	Participants Achieving Low-density Lipoprotein-cholesterol (LDL-C) Target Levels With Co-administration Therapy
NCT00730132 (5) [back to overview]	Percentage of Patients Per Group Who Reach Goal for Total Cholesterol (TC) (< 4.5 mmol/L) According to All-Russian Scientific Cardiologists Society (ARSCS) Recommendations by End of Observation
NCT00730132 (5) [back to overview]	Percentage of Patients Per Group Who Reached Goal for Low Density Lipoprotein (LDL-C) (< 2.6 mmol/L) According to ARSCS Recommendations by End of Observation
NCT00730132 (5) [back to overview]	Percentage of Relative Change of LDL-C Level Measured on Visit 2 Compared With the Baseline (Visit 1) in Each of the Three Therapy Groups
NCT00730132 (5) [back to overview]	Percentage of Relative Change of Total Cholesterol (TC) Level Measured on Visit 2 Compared With the Baseline (Visit 1) in Each of the Three Therapy Groups
NCT00730132 (5) [back to overview]	Percentage of Patients Receiving Each Variant of Modified Lipid-lowering Therapy: Statin Dose Titration, Administration of a New Statin, Administration of a Ezetimibe in Addition to a Current Statin.
NCT00762229 (2) [back to overview]	Total Cholesterol
NCT00762229 (2) [back to overview]	LDL Cholesterol
NCT00782184 (15) [back to overview]	Percent Change From Baseline in LDL-Cholesterol/HDL-Cholesterol Ratio
NCT00782184 (15) [back to overview]	Percent Change From Baseline in Low Density Lipoprotein (LDL)-C
NCT00782184 (15) [back to overview]	Percent Change From Baseline in Non-HDL Cholesterol
NCT00782184 (15) [back to overview]	Percent Change From Baseline in Non-HDL Cholesterol/HDL-Cholesterol Ratio
NCT00782184 (15) [back to overview]	Percent Change From Baseline in Total Cholesterol
NCT00782184 (15) [back to overview]	Percent Change From Baseline in Total Cholesterol/HDL-Cholesterol Ratio
NCT00782184 (15) [back to overview]	Percent Change From Baseline in Triglycerides
NCT00782184 (15) [back to overview]	Number of Participants Reaching LDL-C Target Goal <100 mg/dL
NCT00782184 (15) [back to overview]	Percent Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol
NCT00782184 (15) [back to overview]	Number of Participants Reaching LDL-C Target Goal <77 mg/dL
NCT00782184 (15) [back to overview]	Number of Participants Reaching LDL-C Target Goals of <70 mg/dL
NCT00782184 (15) [back to overview]	Percent Change From Baseline in Apolipoprotein A-1
NCT00782184 (15) [back to overview]	Percent Change From Baseline in Apolipoprotein B
NCT00782184 (15) [back to overview]	Percent Change From Baseline in Apolipoprotein B/A-1 Ratio
NCT00782184 (15) [back to overview]	Percent Change From Baseline in High-sensitivity C-Reactive Protein (Hs-CRP)
NCT00783263 (7) [back to overview]	Number of Participants in Each Stratum Who Reached Their Target LDL-C Level
NCT00783263 (7) [back to overview]	Number of Participants Who Reached the LDL-C Level of <70 mg/dl
NCT00783263 (7) [back to overview]	Number of Participants Who Reached Their Target LDL-C Level
NCT00783263 (7) [back to overview]	Number of Participants in Each Stratum Who Reached the LDL-C Level of <70 mg/dl
NCT00783263 (7) [back to overview]	Percent Change From Baseline in Other Lipid, Lipoprotein, Apolipoprotein and High-sensitivity C-reactive Protein (Hs-CRP)Levels
NCT00783263 (7) [back to overview]	Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment in Each Stratum
NCT00783263 (7) [back to overview]	Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment
NCT00794677 (9) [back to overview]	Percent Change of Fasting Non-high Density Lipoprotein Cholesterol From Baseline
NCT00794677 (9) [back to overview]	Log (AUC of Plasma Total Cholesterol) After an Oral Bolus
NCT00794677 (9) [back to overview]	Log (AUC of Plasma Triglyceride) After an Oral Bolus
NCT00794677 (9) [back to overview]	Log(Fasting Plasma Levels of Diet-derived Oxysterols (7-ketocholesterol))
NCT00794677 (9) [back to overview]	Log(Maximal Plasma Concentration (Cmax) of 7-ketocholesterol) After an Oral Bolus
NCT00794677 (9) [back to overview]	Log[Area-under-the-plasma-concentration-curve(AUC) 0-8 Hours 7-ketocholesterol] After an Oral Bolus
NCT00794677 (9) [back to overview]	Percent Change in Fasting High Density Lipoprotein Cholesterol
NCT00794677 (9) [back to overview]	Percent Change of Fasting Apolipoprotein B From Baseline
NCT00794677 (9) [back to overview]	Percent Change of Fasting Low Density Lipoprotein Cholesterol From Baseline
NCT00810303 (18) [back to overview]	Cmax of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Days 16-20
NCT00810303 (18) [back to overview]	Cmax of Efavirenz (Steady State Pharmacokinetic After Chronic Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Day 30
NCT00810303 (18) [back to overview]	AUC0-24h of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15
NCT00810303 (18) [back to overview]	Cmax of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30
NCT00810303 (18) [back to overview]	Cmax of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15
NCT00810303 (18) [back to overview]	Cmax of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16
NCT00810303 (18) [back to overview]	Cmax of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30
NCT00810303 (18) [back to overview]	Cmax of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16
NCT00810303 (18) [back to overview]	Cmax of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15
NCT00810303 (18) [back to overview]	AUC0-24h of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30
NCT00810303 (18) [back to overview]	AUC0-24h of Free Ezetimibe (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16
NCT00810303 (18) [back to overview]	AUC0-24h of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Single Dose Administration of 400 mg Efavirenz) on Study Day 16
NCT00810303 (18) [back to overview]	AUC0-24h of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe) on Study Day 15
NCT00810303 (18) [back to overview]	AUC of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz) on Study Days 1-5
NCT00810303 (18) [back to overview]	AUC0-24h of Efavirenz (Steady State Pharmacokinetic After Chronic Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Day 30
NCT00810303 (18) [back to overview]	AUC0-24h of Ezetimibe Glucuronide (Steady-state Pharmacokinetic After Chronic Treatment With 10 mg Ezetimibe and Concomitant Chronic Treatment With 400 mg Efavirenz) on Study Day 30
NCT00810303 (18) [back to overview]	Cmax of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz) on Study Days 1-5
NCT00810303 (18) [back to overview]	AUC of Efavirenz (Single Dose Pharmacokinetic After Treatment With 400 mg Efavirenz and Concomitant Chronic Treatment of 10 mg Ezetimibe) on Study Days 16-20
NCT00817843 (1) [back to overview]	Treatment Difference in (Postprandial-Fasting) FMD
NCT00819403 (2) [back to overview]	Biomarkers of Inflammation
NCT00819403 (2) [back to overview]	Ex Vivo Effects of Treatment With Vytorin Versus Zocor for 6 Weeks on Platelet Alpha Thrombin PAR-1 Receptor Expression
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Triglycerides
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC)
NCT00862251 (18) [back to overview]	Percent Change From Baseline in TC/HDL-C Ratio
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).
NCT00862251 (18) [back to overview]	Percent Change From Baseline in LDL-C/HDL-C Ratio
NCT00862251 (18) [back to overview]	In Participants Treated With Simvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of < 70 mg/dL (1.81 mmol/L)
NCT00862251 (18) [back to overview]	In Participants Treated With Simvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Simvastatin
NCT00862251 (18) [back to overview]	In Participants Treated With Atorvastatin at Baseline, Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Atorvastatin
NCT00862251 (18) [back to overview]	Percent Change From Baseline in LDL-C After Switching to Treatment With Ezetimibe/Simvastatin vs Switching Treatment to Rosuvastatin
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Non-HDL-C/HDL-C Ratio
NCT00862251 (18) [back to overview]	Number of Participants Who Reached the Target LDL-Cholesterol Level of < 70 mg/dL (1.81 mmol/L)
NCT00862251 (18) [back to overview]	Percent Change From Baseline Apolipoprotein A-I (Apo A-I)
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Apo B/Apo A-I Ratio
NCT00862251 (18) [back to overview]	Percent Change From Baseline in Apolipoprotein B (Apo B)
NCT00862251 (18) [back to overview]	Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
NCT00862251 (18) [back to overview]	Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP)
NCT00862251 (18) [back to overview]	In Participants Treated With Atorvastatin at Baseline, Number of Participants Who Reached the Target LDL-Cholesterol Level of < 70 mg/dL (1.81 mmol/L)
NCT00863265 (3) [back to overview]	Percent Cholesterol Absorption
NCT00863265 (3) [back to overview]	LDL Cholesterol
NCT00863265 (3) [back to overview]	Cholesterol Excretion
NCT00867165 (49) [back to overview]	Percentage Change From Baseline HDL-C at Week 4
NCT00867165 (49) [back to overview]	Percentage Change From Baseline HDL-C at Week 8
NCT00867165 (49) [back to overview]	Percentage Change From Baseline High-density Lipoprotein Cholesterol (HDL-C) at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Apolipoprotein A-I (Apo A-I) at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Apolipoprotein B (Apo B) at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Campesterol at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Campesterol at Week 2
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Campesterol at Week 4
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Campesterol at Week 8
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Cholestanol at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Cholestanol at Week 2
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Cholestanol at Week 4
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Cholestanol at Week 8
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 4
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Lathosterol at Week 2
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Lathosterol at Week 8
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 2
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 4
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in LDL-C:HDL-C Ratio at Week 8
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Non-HDL-C at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Non-HDL-C at Week 2
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Non-HDL-C at Week 4
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Non-HDL-C at Week 8
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Sitosterol at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Sitosterol at Week 4
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Sitosterol at Week 8
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in TC at Week 2
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in TC at Week 4
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in TC at Week 8
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in TC:HDL-C Ratio at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in TC:HDL-C Ratio at Week 2
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in TC:HDL-C Ratio at Week 4
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in TC:HDL-C Ratio at Week 8
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in TG at Week 2
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in TG at Week 4
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in TG at Week 8
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Total Cholesterol (TC) at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Lathosterol at Week 4
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Triglycerides (TG) at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Apo B:Apo A-I Ratio at Week 12
NCT00867165 (49) [back to overview]	Percentage Change From Baseline in Lathosterol at Week 12
NCT00867165 (49) [back to overview]	Percent Change From Baseline in LDL-C at Week 2
NCT00867165 (49) [back to overview]	Percent Change From Baseline in LDL-C at Week 4
NCT00867165 (49) [back to overview]	Percent Change From Baseline in LDL-C at Week 8
NCT00867165 (49) [back to overview]	Percent Change From Baseline in Sitosterol at Week 2
NCT00867165 (49) [back to overview]	Percentage Change From Baseline HDL-C at Week 2
NCT00871351 (5) [back to overview]	Percent Change in Total Lipids and Hs-CRP
NCT00871351 (5) [back to overview]	Percent Change in Total Lipids and High Sensitivity C-reactive Protein (Hs-CRP)
NCT00871351 (5) [back to overview]	Percent Change in Low-Density Lipoprotein - Cholesterol (LDL-C) Values
NCT00871351 (5) [back to overview]	Percent Change in LDL-C
NCT00871351 (5) [back to overview]	Number of Participants Whose LDL-C Levels Reached the Lipid Management Target Values
NCT00879710 (1) [back to overview]	Changes in LDL Cholesterol
NCT00908011 (1) [back to overview]	The Primary Endpoint is the Difference in Final Value of Serum Apolipoprotein B Between Participants Treated With Rosuvastatin Versus Participants Treated With Both Rosuvastatin and Ezetimibe.
NCT00909389 (1) [back to overview]	Number of Participants Who Had an Adverse Event (AE).
NCT00932620 (2) [back to overview]	Changes in Low-density Lipoprotein Cholesterol (LDL-C)
NCT00932620 (2) [back to overview]	Changes in Small Dense Low-density Lipoprotein Cholesterol (sdLDL-C) Levels
NCT00988364 (2) [back to overview]	L5 Concentration in Metabolic Syndrome Patients
NCT00988364 (2) [back to overview]	L5 Concentration After Treatment of Ezetimibe, Simvastatin, or Vytorin in Metabolic Syndrome Patients
NCT01154036 (28) [back to overview]	Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apo B/Apo A-I Ratio (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apo B (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apo A-I (Phase II)
NCT01154036 (28) [back to overview]	Percentage of Participants That Reach Target LDL-C Level of < 70 mg/dL (Phase I)
NCT01154036 (28) [back to overview]	Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase II)
NCT01154036 (28) [back to overview]	Percentage of Participants That Reach Target LDL-C Level of < 100 mg/dL (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Triglycerides (TG) (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in TC/HDL-C Ratio (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Non-HDL-C/HDL-C Ratio (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Non-HDL-C (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Non-HDL-C (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase II).
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in LDL-C/HDL-C Ratio (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Hs-CRP (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apolipoprotein B (Apo B) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in High-density Lipoprotein-Cholesterol (HDL-C) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Apolipoprotein A-I (Apo A-I) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in HDL-C (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC) (Phase II)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in Triglycerides (TG) (Phase I)
NCT01154036 (28) [back to overview]	Percent Change From Baseline in TC/HDL-C Ratio (Phase II)
NCT01218204 (45) [back to overview]	Cmax of Atorvastatin- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	Cmax of GSK1292263- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	Maximum Observed Concentration (Cmax) of GSK1292263- Part A
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (run-in)
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part B (Washout)
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Washout)
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal Hematology Value of PCI- Part A
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal Hematology Value of PCI- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal Hematology Value of PCI- Part B (Washout)
NCT01218204 (45) [back to overview]	Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs)- Part A
NCT01218204 (45) [back to overview]	Number of Participants With Any AEs and SAEs- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	AUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	AUC (0-24) of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A
NCT01218204 (45) [back to overview]	Area Under the Concentration-time Curve From Time Zero (Pre-dose) to 24 Hours [AUC(0-24)] of GSK1292263- Part A
NCT01218204 (45) [back to overview]	Weighted Mean Area Under Concentration Curve From 0 to 24 Hours (AUC [0-24]) Change From Baseline for Triglycerides at Day 14
NCT01218204 (45) [back to overview]	Tlag of GSK1292263- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	Percent Change From Baseline in Lipid Metabolism: LDL/HDL Ratio at Day 14 (24 Hours)
NCT01218204 (45) [back to overview]	Percent Change From Baseline in Lipid Metabolism: Apolipoprotein E at Day 14 (24 Hours)
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal- Clinically Significant Electrocardiogram (ECG) Findings- Part A
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Run-in)
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal Clinically Significant ECG Findings- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal Clinical Chemistry Value of PCI- Part A
NCT01218204 (45) [back to overview]	Lag Time Before Observation of Drug Concentrations in Sampled Matrix (Tlag) of GSK1292263- Part A
NCT01218204 (45) [back to overview]	Number of Participants With Any AEs and SAEs- Part B (Washout)
NCT01218204 (45) [back to overview]	Number of Participants With Any AEs and SAEs- Part B (Run-in)
NCT01218204 (45) [back to overview]	Time of Occurrence of Cmax (Tmax) and Terminal Phase Half-life (t1/2) GSK1292263- Part A
NCT01218204 (45) [back to overview]	Number of Participants With Vital Signs of PCI- Part B (Washout)
NCT01218204 (45) [back to overview]	Number of Participants With Vital Signs of Potential Clinical Importance (PCI)- Part A
NCT01218204 (45) [back to overview]	Number of Participants With Vital Signs of Potential Clinical Importance- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	Number of Participants With Vital Signs of Potential Clinical Importance- Part B (Run-in)
NCT01218204 (45) [back to overview]	Percent Change From Baseline for Lipid Metabolism: Apolipoprotein A1 and Apolipoprotein B100 at Day 14
NCT01218204 (45) [back to overview]	Percent Change From Baseline in Lipid Metabolism: High Density Lipids Cholesterol (HDLc), Low Density Lipids Cholesterol (LDLc), Tryglycerides, Non-HDLc and Total Cholesterol at Day 14 (24 Hours)
NCT01218204 (45) [back to overview]	Tmax and t1/2 of GSK1292263- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	Tmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A
NCT01218204 (45) [back to overview]	Tmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	Tmax of Atorvastatin- Part A
NCT01218204 (45) [back to overview]	Tmax of Atorvastatin- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	Cmax of Atorvastatin- Part A
NCT01218204 (45) [back to overview]	Cmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	Cmax of Atorvastatin Metabolite (2-Hydroxyatorvastatin)- Part A
NCT01218204 (45) [back to overview]	AUC(0-24) of GSK1292263- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	AUC (0-24) of Atorvastatin- Part B (Pooled Treatment Arm)
NCT01218204 (45) [back to overview]	AUC (0-24) of Atorvastatin- Part A
NCT01218204 (45) [back to overview]	Number of Participants With Abnormal Hematology Value of PCI- Part B (Run-in)
NCT01370590 (6) [back to overview]	Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) After 6 Weeks of Treatment
NCT01370590 (6) [back to overview]	Percent Change From Baseline in Triglycerides (TG) After 6 Weeks of Treatment
NCT01370590 (6) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC) After 6 Weeks of Treatment
NCT01370590 (6) [back to overview]	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment
NCT01370590 (6) [back to overview]	Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks of Treatment
NCT01370590 (6) [back to overview]	Percent Change From Baseline in Apolipoprotein (Apo) B After 6 Weeks of Treatment
NCT01370603 (6) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC) After 6 Weeks of Treatment
NCT01370603 (6) [back to overview]	Percent Change From Baseline in Triglycerides (TG) After 6 Weeks of Treatment
NCT01370603 (6) [back to overview]	Percent Change From Baseline in Apolipoprotein (Apo) B After 6 Weeks of Treatment
NCT01370603 (6) [back to overview]	Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) After 6 Weeks of Treatment
NCT01370603 (6) [back to overview]	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks of Treatment
NCT01370603 (6) [back to overview]	Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) After 6 Weeks of Treatment
NCT01375764 (12) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
NCT01375764 (12) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
NCT01375764 (12) [back to overview]	Percent Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
NCT01375764 (12) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
NCT01375764 (12) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12
NCT01375764 (12) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
NCT01375764 (12) [back to overview]	Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
NCT01375764 (12) [back to overview]	Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
NCT01375764 (12) [back to overview]	Change From Baseline in LDL-C at Week 12
NCT01375764 (12) [back to overview]	Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
NCT01375764 (12) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 12
NCT01375764 (12) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
NCT01375777 (6) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
NCT01375777 (6) [back to overview]	Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
NCT01375777 (6) [back to overview]	Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
NCT01375777 (6) [back to overview]	Change From Baseline in LDL-C at Week 12
NCT01375777 (6) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 12
NCT01375777 (6) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12
NCT01381679 (9) [back to overview]	Number of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level
NCT01381679 (9) [back to overview]	Change From Baseline in Total Cholesterol (TC) at Month 3
NCT01381679 (9) [back to overview]	Change From Baseline in TC at Month 12
NCT01381679 (9) [back to overview]	Change From Baseline in LDL-C at Month 3
NCT01381679 (9) [back to overview]	Change From Baseline in HDL-C at Month 12
NCT01381679 (9) [back to overview]	Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Month 3
NCT01381679 (9) [back to overview]	Change From Baseline in LDL-C at Month 12
NCT01381679 (9) [back to overview]	Change From Baseline in Triglycerides (TG) at Month 3
NCT01381679 (9) [back to overview]	Change From Baseline in TG at Month 12
NCT01420549 (1) [back to overview]	Reduction of LDL Cholesterol Levels
NCT01516879 (15) [back to overview]	Percent Change From Baseline in Triglycerides at Week 52
NCT01516879 (15) [back to overview]	Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at Week 52
NCT01516879 (15) [back to overview]	Percent Change From Week 12 to Week 52 in LDL-C
NCT01516879 (15) [back to overview]	Percentage of Participants With an LDL-C Response at Week 52
NCT01516879 (15) [back to overview]	Change From Baseline in LDL-C at Week 52
NCT01516879 (15) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 52
NCT01516879 (15) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52
NCT01516879 (15) [back to overview]	Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 52
NCT01516879 (15) [back to overview]	Percent Change From Baseline in LDL-C at Week 12
NCT01516879 (15) [back to overview]	Percent Change From Baseline in LDL-C at Week 52
NCT01516879 (15) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 52
NCT01516879 (15) [back to overview]	Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52
NCT01516879 (15) [back to overview]	Percent Change From Baseline in Total Cholesterol at Week 52
NCT01516879 (15) [back to overview]	Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52
NCT01516879 (15) [back to overview]	Percent Change From Baseline in Total Cholesterol at Week 12
NCT01611883 (10) [back to overview]	Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline
NCT01611883 (10) [back to overview]	Percent Change in High-density Lipoprotein Cholesterol (HDL-C) From Baseline
NCT01611883 (10) [back to overview]	"Percentage of Participants With Adverse Event (AE) Exacerbation of Diabetes"
NCT01611883 (10) [back to overview]	Change in Glycoalbumin From Baseline
NCT01611883 (10) [back to overview]	Change in Glycated Hemoglobin (HbA1c) From Baseline
NCT01611883 (10) [back to overview]	Change in Fasting Plasma Glucose (FPG) From Baseline
NCT01611883 (10) [back to overview]	Percentage of Participants With Changes in Diabetes Medications Due to Worsening of Diabetes
NCT01611883 (10) [back to overview]	Percent Change in Triglycerides From Baseline
NCT01611883 (10) [back to overview]	Percent Change in Total Cholesterol (TC) From Baseline
NCT01611883 (10) [back to overview]	Percent Change in Non-HDL-cholesterol From Baseline
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 104 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Calculated LDL--C at Week 24 - On--Treatment Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Apo-B at Week 12 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 104 - On-Treatment Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
NCT01644188 (26) [back to overview]	Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
NCT01644188 (26) [back to overview]	Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
NCT01644188 (26) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
NCT01644474 (18) [back to overview]	Percentage of Participants Achieving Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24 - ITT Analysis
NCT01644474 (18) [back to overview]	Percentage of Participants Achieving Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
NCT01644474 (18) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
NCT01709513 (26) [back to overview]	Percentage of Participants Who Experienced Skeletal Muscle-related Adverse Event (AE)
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Apo A--1 at Week 12 -- ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Apo B at Week 12 -- ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Apo B at Week 24 -- On--Treatment Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 -- ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Calculated LDL--C at Week 12 -- ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - On--Treatment Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--To-Treat (ITT) Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - On--Treatment Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 Versus Atorvastatin - Raw Data Description - Intent-To-Treat (ITT) Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 12 -- ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Non--HDL-C at Week 24 -- On--Treatment Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Non--High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 -- ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total--C) at Week 24 - ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change in Fasting Triglycerides From Baseline to Week 12 -- ITT Analysis
NCT01709513 (26) [back to overview]	Percent Change in HDL-C From Baseline to Week 12 -- ITT Analysis
NCT01709513 (26) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
NCT01709513 (26) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
NCT01709513 (26) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
NCT01709513 (26) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or Moderate or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-treat (ITT) Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
NCT01730040 (24) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - On-Treatment Analysis
NCT01730053 (24) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12 - On-Treatment Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Apo A-1 at Week 24 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
NCT01730053 (24) [back to overview]	Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
NCT01730053 (24) [back to overview]	Percentage of Very High CV Risk Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) or High CV Risk Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 24 - On-Treatment Analysis
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in HDL-C at Week 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12
NCT01763827 (22) [back to overview]	Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at the Mean of Weeks 10 and 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Total Cholesterol/High Density Lipoprotein-cholesterol Ratio at Week 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Triglycerides at Week 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12
NCT01763827 (22) [back to overview]	Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12
NCT01763827 (22) [back to overview]	Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
NCT01763827 (22) [back to overview]	Change From Baseline in LDL-C at Week 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in VLDL-C at Week 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12
NCT01763827 (22) [back to overview]	Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in HDL-C at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Triglycerides at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Very Low-Density Cholesterol (VLDL-C) at Week 12
NCT01763866 (22) [back to overview]	Percentage of Participants Who Achieved LDL-C < 70 mg/dL at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Change From Baseline in LDL-C at Week 12
NCT01763866 (22) [back to overview]	Change From Baseline in LDL-C at at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL
NCT01763866 (22) [back to overview]	Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
NCT01763866 (22) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12
NCT01763905 (22) [back to overview]	Percentage of Participants With Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL (1.8 mmol/L)
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at the Mean of Weeks 10 and 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at the Mean of Weeks 10 and 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in the Total Cholesterol/High Density Lipoprotein Cholesterol Ratio at Week 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in LDL-C at Week 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at the Mean of Weeks 10 and 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 10 and 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at the Mean of Weeks 10 and 12
NCT01763905 (22) [back to overview]	Change From Baseline in LDL-C at Week 12
NCT01763905 (22) [back to overview]	Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Very Low-Density Lipoprotein Cholesterol at Week 12
NCT01763905 (22) [back to overview]	Percentage of Participants With LDL-C < 70 mg/dL (1.8 mmol/L) at Week 12
NCT01763905 (22) [back to overview]	Percent Change From Baseline in Triglycerides at Week 12
NCT01766713 (1) [back to overview]	Change in Liver Fat as Measured by MRI-PDFF
NCT01849068 (2) [back to overview]	Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions
NCT01849068 (2) [back to overview]	Change in Intestinal mRNA Expression Levels of SREBP-2, NPC1L1, ABCG5/8, PCSK9 and HMG CoA Reductase Between the Two 12-week Interventions
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in Free Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (PCSK9) Levels
NCT01890967 (10) [back to overview]	Change From Baseline in High Sensitivity C-Reactive Protein (hsCRP)
NCT01890967 (10) [back to overview]	Number of Participants Who Develop Treatment Emergent Anti-LY3015014 Antibodies
NCT01890967 (10) [back to overview]	Number of Participants With an Injection Site Reaction
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in Lipoprotein(a) [Lp(a)]
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in Total Proprotein Convertase Subtilisin/Kexin Type 9 Antibody (PCSK9) Levels
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in Apolipoprotein A1 (Apo A1), Apolipoprotein B (Apo B)
NCT01890967 (10) [back to overview]	Percentage Change From Baseline in LDL-C, Total Cholesterol (TC), High-Density Lipoprotein Cholesterol (HDL-C), Triglycerides (TG), Non-HDL-C
NCT01890967 (10) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration-Time Curve at Steady-State (AUC,ss) for LY3015014
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in HDL-C at Week 24
NCT01984424 (24) [back to overview]	Change From Baseline in LDL-C at the Mean of Weeks 22 and 24
NCT01984424 (24) [back to overview]	Change From Baseline in LDL-C at Week 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 22 and 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at the Mean of Weeks 22 and 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C) at Week 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in LDL-C at the Mean of Weeks 22 and 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in LDL-C at Week 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 22 and 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at the Mean of Weeks 22 and 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 22 and 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol at Week 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at the Mean of Weeks 22 and 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Triglycerides at the Mean of Weeks 22 and 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Triglycerides at Week 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in Very Low-density Lipoprotein Cholesterol (VLDL-C) at the Mean of Weeks 22 and 24
NCT01984424 (24) [back to overview]	Percent Change From Baseline in VLDL-C at Week 24
NCT01984424 (24) [back to overview]	Percentage of Participants Who Achieved a Mean LDL-C at Weeks 22 and 24 of Less Than 70 mg/dL
NCT01984424 (24) [back to overview]	Percentage of Participants Who Achieved LDL-C at Week 24 of Less Than 70 mg/dL
NCT02055976 (48) [back to overview]	Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Change From Baseline in Triglyceride (TG) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-04950615
NCT02055976 (48) [back to overview]	Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio
NCT02055976 (48) [back to overview]	Apolipoprotein B (ApoB)
NCT02055976 (48) [back to overview]	Apolipoprotein A-II (ApoA-II)
NCT02055976 (48) [back to overview]	Apolipoprotein A-I (ApoA-I)
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 85
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Fasting Low Density Lipoprotein-Cholesterol (LDL-C) at Day 113
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Apolipoprotein A-I (ApoA-I) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Triglyceride (TG) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein- Cholesterol (Non-HDL-C) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Percent Change From Baseline in High Density Lipoprotein- Cholesterol (HDL-C) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Apolipoprotein B (ApoB) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Apolipoprotein B (ApoB) / Apolipoprotein A-I (ApoA-I) Ratio at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Terminal Elimination Half-Life (t1/2) of PF-04950615
NCT02055976 (48) [back to overview]	Percent Change From Baseline in Apolipoprotein A-II (ApoA-II) at Day 85 and Day 113
NCT02055976 (48) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)
NCT02055976 (48) [back to overview]	Non-High Density Lipoprotein- Cholesterol (Non-HDL-C)
NCT02055976 (48) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of PF-04950615
NCT02055976 (48) [back to overview]	Low Density Lipoprotein-Cholesterol (LDL-C)
NCT02055976 (48) [back to overview]	Lipoprotein (a) (Lp[a])
NCT02055976 (48) [back to overview]	Number of Participants With Anti-Drug Antibody (ADA) Response
NCT02055976 (48) [back to overview]	Minimum Observed Plasma Trough Concentration (Cmin) of PF-04950615
NCT02055976 (48) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of PF-04950615
NCT02055976 (48) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-04950615
NCT02055976 (48) [back to overview]	High Density Lipoprotein- Cholesterol (HDL-C)
NCT02055976 (48) [back to overview]	Very Low Density Lipoprotein-Cholesterol (VLDL-C)
NCT02055976 (48) [back to overview]	Triglyceride (TG)
NCT02055976 (48) [back to overview]	Total Cholesterol (TC) / High Density Lipoprotein- Cholesterol (HDL-C) Ratio
NCT02055976 (48) [back to overview]	Total Cholesterol (TC)
NCT02055976 (48) [back to overview]	Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-04950615
NCT02055976 (48) [back to overview]	Plasma Concentration of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
NCT02055976 (48) [back to overview]	Percentage of Participants Achieving Low-density Lipoprotein Cholesterol (LDL-C) Less Than (<) 10, 25, 40, 70 and 100 Milligram Per Deciliter
NCT02227784 (7) [back to overview]	Percent Change From Baseline to 3 Months in Apolipoprotein AI (apoAI)
NCT02227784 (7) [back to overview]	Percent Change From Baseline to 3 Months in Apolipoprotein B (apoB)
NCT02227784 (7) [back to overview]	Percent Change From Baseline to 3 Months in Cholesterol Efflux Capacity
NCT02227784 (7) [back to overview]	Percent Change From Baseline to 3 Months in High-Density Lipoprotein Cholesterol (HDL-C)
NCT02227784 (7) [back to overview]	Percent Change From Baseline to 3 Months in Lipoprotein(a) (Lp[a])
NCT02227784 (7) [back to overview]	Percent Change From Baseline to 3 Months in Low-Density Lipoprotein Cholesterol (LDL-C)
NCT02227784 (7) [back to overview]	Percent Change From Baseline to 3 Months in Non-HDL-C
NCT02260648 (7) [back to overview]	Percent Change From Baseline to Week 12 in LDL-C (Direct)
NCT02260648 (7) [back to overview]	Percent Change From Baseline to Week 12 in Apolipoprotein A-I
NCT02260648 (7) [back to overview]	Percent Change From Baseline to Week 12 in High-Density Lipoprotein Cholesterol (HDL-C)
NCT02260648 (7) [back to overview]	Percent Change From Baseline to Week 12 in Apolipoprotein B
NCT02260648 (7) [back to overview]	Percent Change From Baseline to Week 12 in Non HDL-C
NCT02260648 (7) [back to overview]	Percent Change From Baseline to Week 12 in Lipoprotein-a
NCT02260648 (7) [back to overview]	Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) Measured by Beta Quantification
NCT02304926 (20) [back to overview]	Triglycerides Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Apolipoprotein B Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	High-density Lipoprotein Cholesterol (HDLc) Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Leukocyte Adhesion Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Leukocyte Rolling Flux Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Leukocyte Rolling Velocity Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Levels of E-selectin Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Levels of Glutathione (GSH) Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Levels of High-sensitive C-reactive Protein (hsCRP) Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Levels of Intercellular Adhesion Molecule 1 (ICAM-1) Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Levels of Interleukin-6 (IL-6) Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Levels of Tumor Necrosis Factor α (TNF-α) Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Levels of Vascular Cell Adhesion Molecule 1 (VCAM-1) Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Low Density Lipoprotein Size Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Low-density Lipoprotein Cholesterol (LDLc) Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Membrane Potential Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Mitochondrial Oxygen (O2) Consumption Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Non-HDL Cholesterol Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Reactive Oxygen Species (ROS) Production Before and After Simvastatin/Ezetimibe Administration
NCT02304926 (20) [back to overview]	Total Cholesterol Before and After Simvastatin/Ezetimibe Administration
NCT02476006 (11) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12
NCT02476006 (11) [back to overview]	Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 12
NCT02476006 (11) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12
NCT02476006 (11) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12
NCT02476006 (11) [back to overview]	Percent Change From Baseline in Triglycerides at Week 12
NCT02476006 (11) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <100 mg/dL (2.59 mmol/L) at Week 12
NCT02476006 (11) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) and/or >=50% Reduction From Baseline in LDL-C at Week 12
NCT02476006 (11) [back to overview]	Percentage of Participants Reaching Calculated LDL-C <70 mg/dL (1.81 mmol/L) at Week 12
NCT02476006 (11) [back to overview]	Assessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Feeling About Injections, Self Confidence, Satisfaction With Self-Injections
NCT02476006 (11) [back to overview]	Assessment of Participant's Acceptability of Self-Injection Using Self Injection Assessment Questionnaire (SIAQ): Self Image, Injection-Site Reactions, Ease of Use
NCT02476006 (11) [back to overview]	Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT02550288 (18) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times ULN
NCT02550288 (18) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in ALT and/or AST ≥3 Times ULN
NCT02550288 (18) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in ALT ≥5 Times ULN
NCT02550288 (18) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in ALT ≥10 Times ULN
NCT02550288 (18) [back to overview]	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
NCT02550288 (18) [back to overview]	Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs
NCT02550288 (18) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Limit of Normal (ULN)
NCT02550288 (18) [back to overview]	Percentage of Participants Who Experience 1 or More Hepatitis-related AEs
NCT02550288 (18) [back to overview]	Percentage of Participants Who Experience 1 or More Gastrointestinal-related Adverse Events (AEs)
NCT02550288 (18) [back to overview]	Percentage of Participants With Potential Hy's Law Condition
NCT02550288 (18) [back to overview]	Percentage of Participants Who Have Elevations in Creatine Kinase (CK) ≥10xULN
NCT02550288 (18) [back to overview]	Percentage of Participants Who Have Elevations in CK ≥10xULN With Muscle Symptoms
NCT02550288 (18) [back to overview]	Percentage of Participants Who Have Elevations in CK ≥10xULN and Drug-Related Muscle Symptoms
NCT02550288 (18) [back to overview]	Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥5 Times ULN
NCT02550288 (18) [back to overview]	Percentage of Participants Who Experience 1 or More Gallbladder-related AEs
NCT02550288 (18) [back to overview]	Percentage of Participants Who Have Consecutive Elevations in ALT and/or AST ≥10 Times ULN
NCT02550288 (18) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in AST ≥5 Times ULN
NCT02550288 (18) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in AST ≥10 Times ULN
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Triglycerides at the Mean of Weeks 10 and 12
NCT02634580 (24) [back to overview]	Percentage of Participants Who Achieved a Mean LDL-C at Weeks 10 and 12 of Less Than 70 mg/dL
NCT02634580 (24) [back to overview]	Percentage of Participants Who Achieved a LDL-C of Less Than 70 mg/dL at Week 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in VLDL-C at Week 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in VLDL-C at the Mean of Weeks 10 and 12
NCT02634580 (24) [back to overview]	Change From Baseline in LDL-C at the Mean of Weeks 10 and 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol at Week 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein B at the Mean of Weeks 10 and 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Triglycerides at Week 12
NCT02634580 (24) [back to overview]	Change From Baseline in LDL-C at Week 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at the Mean of Weeks 10 and 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A-1 Ratio at Week 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in HDL-C at the Mean of Weeks 10 and 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in HDL-C at Week 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at the Mean of Weeks 10 and 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol at the Mean of Weeks 10 and 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Non-HDL-C at the Mean of Weeks 10 and 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at the Mean of Weeks 10 and 12
NCT02634580 (24) [back to overview]	Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 12
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Total-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]	Percent Change From Baseline in LDL-C Particle Number at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Apo B at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Measured LDL-C at Week 12: Overall ITT Analysis
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Measured LDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Measured Low-Density Lipoprotein Cholesterol (LDL-C) at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 12: Overall ITT Analysis
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]	Absolute Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12 and 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]	Absolute Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12 and 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]	Absolute Change From Baseline in Number of Glucose-Lowering Treatments at Week 12 and 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 24: Overall ITT Analysis
NCT02642159 (23) [back to overview]	Percent Change From Baseline in HDL-C at Week 24 : Overall ITT Analysis
NCT02642159 (23) [back to overview]	Percent Change From Baseline in HDL-C at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]	Percent Change From Baseline in LDL-C Particle Number at Week 24: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02642159 (23) [back to overview]	Percent Change From Baseline in Measured LDL-C at Week 12: ITT- Intent to Prescribe Fenofibrate Stratum
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Total Cholesterol at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percentage of Participants Reaching Calculated Low Density Lipoprotein Cholesterol <70 mg/dL (1.81 mmol/L) at Week 24: On-Treatment Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: On-Treatment Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein A-1 at Week 12 : ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 24: On-Treatment Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: ITT Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 12: On-Treatment Analysis
NCT02715726 (22) [back to overview]	Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥5 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevation in Alanine Aminotransferase (ALT) ≥10 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience 1 or More Hepatitis-related AEs
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) ≥3 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEs
NCT02741245 (19) [back to overview]	Percentage Change From Baseline in Low-density Lipoprotein-cholesterol (LDL-C)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEs
NCT02741245 (19) [back to overview]	Percentage of Participants With Potential Hy's Law Condition
NCT02741245 (19) [back to overview]	Percentage of Participants Who Had Study Drug Discontinued Due to Adverse Event
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle Symptoms
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience 1 or More Gallbladder-related AEs
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥10 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevation in Aspartate Aminotransferase (AST) ≥5 Times Upper Normal Limit (ULN)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience at Least 1 Adverse Event (AE)
NCT02741245 (19) [back to overview]	Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle Symptoms
NCT02748057 (3) [back to overview]	Percentage of Participants Who Had Study Drug Discontinued Due to an AE
NCT02748057 (3) [back to overview]	Percentage Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
NCT02748057 (3) [back to overview]	Percentage of Participants Who Experience at Least 1 Adverse Event (AE)
NCT02890992 (20) [back to overview]	Percent Change From Baseline in Fasting Triglyceride at Week 8
NCT02890992 (20) [back to overview]	Absolute Change From Baseline in Total Cholesterol (Total-C) at Week 8
NCT02890992 (20) [back to overview]	Percent Change From Baseline in Apolipoprotein (Apo) B at Week 8
NCT02890992 (20) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Week 8
NCT02890992 (20) [back to overview]	Percent Change From Baseline in Apolipoprotein A-1 at Week 8
NCT02890992 (20) [back to overview]	Percentage of Participants Achieving Calculated Low Density Lipoprotein Cholesterol (LDL-C) <130 mg/dL (3.37 mmol/L) at Week 8
NCT02890992 (20) [back to overview]	Percent Change From Baseline in Calculated LDL-C at Week 12: Cohort 4
NCT02890992 (20) [back to overview]	Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8
NCT02890992 (20) [back to overview]	Percentage of Participants Achieving Calculated LDL-C <110 mg/dL (2.84 mmol/L) at Week 8
NCT02890992 (20) [back to overview]	Absolute Change From Baseline in Apolipoprotein A-1 at Week 8
NCT02890992 (20) [back to overview]	Absolute Change From Baseline in Apolipoprotein B at Week 8
NCT02890992 (20) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 8
NCT02890992 (20) [back to overview]	Absolute Change From Baseline in Fasting Triglyceride at Week 8
NCT02890992 (20) [back to overview]	Absolute Change From Baseline in HDL-C at Week 8
NCT02890992 (20) [back to overview]	Absolute Change From Baseline in Lipoprotein(a) at Week 8
NCT02890992 (20) [back to overview]	Absolute Change From Baseline in Calculated Low Density Lipoprotein Cholesterol (LDL-C) at Week 8
NCT02890992 (20) [back to overview]	Absolute Change From Baseline in Ratio Apolipoprotein B/Apolipoprotein A-1 at Week 8
NCT02890992 (20) [back to overview]	Percent Change From Baseline in Lipoprotein(a) at Week 8
NCT02890992 (20) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein (HDL-C) at Week 8
NCT02890992 (20) [back to overview]	Absolute Change From Baseline in Non-High-Density Lipoprotein (Non-HDL-C) at Week 8
NCT02971033 (3) [back to overview]	Change in Alanine Aminotransferase (ALT)
NCT02971033 (3) [back to overview]	Change in Viral Load
NCT02971033 (3) [back to overview]	Second Phase Slope
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Non-High-density Lipoprotein Cholesterol (Non-HDL-C) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Lumen Volume at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Lipoprotein (a) (Lp[a]) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Fasting Triglycerides (TGs) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in External Elastic Membrane (EEM) Volume at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Apolipoprotein B (Apo B) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 36
NCT02984982 (24) [back to overview]	Number of Participants With Cardiovascular (CV) Adverse Events
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Normalized Total Atheroma Volume (TAV) at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Calculated Low-density Lipoprotein Cholesterol at Week 12 and Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Total Cholesterol at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Non-High-density Lipoprotein Cholesterol at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Lumen Volume at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Lipoprotein (a) at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in High-density Lipoprotein Cholesterol at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Fasting Triglycerides at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in External Elastic Membrane Volume at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein B at Week 36
NCT02984982 (24) [back to overview]	Percent Change From Baseline in Apolipoprotein A-1 at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Total Cholesterol (TC) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Percent Atheroma Volume (PAV) at Week 36
NCT02984982 (24) [back to overview]	Absolute Change From Baseline in Normalized Total Atheroma Volume at Week 36
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Weeks 4 and 8 in TGs
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Weeks 4 and 8 in Non-HDL-C
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Weeks 4 and 8 in TC
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C)
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Week 12 in Triglycerides (TGs)
NCT03001076 (14) [back to overview]	Absolute Change From Baseline to Weeks 4, 8, and 12 in LDL-C
NCT03001076 (14) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs)
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Weeks 4 and 8 in HDL-C
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Weeks 4 and 8 in LDL-C
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)
NCT03001076 (14) [back to overview]	Percent Change From Baseline to Week 12 in Apolipoprotein B (apoB)
NCT03051100 (5) [back to overview]	Percent Change From Baseline in Lipid Profile Parameters at Week 6
NCT03051100 (5) [back to overview]	Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 6
NCT03051100 (5) [back to overview]	Percent Change From Baseline in High-sensitivity C-reactive Protein (Hs-CRP) at Week 6
NCT03051100 (5) [back to overview]	Number of Participants With LDL-C Reduction ≥50% From Baseline at Week 6
NCT03051100 (5) [back to overview]	Number of Participants With LDL-C <70 mg/dL at Week 6
NCT03337308 (7) [back to overview]	Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)
NCT03337308 (7) [back to overview]	Percent Change From Baseline to Week 12 in Apolipoprotein B (Apo B)
NCT03337308 (7) [back to overview]	Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)
NCT03337308 (7) [back to overview]	Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)
NCT03337308 (7) [back to overview]	Percent Change From Baseline to Week 12 in Triglycerides (TGs)
NCT03337308 (7) [back to overview]	Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
NCT03337308 (7) [back to overview]	Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Apolipoprotein (Apo) B at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Fasting Triglycerides (TG) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Week 12: On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Lipoprotein a (Lp) (a) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol at Weeks 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Absolute Change From Baseline in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Number of Participants With Tanner Staging at Baseline, Weeks 12, 24 and 48
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12: Intent-to-Treat (ITT) Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Weeks 12, 24 and 48 - ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percent Change From Baseline in Total Cholesterol (Total-C) at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510715 (13) [back to overview]	Percentage of Participants Reporting >=15 Percent (%) Reduction in LDL-C Level at Weeks 12, 24 and 48: ITT Analysis/On-treatment Analysis
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level <130 mg/dL (3.37 mmol/L) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Achieving Low Density Lipoprotein Cholesterol <110 mg/dL (2.84 mmol/L) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Total Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24: Intent-to-treat (ITT) Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol Level Lower Than (<) 130 mg/dL (3.37 mmol/L) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Fasting Triglycerides (TG) at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein B at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein B (Apo B) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein A1 at Week 12: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein A1 (Apo A1) at Week 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	Number of Participants With Tanner Staging at Baseline and Weeks 24, 68 and 104
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 130 mg/dL (3.37 mmol/L) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved Low Density Lipoprotein Cholesterol < 110 mg/dL (2.84 mmol/L) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved at Least 50% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Who Achieved at Least 30 Percent (%) Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percentage of Participants Achieved at Least 30% Reduction in Low Density Lipoprotein Cholesterol Level From Baseline at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Weeks 8, 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Total Cholesterol at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Weeks 12, and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Lipoprotein (a) at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Fasting Triglycerides at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein B at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Percent Change From Baseline in Apolipoprotein A1 at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response
NCT03510884 (44) [back to overview]	DB Period: Number of Participants With Treatment-Emergent (TE) Positive Anti-Alirocumab Antibodies (ADA) Response
NCT03510884 (44) [back to overview]	DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: On-treatment Estimand
NCT03510884 (44) [back to overview]	DB Period: Absolute Change From Baseline in Apo B/Apo A-1 Ratio at Weeks 12 and 24: ITT Estimand
NCT03510884 (44) [back to overview]	Change From Baseline in Cogstate Battery Test - Overall Composite Score at Weeks 24, 68 and 104
NCT03510884 (44) [back to overview]	OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: On-treatment Estimand
NCT03510884 (44) [back to overview]	OL Period: Percent Change in Low Density Lipoprotein Cholesterol From Baseline to Week 104: ITT Estimand
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12 in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) Index
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12 in HbA1c
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12 in Fasting Plasma Glucose
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12 in Apolipoprotein B (Apo B)
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12 in 2-hour Post Prandial Plasma Glucose (PPG)
NCT03531905 (16) [back to overview]	Number of Participants With LDL-C <70 Milligrams Per Deciliter (mg/dL) at Week 12
NCT03531905 (16) [back to overview]	Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
NCT03531905 (16) [back to overview]	Change From Baseline to Week 12 in Hemoglobin A1C (HbA1c)
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12/EOS in LDL-C (Comparing Ezetimibe With Placebo)
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12/End of Study (EOS) in Low-density Lipoprotein Cholesterol (LDL-C)
NCT03531905 (16) [back to overview]	Secondary Outcome Measure: Number of Participants With an LDL-C Reduction of ≥50% From Baseline at Week 12
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12 in Total Cholesterol (TC)
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)
NCT03531905 (16) [back to overview]	Percent Change From Baseline to Week 12 in Triglycerides (TGs)

Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events)

Composite endpoint of AVE (aortic valve events) consists of AVR surgery, CHF (as a result of progression of AS), or cardiovascular death (NCT00092677)
Timeframe: Entire follow-up (median = 4.35 years)

Intervention	Participants (Number)
EZ/Simva 10/40 mg	308
Placebo	326

Intervention	percent change (Least Squares Mean)
Pooled Subjects Who Received Ezetimibe With Simvastatin	-38.23
Pooled Subjects Who Received Simvastatin Monotherapy	-26.28

Intervention	percent change (Least Squares Mean)
Pooled Subjects Who Received Ezetimibe With Simvastatin	-46.84
Pooled Subjects Who Received Simvastatin Monotherapy	-32.68

Intervention	percent change (Median)
Pooled Subjects Who Received Ezetimibe With Simvastatin	-16.56
Pooled Subjects Who Received Simvastatin Monotherapy	-12.28

Intervention	percent change (Least Squares Mean)
Pooled Subjects Who Received Ezetimibe With Simvastatin	-49.45
Pooled Subjects Who Received Simvastatin Monotherapy	-34.43

Intervention	percent change (Least Squares Mean)
Pooled Subjects Who Received Ezetimibe With Simvastatin	-38.92
Pooled Subjects Who Received Simvastatin Monotherapy	-26.69

Intervention	percent change (Least Squares Mean)
Pooled Subjects Who Received Ezetimibe With Simvastatin	6.58
Pooled Subjects Who Received Simvastatin Monotherapy	6.47

Intervention	mg/dl (Mean)
	baseline	12 weeks
Colestipol	39.22	37.56
Ezetimibe	32.90	34.70
Niacin	42.33	43.00

Intervention	Percent change (Mean)
Ezetimibe/Simvastatin	-45.1
Ezetimibe/Simvastatin + Niacin	-52.4

Intervention	Percent change (Median)
Ezetimibe/Simvastatin	23.7
Ezetimibe/Simvastatin + Niacin	-42.5

Intervention	Percent change (Mean)
Ezetimibe/Simvastatin	-53.5
Ezetimibe/Simvastatin + Niacin	-58.5

Intervention	Percent change (Mean)
Ezetimibe/Simvastatin	-49.3
Ezetimibe/Simvastatin + Niacin	-54.0

Intervention	Percent change (Mean)
Ezetimibe/Simvastatin	-47.9
Ezetimibe/Simvastatin + Niacin	-55.6

Intervention	Percent change (Median)
Ezetimibe/Simvastatin	-26.8
Ezetimibe/Simvastatin + Niacin	-44.5

Intervention	Participants (Number)
	<100 mg/dL	≥100 mg/dL
Atorvastatin	45	47
Atorvastatin + Ezetimibe	77	15

Intervention	Participants (Number)
	<70 mg/dL	>=70 mg/dL
Atorvastatin	88	191
Atorvastatin + Ezetemibe	204	73

Intervention	mg/dL (Mean)
	HDL-C at baseline	HDL-C at 6 weeks	Total Cholesterol at baseline	Total Cholesterol at 6 weeks	Triglycerides at baseline	Triglycerides at 6 weeks
Ezetimibe 10 mg	53.250	52.625	219.125	156.375	139.500	115.250
Placebo 10 mg	57.667	53.500	226.000	185.667	131.667	120.250

Intervention	mg/dL (Mean)
	Baseline	6 weeks post treatment
Ezetimibe 10 mg	148.125	106.000
Placebo 10 mg	151.083	108.273

Intervention	Percent Change (Mean)
Atorvastatin 20 mg + Lomitapide 10 mg	-30.99
Simvastatin 20 mg + Lomitapide 10 mg	-26.43
Ezetimibe 10 mg + Lomitapide 10 mg	-28.36
Rosuvastatin 20 mg + Lomitapide 10 mg	-41.74
Fenofibrate 145 mg + Lomitapide 10 mg	-20.12
Atorvastatin 20 mg + Lomitapide 60 mg	-66.02
Rosuvastatin 20 mg + Lomitapide 60 mg	-63.20
Dextrometh-rophan 30 mg + Lomitapide 60 mg	-46.07
ER Niacin 1000 mg + Lomitapide 10 mg	-20.89

Intervention	percent change (Median)
	Before Food (0 hour)	3 Hours Postprandially	6 Hours Postprandially
Ezetimibe	11.6	11.1	13.9
Placebo	12.3	10.9	12.8

Intervention	mg/dl (Mean)
	before food (0 hour)	3 hour postprandial	6 hour postprandial
Ezetimibe	92	89	87
Placebo	102	104	101

ezetimibe

Description

Cross-References

Synonyms (119)

Research Excerpts

Overview

Effects

Actions

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (3)

Pathways (1)

Protein Targets (37)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (121)

Molecular Functions (53)

Ceullar Components (38)

Bioassays (255)

Research

Studies (2,314)

Market Indicators

Research Demand Index: 112.94

Study Types

Clinical Trials (342)

Trial Overview

Trial Outcomes

Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of AVE (Aortic Valve Events)

Incident Cancer

Nonfatal Myocardial Infarction (MI)

Nonhemorrhagic Stroke

Percutaneous Coronary Intervention (PCI)

Percent Change in Time Weighted Average Triglycerides From Baseline to End of Follow-up

Percent Change in Time Weighted Average Total Cholesterol From Baseline to End of Follow-up

Percent Change in Time Weighted Average Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to End of Follow-up

Percent Change in Time Weighted Average High-density Lipoprotein Cholesterol (HDL-C) From Baseline to End of Follow-up

Aortic Valve Replacement (AVR)

Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of ICE (Ischemic Cardiovascular Events)

Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events)

Cardiovascular Death

Change From Baseline in Peak Transaortic Jet Velocity

Congestive Heart Failure (CHF) Due to Progression of Aortic Stenosis (AS)

Hospitalization for Unstable Angina

Death Due to Cancer

Death (Any Cause)

Coronary Artery Bypass Grafting (CABG)

Total Cholesterol Concentration of Chylomicron-remnant (Sf 60-400) Subfractions After a Cholesterol-Rich Test Meal

Total Cholesterol Concentration of Chylomicron (Sf≥400) Fractions After a Cholesterol-Rich Test Meal

Major Vascular Events Analyzed Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo

Major Vascular Events Analyzed Amongst Patients Initially Randomized to Simvastatin Plus Ezetimibe Versus Placebo (Original Protocol-defined Primary Outcome)

Non-hemorrhagic Stroke Among All of Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo

Key Outcome as Per Statistical Analysis Plan = Major Atherosclerotic Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo

Coronary or Non-coronary Revascularization Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo

End-stage Renal Disease Among All Patients Not on Dialysis at the Time of Randomization to Simvastatin Plus Ezetimibe Versus Placebo

Major Coronary Events Among All Patients Ever Randomized to Simvastatin Plus Ezetimibe Versus All Patients Allocated to Placebo

Percent Change From Baseline in Total Cholesterol (TC)

Percent Change From Baseline in Non High-density Lipoprotein Cholesterol (Non HDL-C)

Percent Change From Baseline in Triglycerides (TG)

Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)

Percent Change From Baseline in Apolipoprotein B (Apo B)

Percent Change From Baseline in HDL-C

LDL-C Lowering Efficacy

Time to First Occurrence of CV Death, Nonfatal MI, UA With Hospitalization, All Revascularization Occurring ≥30 Days After Randomization, and Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)

Time to First Occurrence of Death From Any Cause, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)

Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)

Time to First Occurrence of Coronary Heart Disease (CHD) Death, Non-fatal MI, or Urgent Coronary Revascularization With PCI or CABG ≥ 30 Days After Randomization (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event)

LFT Elevation

LDL Goal Attainment

Incidents of Rhabdomyolysis

Change in HDL From Baseline to 12 Weeks.

Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Percent Change From Baseline in Triglycerides (TG)

Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Intervention	Percent Change (Mean)
Combination Therapy	-10.7
Lomitapide Monotherapy	-8.0
Ezetimibe Monotherapy	2.3

Intervention	Percent Change (Mean)
Combination Therapy	-36.6
Lomitapide Monotherapy	-23.7
Ezetimibe Monotherapy	-14.5

Intervention	Percent Change (Mean)
Combination Therapy	-1.4
Lomitapide Monotherapy	-1.0
Ezetimibe Monotherapy	-0.1

Intervention	Percent Change (Mean)
Combination Therapy	-9.2
Lomitapide Monotherapy	-6.2
Ezetimibe Monotherapy	5.9

Intervention	Percent Change (Mean)
Combination Therapy	40.4
Lomitapide Monotherapy	81.3
Ezetimibe Monotherapy	233.3

Intervention	Percent Change (Mean)
Combination Therapy	-46.2
Lomitapide Monotherapy	-29.9
Ezetimibe Monotherapy	-19.6

Intervention	Percent Change (Mean)
Combination Therapy	-12.0
Lomitapide Monotherapy	-11.4
Ezetimibe Monotherapy	7.5

Intervention	Percent Change (Mean)
Combination Therapy	-7.0
Lomitapide Monotherapy	-5.8
Ezetimibe Monotherapy	2.7

Intervention	Percent Change (Mean)
Combination Therapy	-34.4
Lomitapide Monotherapy	-22.8
Ezetimibe Monotherapy	-12.0

Intervention	Percent Change (Mean)
Combination Therapy	-41.3
Lomitapide Monotherapy	-26.9
Ezetimibe Monotherapy	-17.0